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Summary 
Enzymes are the catalysts of life. They accelerate the rate of chemical reactions that would otherwise 
take longer than an organism’s lifetime to take just millisecond. To achieve these remarkable rate 
enhancements enzymes arrange into a three dimensional fold that places its amino acids in a way, 
which binds the transition state of the reaction better than the substrates and products of the reaction, 
thereby lowering the activation energy of the reaction. Enzymes are also very specific and often only 
catalyze one specific chemical transformation without producing side products. They are able to 
achieve all this under ambient temperatures and in cells that contain over 2700 different metabolites.  
In this work we focus on the mechanisms enzyme use to control reactive intermediates both inside 
their active site and between enzymes of a metabolic pathway to avoid the formation of deleterious 
side products. In the first part we investigate the catalytic cycle of NAD(P)H dependent 
oxidoreductases. We show that the two enoyl‐thioester reductases; Etr1p from Candida tropicalis of 
the MDR enzyme superfamily and InhA from Mycobacterium tuberculosis of the SDR enzyme 
superfamily form a covalent adduct between substrate and the C2 carbon of the cofactor. The 
observation of this reactive intermediate at the active site of enzymes from the two largest NAD(P)H 
dependent oxidoreductase superfamilies not only calls for a careful reconsideration of the canonical 
reaction mechanism of these enzymes, but also sets the basis for the development of novel tools to 
study, manipulate and inhibit their catalytic cycle. We demonstrate this by successfully changing the 
protonation specificity of Etr1p from re- to si- face. Using the molecular probe we show that a 
conserved threonine at the active site of Etr1p is mainly responsible for preventing the formation of a 
toxic side product and not for the stabilization of the wanted transition state along the reaction 
coordinate. This effect of destabilization of unwanted transition states, often termed ´negative 
catalysis´, poses a complementary mechanism of reaction control to the canonical transition state 
theory and is discussed in detail in this work. 
In the second part of this thesis we take a look at two enzyme complexes and the strategies they use 
to control the transfer of a reactive intermediate from one active site to the next one. The trifunctional 
propionyl‐CoA synthase forms a closed reaction chamber to sequester the reactive acrylyl‐CoA 
intermediate. This reaction chamber encloses all three active sites of the enzyme fusion protein, but 
does not show the directionality of a conventional tunnel, and the CoA ester intermediates are not 
covalently attached to the enzyme but freely diffuse within the compartment. The substrate 
channeling mechanism of the thiolase/HMG‐CoA synthase complex of archaea most closely resembles 
the covalent swinging arm fatty acid and polyketide synthases use to channel their intermediates. In 
the thiolase/HMG‐CoA synthase complex the intermediate is however not covalently attached, but 
instead tightly bound in a shared CoA binding site, enabling the pantothenyl‐arm of CoA to swing from 
the thiolase active site to the HMG‐CoA synthase active site. The two channeling systems we describe 
in this work therefore represent two alternative ways of channeling CoA ester intermediates in a non‐
covalent fashion. 
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Zusammenfassung 
Enzyme sind die Katalysatoren des Lebens. Sie beschleunigen die Rate chemischer Reaktionen, welche 
unkatalysiert länger als die Lebensspanne eines Organismus dauern würden. Enzyme erreichen diese 
beeindruckende Beschleunigung indem sie den Überganszustand besser als Substrat und Produkt 
binden, wodurch sie die Aktivierungsenergie der Gesamtreaktion senken. Zusätzlich sind Enzyme 
äußerst spezifisch und katalysieren normalerweise exakt eine chemische Reaktion, ohne dabei 
Seitenprodukte zu produzieren. All dies erreichen sie bei moderaten Temperaturen und innerhalb von 
Zellen, welche über 2700 unterschiedliche Metabolite enthalten. 
In dieser Arbeit untersuchen wir die Mechanismen, welche Enzyme nutzen um reaktive 
Zwischenprodukte zu kontrollieren und damit die Bildung von schädlichen Seitenprodukten 
verhindern. Im ersten Teil betrachten wir den katalytischen Zyklus von NAD(P)H abhängigen 
Oxidoreduktasen im Detail. Wir zeigen, dass beide untersuchten Enoylthioesterreduktasen, Etr1p aus 
Candida tropicalis und der MDR Enyzmsuperfamilie und InhA aus Mycobacterium tuberculosis und der 
SDR Enzymsuperfamilie, ein kovalentes Zwischenprodukt zwischen dem Substrat und NAD(P)H bilden. 
Die Beobachtung, dass Enyzme aus beiden Superfamilien ein solches Zwischenprodukt herstellen, stellt 
nicht nur den herkömmlichen Reaktionsmechanismus in Frage, sondern setzt auch die Grundlage für 
die Entwicklung von neuen Methoden zur Manipulierung, Erforschung und Inhibierung solcher 
Oxidoreduktasen. Wir demonstrieren dies mit dem erfolgreichen Umbau der Protonierungsspezifität 
in Etr1p von der re‐ zur si‐Seite. Zusätzlich nutzen wir das kovalente Zwischenprodukt um aufzuzeigen, 
dass ein konserviertes Threonin im aktiven Zentrum von Etr1p hauptsächlich dazu dient, die Bildung 
eines toxischen Seitenproduktes zu verhindern und nicht um den gewünschten Übergangszustand zu 
stabilisieren. Threonin destabilisiert stattdessen den Übergangszustand zum ungewünschten 
Seitenprodukt. Dieser Effekt der Destabilisierung wird oft ´negative Katalyse´ genannt und ergänzt die 
kanonische Theorie des Übergangszustandes. Die Auswirkungen dieses Effektes auf unser Verständnis 
der Enzymkatalyse werden in dieser Arbeit im Detail diskutiert. 
Im zweiten Teil dieser Arbeit untersuchen wir zwei Enzymkaskaden und deren Mechanismen, welche 
den Transfer reaktiver Zwischenprodukte von einem aktiven Zentrum ans nächste ermöglichen. Die 
trifunktionelle Propionyl‐CoA Synthase bildet eine geschlossene Reaktionskammer, um das reaktive 
Zwischenprodukt Acrylyl‐CoA daran zu hindern ins Zytoplasma zu entweichen. Diese Reaktionskammer 
enthält alle drei aktiven Zentren des Fusionsproteins und ermöglicht dadurch Katalyse der gesamten 
Enyzmkaskade innerhalb der Kammer. Sie unterscheidet sich dabei jedoch von zielgerichteten Tunneln 
und anderen herkömmlichen Kanalisierungsmechanismen. Der Thiolase/HMG‐CoA‐Synthasekomplex 
von Archaeen kanalisiert das Zwischenprodukt Acetoacetyl‐CoA, ähnlich wie Polyketid‐ und 
Fettsäurensynthasen, indem er die Pantothenylkomponente von CoA als Arm verwendet, um das 
Zwischenprodukt von einem aktiven Zentrum ans nächste weiterzureichen. Im Unterscheid zu anderen 
Systemen ist der Panthothenylarm hierbei jedoch nicht kovalent gebunden, sondern Teil des CoA‐
Esters, weshalb der Enzymkomplex eine geteilte CoA‐Bindetasche besitzt. Die beiden hier 
beschriebenen Mechanismen stellen daher zwei neue Strategien dar, um mehrere Reaktionen nicht 
kovalent gebundener CoA‐Ester zu kanalisieren. 
 
  
Zusammenfassung 
3 
 
Parts of this thesis have been published or are in preparation for publication: 
Rosenthal, R.G.*; Vogeli, B.*; Quade, N.; Capitani, G.; Kiefer, P.; Vorholt, J.A.; Ebert, M. O.; Erb, T.J. 
(2015) The use of ene adducts to study and engineer enoyl‐thioester reductases. Nat Chem Biol 
11(6): 398‐400 
Rosenthal, R. G., B. Vögeli, T. Wagner, S. Shima and T. J. Erb (2017). A conserved threonine prevents 
self‐intoxication of enoyl‐thioester reductases. Nat Chem Biol 13(7): 745‐749. 
 
Vögeli, B.*; Rosenthal, R.G.*; Stoffel G.M.M.*; Wagner, T.; Kiefer, P.; Cortina, N.S.; Shima, S.; Erb, 
T.J. (2018) InhA, the enoyl‐thioester reductase from M. tuberculosis forms a covalent reaction 
intermediate. submitted 
 
Vögeli, B.; Gerlinger, P.D.; Geyer, K.; Benkstein, S.; Cortina, N.S.; Erb, T.J. (2018) Combining 
promiscuous acyl‐CoA oxidase and enoyl‐CoA carboxylase/reductases for atypical polyketide extender 
unit biosynthesis. Cell Chem Biol 25: 1‐7 
 
Bernhardsgrütter, I.*; Vögeli, B.*; Wagner, T.; Peter, D.M.; Cortina, N.S.; Bange, G.; Engilberge, S.; 
Girard, E.; Riobé, F.; Maury, O.; Shima, S.; Zarzycki, J.; Erb, T.J. (2018) Trifunctional propionyl‐CoA 
synthase: A self‐organizing, multi‐catalytic ‘pico’‐compartment that sequesters a reactive 
intermediate. submitted 
 
Vögeli, B; Engilberge, S.; Girard, E.; Riobe, F.; Maury, O.; Erb, T.J.; Shima, S.; Wagner, T. (2018) 
Archaeal acetoacetyl‐CoA thiolase/HMG‐CoA synthase complex channels the intermediate via a fused 
CoA‐binding site. Proc Natl Acad Sci USA 115(13): 3380‐3385. 
Vögeli, B.; Erb, T.J. (2018) ‘Negative’ and ‘positive catalysis’: Complementary principles that shape the 
catalytic landscape of enzymes. Submitted 
 
Publications that are not discussed in this thesis: 
 
Peter, D. M.*; Vogeli, B.*; Cortina, N.S.; Erb, T.J. (2016). A Chemo‐Enzymatic Road Map to the 
Synthesis of CoA Esters. Molecules 21(4). 
Krink-Koutsoubelis, N.; Loechner, A.C.; Lechner, A.; Link, H.; Denby, C.M.; Vögeli, B.; Erb, T.J.; 
Yuzawa, S.; Jakociunas, T.; Katz, L.; Jensen, M.K.; Sourjik, V.; Keasling, J.D. (2018). Engineered 
Production of Short‐Chain Acyl‐Coenzyme A Esters in Saccharomyces cerevisiae. ACS Synth Biol 7(4): 
1105‐1115. 
 
  
Introduction 
4 
 
1. Introduction 
 Enzymes 
Enzymes make the chemistry of life possible by drastically increasing the rate of chemical reactions 
that would otherwise take too long to sustain life as we know it. They are able to accelerate rates of 
chemical reactions by many orders of magnitude compared to uncatalyzed reaction. In the extreme 
case of arginine decarboxylase the uncatalyzed reaction has a half‐life of approximately the age of 
Earth, while the enzyme catalyzes more than 1000 reactions per second (rate enhancement of 1017)1. 
The mechanism of this rate acceleration was first proposed by Linus Pauling in 1946, without the 
knowledge of any structural information. He proposed that enzymes can accelerate rates due to better 
binging of the transition state than the substrate, therefore lowering the activation free energy of the 
reaction2. This key concept of lowering the activation free energy remains the main strategy of 
enzymes and only needs to be extended by some quantum mechanical effects that change the 
transmission coefficient of reactions, such as tunneling effects in reactions involving hydrogen 
transfers and non‐equilibrium effects3. There are various mechanisms that enzymes can employ to 
lower the activation free energy (along with tight binding of the transition state). If there is a difference 
in charge distribution between the substrate and the transition state, electrostatic effects, such as 
hydrogen bonding often play an essential role in stabilizing the transition state (eg. a charged lysine 
lowers the activation energy of enolate intermediate formation in triosephosphate isomerase (TIM)3‐
4). Conformational stabilization of the reactant can also contribute to the lowering of the activation 
free energy barrier. In chorismate mutases for example, chorismate, the substrate of the reaction, is 
stable in an inactive conformation in solution and gets transformed into the active form upon binding 
to the enzyme. This preorganization of the substrate into a “near‐attack conformer” has been 
estimated to contribute about 5 kcal/mol to lowering of the activation free energy, the more polar 
transition state is then further stabilized by electrostatic interactions5‐6. The ability of enzymes to 
exclude water from the active site can be another effect that lowers the activation free energy. In SN2 
reactions the substrate is better solvated than the transition state, which leads to an energy penalty 
for its removal during the reaction. Haloalkane dehalogenases use this desolvation effect to effectively 
lower the activation free energy by an estimate of 6 kcal/mol compared to the reaction in water7. 
Another strategy that enzymes employ involves the enzyme free energy (often termed enzyme 
conformational change), which can be different for reactant and transition state binding. The binding 
of reactant to orotidine monophosphate decarboxylase for example induces a strain in the enzyme 
that is only relieved at the transition state8. In summary, natural selection has found a wide range of 
molecular mechanisms that allow enzymes to achieve remarkable rate enhancement of chemical 
reactions mostly by reducing the reactions active free energy. 
Next to the rate enhancements, enzymes are also highly specific and are able to work in the complex 
metabolite mixture of the cellular cytoplasm. How do enzymes control the outcome of chemical 
reactions to achieve the remarkable stereo‐ and region‐selectivity they display? How do they control 
highly reactive intermediates in their active site and avoid the formation of deleterious side products? 
These questions are discussed in Chapter 1.2.  
In Chapter 1.3 the challenges enzyme cascades face in the cellular context are discussed. How do they 
avoid cross‐talk between their intermediates and other cytosolic enzymes? How do enzymes in a cell 
manage to catalyze more than 1000 different reactions in parallel? 
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 Control of reactive intermediates in Enzymes 
Enzymes are often referred to as remarkably specific catalysts, meaning that they catalyze one 
chemical reaction with high region‐ and stereo‐selectivity. This raises the question of how enzymes 
control all the reactive intermediates and transition states during a chemical transformation to guide 
the reaction towards the desired product. Note that there are many enzymes that use multiple 
substrates, but still catalyze one chemical reaction. These enzymes should still be regarded as specific, 
regarding their reaction mechanism, as they still catalyze the transformation of one of the substrates 
into exactly one corresponding region‐ and stereospecific product. There are however some enzymes 
that produce considerable amounts of unwanted side products, despite being under strong 
evolutionary pressure to avoid them 9. Analyzing the challenging reactions those enzymes catalyze and 
the solutions nature has come up with to minimize the side reactions helps us to understand the 
general principles of enzymatic reaction control.  
Triosephosphate isomerase, an enzyme that in terms of rate enhancement of its reaction has achieved 
perfection 1, forms the side product methylglyoxal (MG) approximately once every million reactions 
(kcat/Km for the side reaction is 14 M‐1s‐1). MG is produced during the reactive cycle via a phosphate 
elimination reaction from the reactive enediol(ate) phosphate intermediate (Figure 1A, (a)). 
Enediol(ate) phosphate intermediates are unstable in water and eliminate phosphate with estimated 
rate constants between 8·106 and 8·108 s‐1, which is at least 100 times faster than the protonation in 
solution 10. This rapid decomposition of the intermediate in water highlights the need for the enzyme 
to control and stabilize it in the active site to avoid the fast side reaction. Knowles and coworkers 
showed that a loop in the enzyme closes the active site upon substrate binding and contributes 
critically to the stabilization of the enediol(ate) intermediate. The closing of this loop was shown by 
NMR studies to be the rate limiting step of the overall reaction 11. This loop closing allows the enzyme 
to bind the enediol(ate) intermediate stronger than the substrate and product and locks the phosphate 
group in a conformation disfavoring elimination. By lowering the relative free energy of the bound 
intermediate, the enzyme reduces the free energies of the two adjacent transition states, accelerating 
the overall reaction 12. High resolution crystal structures of the tightly binding reaction intermediate 
analogue phosphoglycolohydroxamate (PGH) showed that it is bound in a planar form that minimizes 
the π orbital overlap between the double bond and the bond to the β substituent (the phosphate), 
thus disfavoring β‐elimination 13‐14. Lysine 12 forms direct contacts with both the phosphate and one 
of the hydroxyl groups of the enediol(ate) in the structure and seems to force the intermediate into 
the planar conformation. Mutagenesis of the lysine into a glycine lead to a 12000 fold decrease in kcat 
of the enzyme accompanied by a 180000 fold increase of methylglyoxal formation 15. Lysine 12 is 
therefore involved in stabilizing the enediol(ate) phosphate intermediate and the transition states 
(positive contribution) as well as in destabilizing the transition state for the ‐elimination (negative 
contribution). In summary, the triosephosphate isomerase on one hand reduces the side reaction by 
lowering the activation free energies of the desired reaction and on the other hand increases the 
activation energies for side product formation. 
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Figure 1. Reaction schemes of triosephosphate isomerase (A), ribulosebisphosphate carboxylase/oxygenase (B) and 
taxadiene synthase (C). Side reactions are displayed with red arrows. GAP = glyceraldehyde‐3‐phosphate, DHAP = 
dihydroxyacetone phosphate, MG = methylglyoxal, RuBP = ribulose‐1,5‐bisphosphate, 3PG =3‐phosphoglycerate, GGPP = 
geranylgeranyl diphosphate, CM = cembrene A, V = verticillia‐3,7,12(13)‐triene, V1 
Ribulosebisphosphate carboxylase/oxygenase (RuBisCO) catalyzes the carboxylation of ribulose‐1,5‐
bisphosphate (RuBP) into two molecules of 3‐phosphoglycerate (3PG). Its proposed reaction 
mechanism proceeds through a sequence of four intermediates. Two of them are reactive enediol(ate) 
phosphate intermediates analogous to TIM. In a first step a proton is abstracted from the C3 of RuBP 
yielding a 2,3‐enediol(ate) phosphate intermediate of RuBP (b). This enolysation is readily reversible. 
A nucleophilic attack of the 2,3‐enediol(ate) from the C2 position to CO2 then forms a six carbon β‐
keto acid intermediate. The six carbon intermediate is then hydrated (it is unclear whether CO2 
addition and hydration are concerted or not 16) and cleaved into 3PG and a aci‐carbanion ((c), another 
enediol(ate) phosphate intermediate) of 3PG. The aci‐carbanion (c) is then protonated to generate the 
A
B
C
GAP DHAP
MG
pyruvate
3PG
3PG
RuBP
(a)
(c)
(b)
(d)
(e) (f) (g)
(h)
(i)(k)
GGPP
CM V
V1
taxadiene
(1)
(2)
T1
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second 3PG 17 (Figure 1B). The two enediol(ate) double bonds positioned perpendicular to each other, 
making it difficult for the enzyme to force the phosphate group into a planar conformation with both 
of them to avoid elimination. Elimination from the 2,3‐enediol(ate) phosphate intermediate of RuBP 
(b) forms a deoxypentodiulose phosphate ((d), 1‐deoxy‐D‐glycero‐2,3.pentodiulose‐5‐phosphate) side 
product, elimination from the aci‐carbanion of 3PG (c) forms pyruvate. The formation of pyruvate 
physiologically only results in the cost of one ATP (could be gained in glycolysis in the transformation 
of 3PG to pyruvate), the deoxypentodiulose phosphate (d) on the other hand is a wasteful side product. 
It is therefore not surprising that all natural RuBisCOs characterized so far produce pyruvate 
approximately every 150 carboxylations, but none of them display any deoxypentodiulose phosphate 
(d) production 14. Site‐directed mutagenesis studies identified a threonine, which forms a hydrogen 
bonds to the C1 phosphate, to be important for preventing the elimination in the 2,3‐enediol(ate) 
phosphate intermediate of RuBP (b). Mutagenesis of the threonine into a valine resulted in a 100 fold 
loss of kcat for carboxylation, but was accompanied by 13% production of the deoxypentodiulose 
phosphate side product (d). Interestingly the pyruvate production was reduced to 18% of the WT in 
this variant 14. Threonine therefore seems to stabilize the first enediol(ate) phosphate intermediate 
(b), but by doing so limiting the phosphate to rotate by the required 60‐90° to achieve a conformation 
that minimizes β‐elimination from the second enediol(ate) phosphate intermediate (c) 18. RuBisCO 
seems therefore mechanistically unable to completely avoid both elimination reactions and was 
therefore evolutionarily selected to prevent the more deleterious one. Note that the second side 
reaction of RuBisCO, the oxidation of RuBP, is not affected by this mutation. The mechanistic 
discrimination between carboxylation and oxygenation during the catalytic cycle are not discussed in 
detail here, as the underlying factors are unclear for now (for detailed discussion see the 
comprehensive reviews by Tcherkez for carboxylation 17 and oxygenation 19).  
Another interesting example for the control of reactive intermediates is the family of terpene cyclases 
20. About 60% of all known natural products are terpenoids and they are all derived from relatively 
simple pyrophosphate carrying isoprenoid chains 21. Even though terpene cyclases all use very similar 
acyclic precursors and follow a common reaction mechanism they are able to produce a huge variety 
of carbon backbones. The mechanism involves the formation of a reactive carbocation via the 
elimination of the pyrophosphate (PPi), followed by a sequence of electrophilic cycloadditions and 
rearrangements via further highly reactive carbocation intermediates 21. The multitude of chemical 
transformations in terpene cyclases utilizing these carbocation intermediates involves region‐ and 
stereospecific ring formation, deprotonations to form double bonds, quenching of the carbocation by 
water to generate alcohols and stereospecific hydride, proton, methyl and methylene migrations 22. 
The fact that the cyclized products are much more condensed than the substrates add to the 
complexity to use specific amino acid residues to stabilize formed carbocations along the reaction 
coordinate. It has been shown in multiple terpene cyclases that electrostatic effects stabilize mostly 
early stage cations and preorganization and stabilization of the substrate in a reactive conformation is 
used for late stage cations 23. An interesting example for the control of reactive intermediates in 
terpene cyclases is the taxadiene synthase (TXS) that cyclizes geranylgeranyl diphosphate (GGPP) to 
taxadiene (taxa‐4(5),11(12)‐diene) with a yield of 93.2%, but also forms 4.7% of a taxadiene isomer 
(T1, taxa‐4(20),11‐diene) and 0.8 % of verticillia‐3,7,12(13)‐triene (V) and 1.1 % of verticillia‐3,7,11(12)‐
triene (V1) (Figure 1C) 24. Considering all the possible side products this is a remarkable high yield of 
the desired taxadiene product, which is the first committed biosynthetic step towards the clinically 
important tumor therapeutic Taxol 25. Site‐directed mutagenesis in combination with molecular 
mechanic simulations have identified the function of multiple residues in the active site of TXS that 
play an essential role in guiding the reactive carbocations towards the desired taxadiene product. 
Catalysis is initiated by Mg2+‐mediated GGPP elimination, forming the first reactive carbocation (e). 
The pyrophosphate ion is retained in a hydrophilic pocket in the active site during catalysis and 
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contributes to the electrostatic stabilization of multiple intermediates. The carbocation (e) is then 
converted into the monocyclic carbocation (f). Site‐directed mutagenesis showed that Tryptophane 
753 stabilizes (f) via aromatic π‐π interaction, as all non‐aromatic replacements resulted in inactive 
enzyme variants. The introduction of histidine as a proton acceptor in that position led to the predicted 
quenching of the carbocation and formation of the monocyclic side product (‐)‐(R)‐cembrene A (CM) 
(Table 1). The carbocation (f) is then converted to (g). Valine 584 is positioned very closely to the 
positively charged carbocation. Mutations to methionine and leucine led to premature deprotonation 
and increased formation of V. In silico comparison of the WT and the valine variants showed that the 
carbocation moved closer to the PPi in the active site, which could be the cause for the premature 
deprotonation and side product formation. Precise steric positioning and stabilization of the substrate 
in an active conformation is therefore important to prevent this side reaction. From (g) there are two 
proton transfer pathways, an indirect one (1) forming first (h) and then (i) and a direct one forming (i) 
in one step. QM/MM calculations have shown that in the gas phase the indirect pathway (1) is favored 
compared to the direct one (2) (has a lower activation free energy). In the enzyme on the other hand 
the direct pathway (2) is favored over the indirect one (1) 9. This suggests that TXS might have evolved 
to avoid the indirect pathway, which forms one more intermediate and therefore increased potential 
for side reactions.  
TXS variant activity taxadiene CM V V1 T1 
TXS 100 93.2 N.D. 0.8 1.1 4.7 
W753H 51 N.D. 100 N.D. N.D. N.D. 
V584M 92 13.8 N.D. 83.4 1.4 N.D. 
V584L 92 13.8 N.D. 83.4 1.4 N.D. 
       
Table 1 Product distribution of interesting TXS variants, adapted from Schrepfer et al. 24 
Taken together these three examples show multiple mechanisms enzymes use to stabilize reactive 
intermediates and prevent the formation of undesired side products. Tight binding of the reactive 
intermediate in a conformation disfavoring the side reaction combined with the exclusion of water 
from the active site and the stabilization of the desired transition states are important mechanisms 
active in TIM. The case of RuBisCO additionally highlights an interesting trade‐off that occurs from the 
necessity to prevent multiple competing side reactions. The case of terpene cyclases shows how 
preorganization and stabilization of the substrate in a reactive conformation and electrostatic and 
steric guidance as well as the choice of reaction mechanism help to prevent side reactions. All these 
examples also show how well enzymes are able to tune chemical reactions to achieve their remarkable 
region‐ and stereoselectivity.  
 MDR and SDR superfamily 
The short‐ and medium‐chain dehydrogenase/reductase superfamilies (SDR and MDR) are the two 
biggest enzyme families that use nicotinamide adenine dinucleotides (NAD(P)H) as a cofactor. They 
are old families that appeared early in evolution and catalyze various reduction and oxidation reactions 
in all domains of life. SDRs seem to have emerged earlier than MDRs, as they show greater abundance 
and divergence as well as a less complex fold 26. Both families share similarities in their cofactor binding 
domain, the Rossmann‐fold. SDRs only contain this cofactor binding domain with some extension. 
MDRs on the other hand typically have two domains, the cofactor binding domain and a “catalytic 
domain” 26. The MDRs can then be further split up into metallo‐enzymes using zinc and zinc‐free 
families. The metallo‐enzymes are believed to originate from zinc‐free MDRs that have acquired zinc 
binding 27. The widespread occurrence in all domains of life, their functional diversity as well as their 
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importance as drug targets has made MDRs and SDRs important subjects for mechanistic studies. Out 
of these superfamilies, the reaction mechanism of the subfamily of zinc‐dependent MDRs is 
characterized in most detail. This is due to the early purification of both the yeast and horse liver 
alcohol dehydrogenase in 1935 and 1937, respectively, and the accessibility of their substrate alcohols 
28‐29. Here we study the reaction mechanism of the less well characterized enoyl‐thioester reductases 
and carboxylases, a subfamily of zinc‐independent MDRs and SDRs. 
 Enoyl-thioester reductases and carboxylases 
A subfamily of enoyl‐thioester reductases (ETR) can be found in both the SDR and MDR superfamily. 
They both catalyze the NAD(P)H‐dependent reduction of enoyl‐thioesters into acyl thioesters involving 
a hydride transfer from NAD(P)H to the β‐carbon and a proton from water or an active site proton 
donor to the α‐carbon of the enoyl‐thioester. There are however some differences in the active site 
architecture between the two families. In MDRs the pro‐(4R) hydride of NADPH is transferred to the 
re‐face of the β‐carbon 30. In SDRs on the other hand the pro‐(4S) hydride of NADPH is transferred to 
the si‐face of the β‐carbon 31. The stereochemistry of the proton donor can vary between different 
classes and both re‐ and si‐face donation can be found in either. A special case are the enoyl‐CoA 
reductase/carboxylases (ECR) that are able to use CO2 instead of a proton as the resolving electrophile 
of the reaction and add it to the re‐face of the α‐carbon 30. There are three subfamilies of ETRs in the 
MDR superfamily; (i) the ER domains of mammalian and insect fatty acid synthase multi‐enzyme 
complex (called FAS I), (ii) the ER domains of bacterial and fungal polyketide synthases and (iii) the 
stand‐alone enzymes in mitochondrial fatty acid biosynthesis (mtFAS II). Plants, apicomplexan 
protozoa (eg. P. falciparum, T. gondii) and most bacteria use SDR ETRs for fatty acid biosynthesis 32. 
This difference makes the SDR ETRs very important drug targets for specific inhibition of fatty acid 
biosynthesis and interesting objects for mechanistic studies. Another important SDR drug target is the 
human 5α‐reductase that reduces testosterone into dihydrotestosterone, thereby activating it. 
Finasteride, a mechanism‐based 5α‐reductase inhibitor that forms a covalent adduct with the NADPH 
cofactor, is used in treatment for benign prostatic hyperplasia and as a drug against male hair loss 33. 
Recent reports describe the detection of a covalent adduct between the substrate crotonyl‐CoA and 
NADPH in enoyl‐CoA reductase/carboxylase (ECR) when CO2, the resolving electrophile is omitted from 
the reaction 34. Similar covalent adducts between the substrate and the dihydropyridine ring of the 
NAD(P)H cofactor have also been reported recently in chemical model reactions 35, in the natural 
product sanguinarine 36 and in the catalytic cycle of polyketide associated enoyl‐CoA reductases of the 
MDR superfamily 37. These observations raise the question, whether these adducts are true 
intermediates in the catalytic cycles of these zinc‐free MDRs, which would suggest an alternative 
reaction mechanism for the hydride transfer from NAD(P)H to the substrate. Alternatively these 
adducts could also be part of a mechanism to stabilize the reactive enolate intermediate through this 
covalent bond and thereby preventing it to react with the wrong resolving electrophile (eg. in ECRs 
with a proton instead of CO2). In chapter 2 we investigate the detailed reaction mechanism of the 
mitochondrial ETR from C. tropicalis from the MDR superfamily and show that it forms multiple 
covalent adducts between its substrate crotonyl‐CoA and the cofactor NADPH when the resolving 
electrophile (a proton from an active site tyrosine) is removed. In chapter 3 we then show that the 
active site of Etr1p contains a conserved threonine that specifically prevents the formation of one of 
these adducts, which turned out to be a very competent inhibitor for the enzyme. In chapter 4 we take 
a detailed look at the reaction mechanism of the SDR ETR InhA from M. tuberculosis and show that this 
enzyme forms similar covalent adducts. The detection of such covalent adduct in both MDR and SDR 
superfamily ETRs calls for a careful reconsideration of the reaction mechanism of nicotinamide 
dependent oxidoreductases and in case of Etr1p highlights an interesting case of an single amino acid 
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residue in an active site, which prevents the highly reactive enolate intermediate from forming a toxic 
side product. 
 Reactive intermediates in enzyme complexes 
The high rate enhancements under mild conditions, stereo‐ and region‐specificity and the ability to 
precisely control reactive intermediates during their catalytic cycle are not the only remarkable 
features that make enzymes such proficient catalysts. Enzymes additionally face the challenge that all 
enzymes of a metabolism need to be able to work in parallel in the cytoplasm of living organisms. An 
E.coli cell for example is able to catalyze almost 2000 different reactions, contains about 1600 enzymes 
and about 2700 metabolites 38.  Diffusion is relatively fast compared to biochemical reactions, which 
leads to uniform concentration of metabolites in the cytoplasm, in particular when microbial cells are 
considered. This means that the enzymes need to be able to function efficiently in presence of most 
other metabolites of a cell. This can cause the problem of 'cross‐talk' between metabolic pathways and 
in extreme cases cause cross‐inhibition, inactivation or even irreparable damage to metabolism. 
Nature therefore has evolved several strategies to prevent free diffusion of problematic pathway 
intermediates into the bulk solvent. These strategies include i) compartmentalization and 
encapsulation of intermediates in membrane or protein delimited organelles (e.g., peroxisomes, 
bacterial microcompartments, encapsulins), ii) covalently linking of the intermediates to multi‐domain 
enzyme complexes or carrier proteins (e.g., polyketide synthases, fatty acid synthesis type I, pyruvate 
dehydrogenase complex), iii) electro‐statically guiding intermediates over charged protein surface 
from one active site to the other (e.g., dihydrofolate‐thymidylate synthase, malate dehydrogenase‐
citrate synthase complex) and iv) formation of intramolecular tunnels between two active sites (e.g., 
tryptophan synthase, carbamoyl‐phosphate synthetase)39. All these strategies ensure that the 
respective intermediates are not released into the bulk solvent, but directly transferred to the next, 
subsequent enzyme or active site; a process called substrate channeling. Besides protecting cells from 
toxic intermediates, substrate channeling can help to prevent the loss of unstable and volatile 
intermediates (e.g. loss of the indole intermediate in tryptophan synthase, which freely diffuses over 
the membrane), or to control the reaction sequence within a pathway (e.g. modifications of a growing 
polyketide chain). In the case of malate dehydrogenase the channeling of the intermediate 
oxaloacetate to the citrate synthase produces a low concentration microenvironment that helps to 
overcome the unfavorable thermodynamic equilibrium of the malate dehydrogenase reaction. This 
leads to an increase of the catalytic efficiency of the overall reaction. However, it is important to keep 
in mind that there is also a cost to benefit tradeoff for all of these mechanisms. In the case of 
compartmentalization the cost comes in form of the energy that is required to produce and maintain 
the compartment. The other three mechanisms require the stoichiometric assembly of the pathway’s 
enzymes thus limiting the overall speed to the slowest enzyme within the reaction sequence. It follows 
that pathways that organize their enzymes in stoichiometric complexes or within a compartment must 
gain a benefit from doing so to compete with freely diffusing pathways. 
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 Aims of this thesis 
The general aim of this thesis was to gain a better understanding into the mechanisms that enzymes 
use to control reactive intermediate, both inside one active site and between enzymes of a metabolic 
pathway. 
In the first part of the thesis the function of the recently discovered covalent intermediate between 
the substrate and the C2 carbon of the NADPH cofactor in ECR was studied in detail and the 
implications that this discovery has for our understanding of the reaction mechanism of NADPH 
dependent zinc‐free MDR and SDR oxidoreductases are discussed. In Chapter 2 we show that the 
mitochondrial enoyl‐thioester reductase Etr1p of C. tropicalis forms two covalent intermediates; a 
catalytically competent C2‐adduct (analogous to the above discussed ECR) and a toxic, dead‐end 
C4‐adduct, when the resolving electrophile is removed from the reaction. We then use the competent 
C2‐adduct as a chemical probe to access and engineer the second part of the reaction, the protonation, 
independent of the first part, the hydride transfer. Chapter 3 then investigates how active site residues 
in Etr1p prevent the formation of the toxic C4‐adduct by destabilizing the transition state of the side 
reaction (´negative catalysis´) and shows that this feature of negative catalysis is conserved in many 
enzymes of the MDR superfamily. In Chapter 4 we show that the C2‐adduct is also formed in InhA, an 
enoyl‐thioester reductase of the SDR superfamily, which indicates that these adducts might be more 
wide spread as previously recognized. In Chapter 5 the gained insights into the reaction mechanism of 
ETRs and especially ECRs are then used for the biosynthesis of a large library of atypical malonyl‐CoA 
derivatives. These derivatives are important tools for studying the function of polyketide synthases. 
In the second part of the thesis we investigate two systems where reactive intermediates are 
transferred between two active sites of enzymes within a pathway. In Chapter 6 we analyze the 
trifunctional fusion protein propionyl‐CoA synthase of Erythrobacter sp. NAP1 and show that the 
enzyme forms a self‐assembling, multi‐catalytic compartment to sequester the reactive intermediate 
acrylyl‐CoA. In Chapter 7 we investigate the initial steps in archaeal isoprenoid biosynthesis, the 
mevalonate pathway. We show that archaea use an enzyme complex to couple the first reaction of the 
pathway, the condensation of two molecules of acetyl‐CoA (catalyzed by an acetoacetyl‐CoA thiolase), 
to the second reaction of the pathway, the condensation of acetoacetyl‐CoA and acetyl‐CoA to HMG‐
CoA (catalyzed by an HMG‐CoA synthase). Channeling of acetoacetly‐CoA between the active site of 
the thiolase and the HMG‐CoA synthase allows archaea to overcome the thermodynamically 
unfavorable endergonic first reaction by coupling it to the exergonic second one. 
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2.  The use of ene adducts to study and engineer enoyl-thioester 
reductases 
 Abstract 
An improved understanding of enzymes’ catalytic proficiency and stereoselectivity would further 
enable applications in chemistry, biocatalysis and industrial biotechnology. We use a chemical probe 
to dissect individual catalytic steps of enoyl‐thioester reductases (Etr), validating an active site tyrosine 
as the cryptic proton donor and explaining how it had eluded definitive identification. This information 
enabled the rational redesign of Etr, yielding mutants that create products with inverted 
stereochemistry at wild‐type like turnover. 
 Introduction 
Synthetic chemistry aims at achieving high regio‐ and stereoselectivity. Enzymes are Nature's solution 
to obtain both goals with unmatched catalytic efficiency. The demand for enzymes in green chemistry, 
biocatalysis and industrial biotechnology is reflected by the efforts that are put into creating novel 
enzyme activities by rational or de novo approaches1‐2. Computational design is a powerful tool for 
designing enzyme catalysts de novo3-4. Yet, the ab initio design of cofactor‐dependent enzyme 
reactions is still an unsolved problem as it involves poorly understood reactions that depend on the 
accurate alignment of multiple reactants and active site residues. Therefore new experimental tools 
are required that allow resolving catalysis beyond current limitations. 
One of the evolutionary oldest and largest superfamilies of cofactor‐dependent enzymes is the class 
of medium chain dehydrogenase reductases (MDRs) that contains ketoreductases and enoyl‐thioester 
reductases (Etrs), which are essential in fatty acid as well as secondary metabolite biosynthesis5. Etrs 
catalyze the NAD(P)H‐dependent reduction of enoyl‐thioesters into acyl‐thioesters. This reaction 
involves addition of a hydride from NAD(P)H to the ‐carbon and a proton from an active site acid or 
water‐molecule to the ‐carbon of the enoyl‐thioester. Several crystal structures of Etrs have been 
solved. Yet, the proton donor that determines reaction stereochemistry is still cryptic because no single 
knock‐out of putative catalytic residues renders these enzymes inactive6‐11.   
The obstacle to accurately study and manipulate the role of specific active site residues in Etrs was 
recently put in a new perspective by the suggestion12 and experimental validation13 that MDR family 
members could follow an ene‐mechanism14, which involves the formation of a transient covalent, 
NADPH‐substrate adduct ('C2‐ene adduct') for the transfer of the hydride equivalent (Figure 1a). 
Besides having mechanistic implications, the observation of such C2‐ene adducts opens new options 
in experimental biochemistry. These adducts represent catalytically competent intermediates in which 
the first half of the reduction reaction i.e., the transfer of a hydride equivalent has taken place, while 
protonation has not yet. Here, we sought to use the isolated C2‐ene adduct to investigate the catalytic 
cycle of Etr1p, a well‐studied model enzyme from yeast mitochondria. This adduct is accepted by Etr1p, 
albeit with a reduced kcat and kcat/Km values compared to the natural substrates13. Despite lower 
catalytic parameters, we assume that the ene‐adduct is close to ‐ if not on ‐ the reaction coordinate, 
as other steps might become rate limiting when using the C2‐ene adduct as substrate (e.g. limited 
diffusion into the barrel shaped active site or NADPH binding related conformational changes8). 
Applying the C2‐ene‐adduct as molecular probe allowed us to resolve the catalytic cycle of Etr1p (and 
mutants) at unprecedented detail, assigning tyrosine 79 as the proton donor, and controlling the 
stereochemistry of reduction by rationally inverting the active site chemistry of the enzyme.  
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 Results 
 Identification of the cryptic proton donor in Etr1p 
Because several Etr structures are available, but none as ternary complex6‐8 we first solved the 
structure of yeast Etr1p in complex with crotonyl‐CoA and NADP+ (protein data base: 4WAS, Table S1). 
Inspection of the active site suggested a serine (S70), tyrosine (Y79), and threonine (T324) as possible 
proton donating residues (Figure 1b). These active site amino acids were individually mutated to yield 
Etr1p mutants S70V, Y79F, and T324A, which were tested for activity with the C2‐ene adduct13 of 
NADPH and crotonyl‐CoA as molecular probe. Starting the enzyme reaction with the molecular probe, 
we expected only mutations that are affected in proton transfer to be severely impaired in activity 
(Table S2). Compared to Etr1p wild type (WT), Etr1p Y79F was affected by more than two orders of 
magnitude in conversion of the C2‐ene adduct, indicating a direct role for this residue in proton 
donation. In contrast Etr1p S70V and T324A showed only minor losses in catalytic activities (Table S2), 
corresponding to a secondary role15‐16 of these active site residues in catalysis (e.g., in transition state 
stabilization by hydrogen bonding).  
 
Figure 1. Proposed reaction mechanisms of enoyl-thioester reductases. (a) The classical mechanism for enoyl‐thioester 
reductases (black arrows) assumes a direct hydride transfer from NAD(P)H onto the substrate to create an enolate 
intermediate that is subsequently protonated to yield the reaction products. The ene‐mechanism14 (blue arrows) proceeds 
through a distinct C2‐ene intermediate that was experimentally verified recently13. This intermediate is further converted to 
the consensus enolate intermediate (in brackets) and subsequently protonated. (b) Active site of Etr1p WT showing potential 
proton donors S70, Y79 and T324. 
 A dead-end product is formed by Etr1p Y79F 
In line with previous investigations using natural substrates6, 8, but nevertheless surprising was the 
observation that Etr1p Y79F still catalyzed the consumption of the molecular probe even though it 
apparently lacked a key active site residue. However, in contrast to the WT enzyme that was able to 
consume the C2‐ene adduct directly, as inferred from the rapid depletion of the molecular probe at 
max = 370 nm, Etr1p Y79F formed a species that absorbed at λmax = 328 nm, when incubated with the 
molecular probe (Figure 2a, b, Figure S1). This buildup indicated that Etr1p Y79F was not able to 
protonate the probe in the same fashion as the WT enzyme. The novel compound was purified from 
the reaction mixture and demonstrated to be a covalent C4/C‐adduct (1) of NADPH and crotonyl‐CoA 
(Figure S2 and S3). In contrast to the C2‐ene adduct that is a bona fide substrate for Etr1p WT 13, the 
isolated C4/C‐ene adduct is not converted by the WT enzyme. Instead, the C4/C‐adduct is a 
competitive inhibitor for NADPH in Etr1p WT with a Ki of 70   45 nM and as a non‐competitive inhibitor 
with respect to crotonyl‐CoA, decaying slowly in solution with a first order constant of k = 0.02490  
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0.00001 min‐1 at 31 C (Figure S4). In summary, these properties suggested that the C4/C‐adduct 
represents a dead‐end metabolite rather than a catalytic intermediate.  
 Time resolved analysis of Etr1p Y79F via NMR and stopped-flow spectroscopy 
The detection of the C4/C‐adduct in assays initiated with the molecular probe raised the question 
whether formation of this C4/C‐adduct might be also of importance for the complete catalytic cycle 
of Etr1p Y79F. Therefore, we monitored the full reaction of the mutant enzyme by 1H‐NMR, starting 
the assay with the original substrates NADPH and crotonyl‐CoA. Integration of protons specific to each 
compound showed a quick consumption of NADH (d, =5.57 ppm) and crotonyl‐CoA (t, =1.49 ppm) 
and a build‐up of the C2‐ene adduct (d, =6.25 ppm). The C2‐ene adduct was then further transformed 
into the C4/C‐adduct (t, =0.42 ppm), which subsequently decomposed slowly into the final products 
butyryl‐CoA (t, =2.18 ppm) and NADP+ (d, = 8.71 ppm) (Figure 2c,d). Stopped flow measurements 
with Etr1p Y79F on the natural substrates showed an increase in absorption between 370‐380 nm 
during the first 50 ms that matched the decrease in NADPH absorbance, confirming that only the C2‐
ene adduct is initially formed (Figure S4). Taken together the results show that Y79 is needed for direct 
conversion of the substrates to the products avoiding buildup of C4/C‐adduct. 
 
Figure 2. Identification and characterization of the proton donation deficient Etr1p Y79F mutant. (a) Scanning kinetic assay 
of Etr1p WT using the C2‐ene adduct as a molecular probe. Rapid depletion of the molecular probe is observed. (b) Scanning 
kinetic assay of Etr1p Y79F with C2‐ene adduct. Formation of a novel photoactive species (C4/C‐adduct) with an absorption 
maximum at 328 nm is observed. (c) Time course assay of Etr1p Y79F. The characteristic peaks from 1H‐NMR spectra were 
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integrated, to follow the kinetics of the substrates NADPH (dark blue) and crotonyl‐CoA (light blue), the labile C2 intermediate 
species (purple) and the C4/C‐adduct (dark red) as well as the products butyryl‐CoA (red) and NADP+ (orange). The dotted 
lines represent a fit of the data, collected for 500 min, modeled according to reactions (1)‐(4) and simulated to 1,500 min. (d) 
The proposed reaction scheme for Etr1p Y79F with all the compounds in colors corresponding to the time course experiment.  
 Using the ene adduct to screen for new proton donors with inverted stereochemistry 
With this new understanding of Y79’s role, we sought to rationally control the stereochemistry of 
protonation in Etrs. This long‐standing challenge in biocatalysis is of particular importance for Etrs that 
are responsible for determining chiral centers in polyketide biosynthesis9, 17‐19. As a proof‐of‐principle 
we aimed at re‐designing the last step of Etr1p catalysis by changing the stereochemistry of 
protonation from re- to si-face. To prevent competition for substrate protonation from the re‐face, we 
started with the Y79F mutant and sought to introduce additional residues that could serve as si‐face 
proton donor. Inspection of Etr1p´s active site suggested position 322 (see Figure 1) as good candidate 
for placing the new proton donor. When the corresponding double mutants were screened with the 
molecular probe, mutants Y79F/W322D, Y79F/W322H, and Y79F/W322K showed only unproductive 
conversion of the molecular probe into C4/C‐adduct (Figure 3a, Figure S5). In contrast, Y79F/W322E 
was able to directly consume the C2‐ene adduct like the WT enzyme suggesting this variant contained 
a competent si‐face proton donor (Figure 3b). 
 
Figure 3. Screening of Etr1p mutants for si-face proton donors using the C2-ene adduct as a molecular probe. (a) Scanning 
kinetic assay of Etr1p Y79F W322K. Formation of C4/C‐adduct shows that lysine does not serve as a proton donor. (b) 
Scanning kinetic assay of Etr1p Y79F W322E. The mutant behaves similar to Etr1p WT suggesting that the glutamate functions 
as novel proton donor. (c) Active site structure of Etr1p Y79F W322E site showing the mutated WT proton donor Y79 and the 
catalytic residue E322 with a hydrogen bond to the T324 OH‐group (yellow) that positions E322 correctly for proton donation. 
The successful engineering of a pro‐2S‐specific enoyl‐CoA reductase was confirmed by isotopic 
labeling. Etr1p Y79F/W322D incorporated a deuteron with an efficiency of 97  2% into the 2S‐position 
compared to 2  2% for the WT (for Etr1p Y79F and W322E see Table S3). The Y79F/W322E crystal 
structure (protein data base: 4W99, Table S1) showed that E322 is positioned in proximity to the 
substrate by hydrogen bonding to T324 (Figure 3c) and oriented in a fashion that allows for a stereo‐
selective si‐face proton transfer either directly or through a water molecule. The pH optimum of Etr1p 
Y79F/W322E was lower compared to Etr1p WT, most likely due to the lower pKa of the engineered si-
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glutamate compared to the re-tyrosine of the WT enzyme (Figure S6). At pH 5.0 the catalytic efficiency 
of Etr1p Y79F/W322E was 2.7  0.3·105 s‐1 M‐1, corresponding to 3.3% of the WT (Table S2). Given the 
fact that our design was solely based on the newly obtained insights into the biochemistry of Etrs and 
did not involve directed evolution, the high catalytic efficiency achieved is remarkable. 
 Discussion 
Summarizing, while our results revealed a surprising complexity of events in the Etr1p mutant reaction, 
they also provide the first real explanation for the enigmatic residual activity that has been reported 
to persist in Etr1p and other NAD(P)H‐dependent reductases in the absence of the putative proton 
donor 6, 8‐11, 20. First, and in line with an ene‐mechanism13, these enzymes are still able to catalyze the 
initial transfer of a hydride equivalent, as shown by formation of the C2‐ene adduct. However, because 
the subsequent enzymatic resolution of the C2‐ene adduct through protonation is prevented, this 
leads to the formation of an unproductive, dead‐end C4/C‐adduct which decays non‐enzymatically 
into butyryl‐CoA and NADP+. Because of overlapping spectral information of the different transient 
adducts formed, which cannot be resolved by standard UV‐Vis assays, the chemical complexity of these 
(mutagenized) enzyme reactions have gone unnoticed so far. Even more seriously, the change of 
absorbance recorded in these widely used assays has been misinterpreted as simple Michaelis‐Menten 
kinetics of the NAD(P)H chromophore, although it actually represents the sum of a complex series of 
enzymatically (and non‐enzymatically) transformations. This has masked identification of a key active 
site residue. Our molecular probing approach represents a convenient way to distinguish between slow 
productive and unproductive protonation mutants. We suggest that future mutagenesis studies on 
Etrs and possibly other NAD(P)H‐dependent enzymes should make use of a similar probing approach 
as chosen here to untangle the true catalytic events of these enzymes. Translation of our engineering 
strategy to enzymes involved in polyketide biosynthesis could lay the foundation for the (bio)synthetic 
production and directed manipulation of complex chemical compounds. 
Lastly, our results also have implications for understanding the evolution of novel enzymatic functions. 
The observation that hydride equivalent transfer and protonation can be separated by transient 
substrate‐NAD(P)H adducts, as shown here for Etr1p by molecular probing, demonstrates an implicit 
modularity of catalysis that might facilitate NAD(P)H‐dependent enzymes to diverge in both substrate‐ 
and reaction‐specificity. If novel substrates can be accommodated at the active site of enzymes that 
allow for formation of such adducts, reduction can take place through non‐enzymatic decay (for the 
proposed mechanism, see Figure S7). Evolutionary pressure could then select for variants with a better 
proton donor or completely different electophiles. Notable examples for such scenarios might be the 
evolution of 2S‐stereoselectivity in methylenoyl‐thioester reductase domains of polyketide synthases9 
and FAS I megasynthases21 from their 2R‐specific ancestors, or the emergence of the CO2‐fixation 
function in the scaffold of ordinary reductases22‐23.  
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 Methods 
 Chemicals 
Butyryl‐CoA and NADP+ and crotonic anhydride were purchased from Sigma Aldrich AG, coenzyme A 
from Roche Diagnostics. Crotonyl‐CoA and C2‐ene adduct were synthesized and purified according to 
13. All salts and solvents were of analytical grade. 
 Cloning and mutagenesis 
The gene encoding for enoyl thioester reductase (etr1p) was codon optimized for expression in 
Methylobacterium extorquens and synthesized by Eurofins MWG Operon (Ebersberg, Germany), see 
below for codon optimized sequence. An NdeI restriction site followed by an N‐terminal His10‐tag was 
added in front of the start codon and an EcoRI site after the stop codon. The synthesized gene was 
cloned into the expression vector pT7‐7 24  yielding pTE260. The plasmids carrying desired point 
mutations were generated using the QuikChange® Site‐Directed Mutagenesis Kit (Stratagene, La Jolla, 
USA) with 60 ng of template plasmid and the primers listed in Table S4. The resulting mutated plasmids 
were confirmed by sequencing (Microsynth AG, Balgach, Switzerland). Plasmids carrying the correct 
mutations were transformed into E.coli BL21(DE3) for protein expression.  
DNA sequence of Etr1p WT, His10‐tagged and codon optimized for expression in Methylobacterium 
extorquens: 
ATGGGCCACCACCATCATCACCACCATCACCACCACTCCTCGGGCCACATCGAAGGCCGGCACATGATCACGGCCCAAGCCGTCCTCTACACGCAGCATGG
CGAGCCCAAGGACGTGCTGTTCACGCAGTCCTTCGAGATCGACGACGACAACCTGGCGCCGAACGAGGTGATCGTCAAGACCCTGGGCTCGCCGGTCAAC
CCGAGCGACATCAACCAGATCCAGGGCGTCTATCCGAGCAAGCCGGCCAAGACCACCGGGTTCGGCACCACCGAGCCCGCGGCGCCGTGCGGCAACGAG
GGCCTCTTCGAGGTGATCAAGGTCGGCTCGAACGTGAGCTCGCTCGAAGCCGGGGACTGGGTGATCCCCTCGCACGTGAACTTCGGCACCTGGCGCACGC
ACGCCCTGGGGAACGACGACGACTTCATCAAGCTCCCCAATCCCGCCCAGTCGAAGGCCAATGGCAAGCCGAACGGCCTCACCATCAACCAGGGCGCCAC
CATCTCGGTCAATCCCCTGACGGCCTACCTCATGCTCACCCACTACGTCAAGCTGACGCCGGGCAAGGACTGGTTCATCCAGAACGGCGGCACCAGCGCGG
TGGGCAAGTACGCCAGCCAGATCGGCAAGCTCCTCAACTTCAACTCGATCAGCGTGATCCGCGATCGCCCGAATCTCGATGAGGTCGTCGCCTCGCTGAAG
GAGCTGGGCGCCACCCAGGTCATCACCGAGGACCAGAACAACTCGCGGGAGTTCGGCCCGACCATCAAGGAGTGGATCAAGCAGTCGGGCGGCGAAGC
GAAGCTGGCGCTGAACTGCGTGGGCGGCAAGTCGTCCACGGGGATCGCCCGCAAGCTGAACAACAACGGGCTCATGCTCACGTATGGCGGCATGAGCTT
CCAGCCGGTCACCATCCCGACCTCCCTGTACATCTTCAAGAACTTCACCTCCGCGGGCTTCTGGGTGACCGAGCTGCTCAAGAACAACAAGGAGCTCAAGA
CCTCCACGCTGAACCAGATCATCGCCTGGTATGAGGAGGGCAAGCTCACCGATGCGAAGTCGATCGAAACCCTCTACGACGGCACCAAGCCCCTCCACGA
GCTCTACCAGGATGGCGTCGCGAACTCCAAGGATGGCAAGCAGCTCATCACGTACTGA 
 Protein expression 
A single colony of E. coli BL21 (DE3) bearing the correct plasmid (Table S5) was grown over night in LB 
medium containing 100 g/ml ampicillin at 37 C. Of this overnight culture 1 ml was used to inoculate 
1 l of auto‐inducing medium 25 containing 100  g/ml ampicillin. Cells were grown for 24 h at 30 C 
under constant shaking before harvesting by centrifugation (10 min at 8000 x g, 4 C). Harvested cells 
were resuspended in 15 mL of buffer A (20 mM Tris(hydroxymethyl)aminomethane (Tris‐HCl), pH 7.8, 
200 mM KCl) containing 0.1 mg/ml of DNase I (Bovine pancreas, AppliChem) and 10% glycerol. The 
solution was sonicated 6 times for 20 s with 40 s cooling on ice in between cycles. The lysate was 
centrifuged for 1 h at 40,000 x g, 4 C. The supernatant was applied at a flow rate of 1 ml/min onto an 
equilibrated HisTrap FF (GE Healthcare, Little Chalfont, UK) and washed with 30 column volumes of 
buffer A containing 75 mM imidazole. The protein was then eluted with buffer A containing 500 mM 
imidazole, desalted with a PD‐10 desalting column (GE Healthcare, Little Chalfont, UK) and 
concentrated by ultrafiltration (Amicon® Ultra‐4 30 K centrifugal filters, Merk Millipore). For NMR 
experiments the protein was exchanged into a buffer containing 100 mM Na2HPO4 pH 7.9, 200 mM 
NaCl, stored on ice and used the same day. For crystallization the protein was stored in 20 mM TrisHCl 
pH 7.9, 100 mM NaCl at 4 C and for spectrophotometric assays the protein was stored at ‐20 C in 50 
mM Na2HPO4 pH 7.9, 100 mM NaCl with 50% glycerol. Protein concentrations were determined 
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spectrophotometrically (280 nm = 49.5 cm‐1 mM‐1). Mutations were confirmed additionally by trypsin 
digestion and subsequent peptide sequencing at the functional genomics center, Zurich 
 Spectrophotometric enzyme assays 
Assays were carried out on a Carry‐50 UV/Vis spectrometer (Agilent) at 30 C using quartz cuvettes (1‐
, 3‐, or 10‐mm path‐length; Hellma). All assays were carried out in 100 mM Na2HPO4, pH 7.9. For 
determination of the kinetic parameters starting from NADPH and crotonyl‐CoA assays contained 200 
M NADPH and were started by adding enzyme to the following end concentrations: 3.3 nM Etr1p WT, 
39 nM Etr1p S70V, 11 nM Etr1p T324A or 6.8 M Etr1p Y79F. Kinetic parameters were determined by 
varying the crotonyl‐CoA concentration and following disappearance of NADPH at 340 nm using an 
absorption coefficient of 340 nm = 6.2 cm‐1 mM‐1 and for Etr1p Y79F D340 nm = 2.5 cm‐1 mM‐1 (340 nm 
NADPH = 6.2  cm‐1 mM‐1, D 340 nm C4 = 3.7 cm‐1 mM‐1 was used. Assays for determination of kinetic 
parameters on C2‐ene adduct were started by adding varying concentrations of C2‐ene adduct and 
following its disappearance at 370 nm using an extinction coefficient of  370 nm = 6.9 cm‐1 mM‐1 13. 
The screen for protonation of C2‐ene adduct was done by monitoring the kinetics between 300 and 
500 nm adding 0.033 M Etr1p WT, 34 M Etr1p Y79F, 9.3 M Etr1p Y79F W322K, 3.4M Etr1p Y79F 
W322D or  0.62 M Etr1p Y79F W322E to start the reaction. For these assays the C2‐ene adduct was 
dissolved directly into the assay buffer immediately before the assay was started.  
For the inhibition assay C4‐adduct determined using D 340 nm C4 = 3.7 cm‐1 mM‐1  was added to an end 
concentration of 5 nM to a reaction mixture containing 125 M crotonyl‐CoA and varying 
concentrations of NADPH or to assays containing 100 M NADPH and varying the crotonyl‐CoA 
concentration. The reactions were started by adding 3.3 nM Etr1p WT. 
 Purification and characterization of C4/C -adduct 
A reaction mixture of 30 mM crotonyl‐CoA, 30 mM NADPH and 0.17 mM Etr1p Y79F in 100 mM 
Na2HPO4 (pH 7.9, 100 l) was reacted at 30 C for 1.5 h. The mixture was separated on a Waters 2690 
HPLC system on a Gemini 10 m NX‐C18 110 Å, 100 x 21.2 mm, AxiA packed column (Phenomenex) 
using a previously described elusion profile 13. The C4‐adduct was collected directly into liquid nitrogen, 
lyophilized (0.01 mbar, ‐70 C) and stored at ‐80 C. C4/C adduct was dissolved in 100 mM Na2HPO4 
buffer and its absorption spectrum was measured between 200 and 400 nm (Figure S1). The extinction 
coefficients at 328 nm and 340 nm were calculated to be 4.1  0.2 cm‐1mM‐1 and 3.7  0.2 cm‐1mM‐1 
assuming a total absorbance of 33.8 cm‐1mM‐1 at 260 nm ([260 nm NADPH + 260 nm CoA] = [16.9 cm−1 
mM−1 + 16.9 cm−1 mM−1] 26). For structural analysis by NMR the purified C4/C adduct was lyophillized 
three times. 2‐3 mg compound were dissolved in 540 l D2O buffered with 60 l > 90% deuterated 500 
mM NaH2PO4 pD 7.9. NMR spectra were acquired at 4.4 ˚C. 
 HPLC-ESI-MS analysis 
HPLC‐ESI‐MS analysis of the C4/C ‐adduct was performed exactly as described earlier for the C2‐ene 
adduct 13 
 Crystallization of Etr1p WT and Y79F/W322E 
Crystallization was performed similarly to established protocols 27. In short, first crystals were obtained 
by sitting drop vapor diffusion using 15 mg/mL enzyme in crystallization buffer mixed in a 1:1 ratio 
with reservoir solution containing 0.1 M N‐(2‐acetamido)‐2‐iminodiacetic acid (ADA)/NaOH (pH 6.3), 
2 M (NH4)2SO4, 20 mM crotonyl‐CoA and 10 mM NADP+ at 19 C.  Large crystals were obtained by 
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streak seeding 20 h after setting up crystallization plates and they reached their final size after a few 
weeks. For cryostabilisation a cryosolution containing 0.1 M ADA pH 6.3, 2.4 M (NH4)2SO4 and 25% 
glycerol was added and the crystal immediately frozen in liquid nitrogen. 
 Structural data collection and refinement 
The crystals were measured at beamline X06SA at the Swiss light source, SLS, at a wavelength of 1Å in 
a cryo stream.. The data processing was carried out using XDS 28and scaling was done with XSCALE. A 
set of randomly chosen reflections were set aside for the calculation of the free R factor (Rfree). To 
obtain initial phases molecular replacement by Phaser 29 was performed using the structure of Etr1p 
containing NADP+ (1N9G) as a search model, finding two and three monomers in the asymmetric unit 
for the double mutant and the wild type complex, respectively. The structures were refined with 
REFMAC5 30 and Phenix (wt complex) and completed in Coot 31. For the double mutant, clear difference 
density for the mutated side chains was visible. Water molecules were added and edited manually as 
well as using the water find tool in Coot with a cutoff of 1 sigma within hydrogen bonding distance to 
protein residues. A final TLS refinement step using five TLS groups per monomer as determined by the 
TLS Motion Determination Server 32 was carried out with REFMAC5 for the double mutant. Both 
structures were refined to good geometry with more than 97% of residues in the favored region of the 
Ramachandran plot in both cases as well as 0.3% outliers for the double mutant structure and no 
outliers for the wild type structure. 
 Stereo-specific incorporation of solvent protons at C by Etr1p WT and mutants 
HPLC‐ESI‐MS analysis was performed as described previously 33. For the isotope labeling experiment 
the storage buffer of Etr1p WT, Etr1p Y79F , Etr1p W322E and Etr1p Y79F W322E was exchanged by 
three subsequent ultracentrifugation steps (Amicon® Ultra‐4 30 K centrifugal filters, Merck Millipore) 
diluting the original buffer over 10,000 x with deuterated (98%) 50 mM Na2DPO4, pD 7.9. 100 l assays 
containing 210 M NADPH and 200 M crotonyl‐CoA in 100 mM NaD2PO4 buffer (pD 7.9) were started 
with 0.07 M Etr1p WT, 0.1 M Etr1p W322E, 0.5 M Etr1p Y79F W322E or 5.4 M Etr1p Y79F. The 
reactions were followed spectrophotometrically at 340 nm and run at 30 C until complete 
consumption of NADPH and decay of formed C4‐adduct, in case of Etr1p Y79F, occurred. butyryl‐CoA 
was purified from the reaction mixture using the above‐mentioned HPLC protocol, lyophilized (0.01 
mbar, ‐70 C) and dissolved in 100 l 50 mM Na2HPO4 (pH 7.9). Label incorporation was checked by 
HPLC‐ESI‐MS. The samples were then incubated for 1 h at 37 C in a reaction mixture containing 2 mM 
ferrocenium hexafluorophosphate (Sigma Aldrich), 2 M FAD (Sigma Aldrich) and 2 M H. sapiens 
SCAD (expressed and purified from SGC clone 2VIG, IMAGE:4842286, according to the provided 
protocols http://www.thesgc.org/). The reaction was quenched by adding 1 l of 50% formic acid, 
centrifuged for 3 min at 16,000 x g and the supernatant analyzed by HPLC‐ESI‐MS. 
 NMR assays and data fitting 
NMR analysis was done on a Bruker 600 MHz spectrometer at 4.4 C. For NMR reaction kinetics of 
Etr1p Y79F a previously described method was used 13. Water suppression using excitation sculpting 
was set on a 570 l mixture containing 50 mM Na2HPO4 pH 7.9, 5% D2O, 10 mM crotonyl‐CoA and 
5 mM NADPH. 30 l of a freshly purified 8.16 mg/mL Etr1p Y79F solution was added and 1H‐NMR 
spectra recorded every 3 min for 500 min. For structural characterization of isolated C4‐adduct, 5 mg 
of purified lyophilized C4‐adduct was dissolved in 600 l D2O to acquire 1H‐NMR, COSY, HSQC, NOE 
and HMBC‐spectra. Characteristic peaks of all reaction components were integrated and plotted 
against time. These data points were fitted to reactions 1‐4 of which equations 1 and 2 were fitted 
according to enzyme catalyzed Michaelis Menten models and 3 and 4 according to uncatalyzed decay. 
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The uncatalyzed decay of the C2‐ene adduct was described previously13. Fitting was performed in 
COPASI 34. 
 (1) 
  (2) 
  (3) 
  (4) 
 Stopped flow spectroscopy 
Measurements were recorded on a thermostated stopped flow unit (SX17MN, Applied Photophysics, 
Leatherhead, UK) and detected by a 32‐channel 0.2 ms photomultiplier array (Hamamatsu Photonics, 
SZK, Japan). Syringe 1 contained 100 M NADPH and 100 M crotonyl‐CoA (left out in control 
experiment) in 100 mM Na2HPO4 buffer pH 7.9 and syringe 2 contained 40 M of Etr1p Y79F in the 
same buffer at 5 C. Data was collected every 0.5 ms for 1 s and the every 5 ms for a total of 15 s 
covering a range between 300 and 420 nm. 
  
1 79 2Etr p Y Fcrotonyl CoA NADPH C ene adduct   
1 792 4 /Etr p Y FC ene adduct C C adduct  
.2 uncatC ene adduct butyryl CoA NADPH   
.4 / uncatC C adduct butyryl CoA NADPH    
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 Supplementary Information 
 
Figure S1. UV-Vis characterization of the C2-ene adduct, the C4/Cα-adduct and NADPH. Absorption spectra of NADPH, C2‐
ene adduct and the C4/Cα‐adduct. NADPH (dark blue) has a local maximum at 340 nm, C2‐ene adduct (purple) at 370 nm and 
C4/Cα‐adduct (red) at 328 nm. 
 
Figure S2. High-resolution MS analysis of the purified compound (C4/Cα-adduct) demonstrating its nature as a crotonyl-
CoA-NADPH adduct. (a) HPLC‐ESI‐MS spectra of the purified dead end product showing the [M+2H]2+ ion with its isotopic 
pattern. (b) MS2 spectrum of the parent ion at m/z 791.1244 showing fractioning into butyryl‐CoA (838), NADP+ (744) and 
NADP+ without nicotinamide (622, loss of 122). 
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Figure S3. NMR analyses of the purified compound demonstrating its C4/Cα-adduct nature. (a) 1H‐NMR spectrum, (b) DQF‐
COSY‐, (c) HSQC‐, (d,e) HMBC‐ and (f) NOE‐ spectra of the C4/Cα‐adduct. (g) C4/Cα‐adduct structure and proton numbering. 
(h) Assignment table for the C4/Cα‐adduct. 
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Position 1H-Shift 13C-Shift HMBC COSY 
     
 2.35 60.2 6*, 11.0, 20.6, 36.0, 104.1 a, b,  
a 0.98 20.6 6*, 11.0, 44*, 46*, 60.2, 68* , b,  
b 1.27 20.6 4.9*, 11.0, 12.3*, 44.9*, 60.2 , a,  
 0.42 11.0 20.6, 60.2  a, b 
2 6.61 139.0 36.0, 94.5, 100.7, 123.5, 172.5 ‐ 
3 ‐ 100.7 ‐ ‐ 
4 2.89 36.0 6*, 20.6, 60.2, 100.7, 104.1, 123.5, 
139.0, 172.5 
5 
5 4.41 104.1 36.0, 100.7, 123.5 4, 6 
6 5.74 123.5 36.0, 94.5, 104.1, 139.0 α, 5 
1"a 3.20 71.6 17.6, 20.6, 38.1, 73.5 1"b 
1"b 3.49 71.6 17.6, 20.6, 38.1, 73.5 1"a 
2" ‐ 38.1 ‐ ‐ 
3" 0.38 17.6 17.6, 38.1, 71.6, 73,5 ‐ 
4" 0.54 20.7 20.7, 38.1, 71.6, 73,5 ‐ 
5" 3.68 73.5 17.6, 20.7, 38.1, 71.6, 73,5, 174.6 ‐ 
6" ‐ 174.6 ‐ ‐ 
7" ‐ ‐ ‐ ‐ 
8" 3.11 35.2 35.2, 173.7 9" 
9" 2.08 35.2 35.2, 173.7 8" 
10" ‐ 173.7  ‐ 
11" ‐ ‐  ‐ 
12"a 2.82 38.4 28.0, 173.7 12"b, 13"a, 13"b 
12"b 2.98 38.4 28.0, 173.7 12"a, 13"a, 13"b 
13"a 2.49 28.0 38.4 12"a, 12"b, 13"b 
13"b 2.62 28.0 38.4 12"a, 12"b, 13"a 
14'' ‐ 206  ‐ 
1' 4.38 94.5 71.5, 123.5, 139.0 2' 
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Position 1H-Shift 13C-Shift HMBC COSY 
 
2' 
 
3.75 
 
71.5 
 
94.5 
 
1', 3' 
3' 3.85 70.5 65.8, 94.5 2', 4' 
4' 3.76 82.3 70.5, 94.5 3', 5' 
5'a 3.73 65.8 70.5 4' 
5'b 3.78 65.8 70.5 4' 
C1' 5.83 85.9 74.0, 139.5, 149.1, 75.7* 2''' 
C2' 4.50 74.0 85.9  1''', 3''' 
C3' 4.42 73.4 65.5, 83.8 2''', 4''' 
C4' 4.25 83.8 73.4 3''', 5''' 
     
C5' 3.90 65.5 73.4, 83.8 4''' 
     
N1' 5.85 86.0 76.6 2'''' 
N2' 4.60 76.6 74.0* 1'''', 3'''' 
N3' 4.30 70.1 86.0, 65.1 2'''', 4'''' 
N4' 4.07 82.7 64.8*, 99.8* 3'''', 5'''' 
N5a' 3.88 65.1 70.3, 73.4* 4'''' 
N5b' 3.99 65.1 70.3, 82.8, 86.8  
NA2 7.81 152.0 118.1, 133.2*, 142.0*, 148.5, 154.9  
NA4 ‐ 148.5   
NA5 ‐ 116.3   
NA6 ‐ 155.0   
NA8 8.12 152.5 118.1, 149.0, 155.1  
CA2 7.87 139.4 118.1, 148.5  
CA4 ‐ 149.0   
CA5 ‐ 116.2   
CA6 ‐ 155.2   
CA8 8.22 139.4 118.1, 149.0  
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Figure S4. Inhibition assay and uncatalyzed decay of the C4/C-adduct. Inhibition assays for Etr1p wt catalyzed reduction of crotonyl‐CoA 
with NADPH were measured in 100 mM Na2HPO4 pH 7 buffer at 31C A) Inhibition assay of C4/C‐adduct, measured at a constant crotonyl‐
CoA concentration of 128 M, shows competitive inhibition towards NADPH with a Ki of 70  45 nM. B) Inhibition assay of C4/C‐adduct, 
measured at a constant NADPH concentration of  100 M, shows non‐competent inhibition towards crotonyl‐CoA. C) Adduct decay was 
measured at 328 nm in 100 mM Na2HPO4 pH 7.9 at 31 C. The concentration of the C4/C‐adduct was calculated using an extinction 
coefficient of 4.1  0.2 cm‐1 mM‐1. The resulting decay constant of the C4/C‐adduct is 0.02490  0.00001 min‐1. Errors bars represent 
standard deviations of triplicates. Errors are given as 95% confidence intervals as determined from nonlinear fits of at least ten data points. 
D) Stopped flow measurements at 382 nm of enzyme assay with Etr1p Y79F (purple) show an initial buildup of C2‐ene adduct (note that 
the C4/C‐adduct does not show substantial absorption at 382 nm, see also Supplementary Figure 1). A control reaction without crotonyl‐
CoA is shown in black. 
 
Figure S5: Scanning kinetic screening of C2-ene adduct conversion to detect si-face proton donor enzyme variants. All 
assays were performed in 100 mM Na2HPO4 pH 8 buffer at 30 C. (a) Etr1p Y79F W322D, forms mostly C4/C‐adduct. (b) 
Etr1p Y79F W322H forms only C4/C‐adduct. 
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Figure S6. pH dependence of kcat for Etr1p WT (black) and Etr1p Y79F W322E (red). The kcat values of each mutant are fitted 
with a one proton‐donor model (fit shown in respective color) to approximate the pKa of the donating residue (Y79 for Etr1p 
WT and E322 for Etr1p Y79F W322E). The fitted values are shown below the graph. All shown data points represent Michaelis 
Menten fits of a minimum of 18 measurements. Error bars represent the standard deviation of those fits. 
 
Figure S7. Proposed mechanism for formation of C4/C-adduct. Steps in bracket take place in the active site that lacks a 
proton donor (e.g., Etr1p Y79F), protonation of the formed enolate is prevented and instead a Michael addition takes place 
between the enolate and NADP+, forming the C4/C‐adduct which can subsequently decay in solution into butyryl‐CoA and 
NADP+. 
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3. A conserved threonine prevents self-intoxication of enoyl-
thioester reductases 
 Abstract 
Enzymes are highly specific biocatalysts, yet they can perform unwanted side reactions. Here we 
investigated the factors that direct catalysis in the enoyl‐thioester reductase Etr1p. We show that a 
single conserved threonine is essential in suppressing the formation of a side product that otherwise 
acts as a high‐affinity inhibitor of the enzyme. Substitution of this threonine with isosteric valine 
increases side product formation by more than six orders of magnitude, while decreasing turnover 
frequency by only one order of magnitude. Our results show that promoting wanted reactions and 
suppressing unwanted side reactions are independently operating principles at the active site of Etr1p, 
and that the active suppression of side reactions is highly conserved in the family of medium chain 
dehydrogenases/reductases (MDR). Our discovery emphasizes that the active destabilization of 
competing transition states is an important factor during catalysis, which has implications for the 
understanding and the de novo‐design of enzymes. 
 Introduction 
Enzymes are known to be highly efficient and highly specific biocatalysts. Yet, many enzymes catalyze 
intrinsic side activities that give rise to (unwanted) side products despite sustained evolutionary 
pressure1. One prominent example is the oxygenase side reaction of ribulose‐1,5‐bisphosphate 
carboxylase/oxygenase that leads to the fixation of O2 instead of CO2, wasting up to 20% of the energy 
harvested by photosynthesis2. During glycolysis, the cytotoxic compound methylglyoxal is formed as 
side reaction of triose phosphate isomerase3‐5. Side reactions also occur in terpene synthases that react 
through highly reactive intermediates, which has raised the question, how in these enzymes the 
reaction is guided to produce preferentially the desired product against a myriad of different reaction 
outcomes6. From these examples it becomes apparent that enzyme catalysis is a balance between 
positive contributions that promote the wanted reactivity along the substrate‐to‐product reaction 
coordinate, as well as negative contributions that suppresses unwanted side reactions on the same 
reaction coordinate7‐8. Most research has focused on understanding the principles of positive catalysis, 
i.e., the active site geometry that leads to stabilization of a productive transition state. Much less, 
however, is understood about the mechanisms that protect enzymes from performing unwanted side 
reactions, which have been termed ‘negative catalysis’7.  
An interesting example with which to investigate these principles are nicotinamide (NAD(P)H)‐
dependent reductases that are among the most abundant enzymes in biology (16% of all BRENDA 
entries are NAD(P)H‐dependent enzymes)9. NAD(P)H‐dependent reductases serve in essential cellular 
processes, such as energy conservation and fatty acid metabolism10‐11. They are important drug targets 
(e.g., in tuberculosis treatment and hypercholesterolemia therapy12‐13, and they are increasingly used 
in biocatalysis and biotechnology14‐15. For more than half a century, NAD(P)H‐dependent reductases 
have been the prime study objects for understanding, inhibiting and engineering cofactor‐dependent 
enzyme catalysis. Only recently, however, has it been realized that mutagenesis can perturb the 
catalytic cycle of NAD(P)H‐dependent reductases and lead to the accumulation of catalytic 
intermediates and side products9, 16.  
Mitochondrial enoyl‐thioester reductase Etr1p from Candida tropicalis17-18 catalyzes the reduction of 
enoyl‐CoAs during fatty acid biosynthesis (Figure 1a, 1b). Mutation of the active site proton donor, 
tyrosine 79, to phenylalanine leads to build‐up of several covalent adducts between NADPH and the 
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enoyl‐thioester substrate crotonyl‐CoA16 (Figure 1c, 1d). When the Y79F variant is incubated with 
crotonyl‐CoA and NADPH a covalent adduct between the C2‐carbon of NADPH and the C‐carbon of 
crotonyl‐CoA, a “C2‐ene adduct”, is formed. Note that the purified C2‐ene adduct is catalytically 
competent for the wild type (WT) Etr1p reaction. Etr1p WT effectively converts and protonates the C2‐
ene adduct, indicating that this adduct lies on (or near to) the reaction coordinate (Figure 1b, 1d)9. In 
the Y79F variant, however, that is impaired in protonation, the C2‐ene adduct is further converted into 
another covalent adduct between the C4 carbon of NADPH and the C‐carbon of crotonyl‐CoA, “C4‐
adduct”16. In contrast to the C2‐ene adduct, the C4‐adduct acts as competitive inhibitor of Etr1p WT 
with nanomolar affinity, indicating that it is a dead‐end product of the mutated enzyme reaction 
(Figure 1d). Thus, Etr1p (and putatively other reductases) must have evolved mechanisms to funnel 
the reaction towards product formation while suppressing formation of the inhibitory C4‐adduct.  
 
Figure 1. Reaction schemes of Etr1p WT and variants and their effect on a hypothetical catalytic landscape. a) Reaction 
scheme of Etr1p WT that catalyzes the NADPH‐dependent conversion of crotonyl‐CoA into butyryl‐CoA. b) Hypothetical 
landscape of Etr1p WT catalysis. c) Reaction scheme of Etr1p Y79F that converts crotonyl‐CoA with NADPH to the C2‐ene 
adduct and subsequently to the C4‐adduct. The C4‐adduct is a strong inhibitor of Etr1p (red line) and decays slowly in solution 
(dotted blue lines). d) Hypothetical landscape of Etr1p Y79F catalysis. Mutation of the proton donor Y79F raises the energetic 
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barrier of the protonation step, causing formation of the C4‐ene adduct. e) Reaction scheme of Etr1p T175V that also 
catalyzes formation of a C4‐ene adduct from crotonyl‐CoA with NADPH. f) Hypothetical landscape of Etr1p T175V catalysis. 
Mutation of T175 lowers the energetic barrier to form the C4‐adduct leading to C4‐adduct accumulation and self‐intoxication 
of the enzyme even though the protonation step in the T175V is still functional. Abbreviations used: S, substrates; P, products; 
C2, C2‐ene adduct; C4, C4‐adduct.  
Here, we show that the large family of MDRs feature a highly conserved threonine residue that almost 
exclusively serves in suppressing formation of the inhibitory C4‐adduct in Etr1p. We demonstrate that 
the single hydroxyl group of the conserved threonine is essential to maintain a remarkably high 
suppression of side reactions but has only marginal effects on the catalytic rate of Etr1p (Figure 1e, 1f). 
This provides evidence that promoting catalysis and suppressing side reactions can be independently, 
co‐existing functions at the active site of enzymes. Notably, the threonine residue is more conserved 
in the MDR enzyme family than residues promoting catalysis, indicating a strong evolutionary pressure 
on side‐reaction suppression in these enzymes. Taken together, our results suggest that the active 
destabilization of competing transition states, commonly termed as ‘negative catalysis’, is fundamental 
to enzyme catalysis and serves as complementary force to transition state stabilization. 
 Results 
 A remote T175 contributes to catalysis 
To understand which residues contribute to the productive resolution of the C2‐ene adduct (positive 
catalysis) and which prevent formation of C4‐adduct (‘negative catalysis’), we combined site directed 
mutagenesis of Etr1p with kinetic isotope effect (KIE) profiling. Our previous studies showed that 
hydride transfer and protonation become uncoupled when the active site of Etr1p is mutated16. This 
uncoupling of NAD(P)H consumption and proton transfer makes classical spectrophotometric assays 
not suited to measure protonation KIEs in Etr1p, and likely in other reductases. For that reason, we 
established a mass spectrometry based assay that is able to measure the intramolecular KIE on 
protonation, similar to earlier work by Northrop and coworkers19. The assay quantifies the 
incorporation ratios of hydrogen versus deuterium from the solvent into the products, which is given 
as a Dkobs (refer to 3.5 Methods for details).  
Enzyme/reaction Dkobs (NADPH/NADPD)(kcat) (NADPH/NADPD)(kcat/Km) 
WT 1.78 ± 0.08 4.3 ± 0.2 1.94 ± 0.95 
S70A 1.11 ± 0.07 4.2 ± 0.2 1.1 ± 0.5 
T324A 1.92 ± 0.15 3.6 ± 0.1 1.1 ± 0.3 
S70A T324A 1.20 ± 0.08 n.d. n.d. 
Y79F  4.8 ± 0.8 n.d. n.d. 
T175V 4.4 ± 0.8 0.96 ± 0.04 2.0 ± 0.7 
C2‐ene adduct decay 4.5 ± 0.2 n.a. n.a. 
C4‐adduct decay  4.4 ± 0.2 n.a. n.a. 
 
Table 1 Observed kinetic isotope effects in Etr1p and variants as measured by incorporation ratios of H/D from buffers with 
defined H/D ratios, Dkobs, (NADPH/NADPD)(kcat) and (NADPH/NADPD)(kcat/Km) were measured in a non‐competitive fashion, for assay 
details see Methods 3.5.10. All values represents averages of two independent values, based on at least four data points 
each. Errors given as 95% confidence intervals. Abbreviations: n.d.= not determined, n.a.= not applicable. 
With this method we systematically assessed the intramolecular KIE of different Etr1p active site 
variants on protonation (Table 1). In a T175V variant, we measured a large intramolecular KIE on 
protonation (Dkobs = 4.8 ± 0.8) compared to the WT (1.8 ± 0.1). This result was surprising considering 
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that T175 is located more than 6 Å away from the C of crotonyl‐CoA and almost 9 Å away from the 
Y79 hydroxyl group, the proton donor in Etr1p (Figure S1). The finding was even more surprising given 
that S70 and T324 which are in close proximity to Y79 did not show a strong KIE on protonation upon 
mutation (Table 1) raising the question how such a remote residue like T175 can affect the protonation 
step. At the same time, the T175V variant also appeared to be affected in hydride transfer. Compared 
to the WT, the apparent (NADPH/NADPD)kcat was reduced from 4.3 ± 0.2 in the WT to 0.96 ± 0.04. Reduction 
of the KIE on hydride transfer to unity in the T175V variant was also remarkable, considering the close 
proximity of the ‐OH of T175 to the C4 position of the NADPH‐nicotinamide ring. In summary, KIE 
profiling indicated an essential contribution of T175 to catalysis, although the exact role of this active 
site residue remained unclear. 
 T175 is not essential to catalysis 
Spectrophotometric characterization of T175V with crotonyl‐CoA and NADPH showed a consumption 
of several equivalents of NADPH compared to enzyme during manual mixing time. This very fast initial 
decrease of NADPH was followed by a slow phase with apparent kinetic parameters of kcat = 0.082 ± 
0.005 s‐1 and a Km NADPH of 2.7 ± 0.8 M, which corresponded to approximately 0.05 % of WT activity. 
We investigated this unusual NADPH consumption behavior in more detail by stopped flow UV‐Vis 
spectroscopy. In the burst phase, the initial turnover of T175V was 12 ± 1 s‐1 at 30 °C, which was 150‐
fold higher than under steady state conditions, corresponding to 4 % of WT activity under the same 
conditions (Figure 2a). The burst amplitude was directly proportional to the amount of enzyme 
(Figure S2) and lasted more than 3 turnovers, indicating that the biphasic behavior was not caused by 
slow conformational changes of Etr1p T175V or slow product release. Because the initial turnover 
frequency of T175V was only reduced by one order of magnitude compared to the WT, we concluded 
that T175 affected the energetics on the substrate‐to‐product reaction coordinate but was not 
essential to catalysis.  
 T175 controls the correct outcome of catalysis 
Because results above excluded an essential role of T175 in promoting catalysis, we speculated that 
the residue might function in funneling intermediates along the reaction coordinate, suppressing the 
formation of deleterious side products, such as the inhibitory C4‐adduct (Figure 1e, 1f). We thus 
devised experiments to detect whether the C4‐adduct was indeed formed in the T175V variant during 
catalysis. We used UPLC‐MS to screen for C4‐adduct formation under steady state conditions. The 
T175V variant accumulated C4‐adduct at an adduct to enzyme ratio of 1.25 ± 0.07 (Figure 2b). C4‐
adduct formation was independently confirmed by UV‐Vis difference scanning (Figure S3). Notably, we 
could not detect any C4‐adduct formation in the WT with either method, even not in a reaction with 
40 mM NADPH, 40 mM crotonyl‐CoA, and 15 M WT (Figure 2b). At a detection limit of 24 nM for the 
C4‐adduct with the UPLC‐MS method (defined as detection of the target ion and isotopic pattern in 5 
consecutive spectra), WT forms the C4‐adduct in less than one in 1.7·106 turnovers. In other words, 
whereas the WT did not show detectable deviations from the substrate‐to‐product reaction 
coordinate, almost every third reaction fell off this reaction coordinate in the T175V variant. 
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Figure 2. Detailed characterization of the reactions catalyzed by Etr1p WT and variants. The experiments show that T175V 
is still active but intoxicates itself rapidly by formation of the C4‐adduct. a) Stopped flow kinetics of Etr1p WT (green), the 
proton donor mutant Y79F (orange) and the T175V variant (purple). T175V shows a two phasic behavior. An initial burst‐
phase followed by a slow linear phase (see close up). The burst phase lasted over 3 turnovers. All assays contained 2.5 M 
enzyme, 160 M NADPH and 120 M crotonyl‐CoA in 20 mM Tris‐HCl buffer (pH 7.9) with 150 mM NaCl. Data shown are 
representatives of at least three independent experiments. b) UPLC‐MS analysis of assays with either Etr1p WT (green) or the 
T175V variant (purple). The T175V variant shows accumulation of a C4‐adduct (compare to authentic C4‐adduct standard, 
orange trace), while the Etr1p WT did not accumulate detectable amounts of the C4‐adduct. Data shown are representatives 
of at least three independent experiments. 
To confirm that the observed effects were not due to changes in the secondary or tertiary structure of 
the variant, we investigated its folding state by circular dichroism (CD). The CD spectrum of T175V was 
practically superimposable with the WT and all other enzyme variants created in this study, confirming 
a correct folding state (Figure S4). To test whether cofactor binding was altered in the T175V variant, 
we determined the binding affinities of NADPH by isothermal titration calorimetry. T175V showed a 
binding constant of 1.6 ± 0.5 ·105 M‐1 for NADPH, which was comparable to the WT enzyme 
(3.8 ± 1.0 ·105 M‐1), and all other variants tested albeit with slower binding kinetics. From these 
experiments, we concluded that the T175V variant was unaltered in its biophysical properties, and that 
the observed loss of catalytic control was indeed caused by an altered catalytic behavior. 
 Structural basis for the loss of catalytic control in T175V 
To understand the structural base for the loss of catalytic control in T175V compared to WT we 
crystallized T175V. The structure confirmed a correct folding of the enzyme. The active site including 
the water network of apo‐WT (PDB: 4W99 at 2.0 Å) and T175V (PDB: 5LB9 at 2.1 Å monoclinic crystals 
and 5LBX at 2.5 Å trigonal crystals) were superimposable with a root‐mean‐square deviation of 0.44 Å 
for all Cα atoms. There was one notable exception. A water molecule in direct contact with T175 was 
shifted by 1 Å in the T175V variant compared to the WT (Figure S5). We note that in contrast to earlier 
assumptions20‐21, this specific change in the water network did not cause a collapse of the apoenzyme’s 
active site.  
The tertiary complex of T175V occupied by NADP+ and crotonyl‐CoA also showed a WT‐like active site 
geometry with a root‐mean‐square deviation of 0.49 Å for all Cα atoms compared to tertiary WT 
complex (PDB: 4WAS). The small movement of the water molecule observed in the apo‐form of T175V 
translated to a tilt of the nicotinamide ring by 17.5° in the tertiary complex of T175V compared to the 
WT (Figure 3, Figure S6 and S7). This tilt was observed in monoclinic and trigonal crystals of T175V 
(Figure S8), ruling out a crystal packing artifact. The tilt of the nicotinamide caused a 1 Å shift of the 
nicotinamide‐C4 towards the C of crotonyl‐CoA in T175V. This small difference seems to form the 
basis for the remarkable loss of discrimination against C4‐adduct formation in the T175V variant by 
more than 106 compared to the WT. 
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Figure 3. Crystal structure of Etr1p WT and the T175V variant. Overlay of crystal structures of Etr1p WT and the T175V 
variant, co‐crystallized with NADP+ and soaked with crotonyl‐CoA. The structures superimpose with a rmsd of 0.45 Å. The 
only notable difference near the active site is a slight shift in the nicotinamide ring of NADP+. 
 Catalytic control is highly conserved in the MDR family 
Interestingly, C4‐adducts are already known to be potent inhibitors of NAD(P)H‐dependent enzymes. 
A C4‐adduct of lactate and NAD+ was reported to inhibit lactate dehydrogenase22 , the C4‐adduct of 
NAD+ and 3‐pentanone was described to act as inhibitor of Drosophilla melanogaster alcohol 
dehydrogenase23, and the C4‐adduct of finasteride (a steroid analog) and NADH inhibits human 5‐
reductase, which is used to treat benign prostatic hyperplasia and male pattern baldness24. This 
inhibitory potential of C4‐adducts postulates a strong evolutionary driving force to suppress their 
formation of during catalysis, which is reflected in the fact that T175V is one of the most conserved 
residues in the MDR superfamily (Figure S9).  
Moreover, the high grade of conservation of T175 in the MDR superfamily suggests that suppressing 
off‐pathways on the substrate‐to‐product reaction coordinate seems to be a stronger evolutionary 
constraint than lowering the energetics of the reaction coordinate itself. While the electrophilic donor 
in different members of the MDR superfamily can be 1) a proton donor, such as tyrosine (Etr1p), lysine 
or aspartate (human FAS25 and polyketide synthase enoyl‐reductase domains9, 26), 2) a CO2 co‐substrate 
(Ccr)27‐28, or 3) might even lack an active site electrophile (LovC)29, a homologue of T175 is strongly 
conserved in all these enzymes. This indicates that the role of T175 in preventing C4‐adduct formation 
is essential across the entire MDR enzyme family. We tested this hypothesis by introducing an 
analogous T195V mutation into crotonyl‐CoA carboxylase/reductase (Ccr), a CO2‐fixing member of the 
MDR superfamily30. This also resulted in the formation of the C4‐adduct during catalysis (Figure S10).  
We noted that the C4‐adduct is a diffusible compound that once formed is not limited to self‐intoxicate 
the enzyme that formed it, but could also inhibit other enzymes with overlapping substrate 
specificities. Such postulated cross‐inhibition would have direct implications for the evolutionary 
pressure to avoid C4‐adduct formation could act beyond the individual enzyme level. We tested this 
hypothesis with two different members of the MDR superfamily that catalyze completely different 
reactions, the enoyl‐CoA reductase Etr1p, and above mentioned reductive enoyl‐CoA carboxylase 
Ccr30. Etr1p WT was practically inactive in reactions mixtures of Ccr T195V with NADPH and crotonyl‐
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CoA indicating an effective cross inhibition between the two enzymes (Figure 4). This finding strongly 
suggests that guiding substrates effectively along the reaction coordinate by suppressing deleterious 
side reactions is a complementary evolutionary force to transition‐state‐stabilization, which is as 
fundamental to enzyme evolution as the latter one. 
 
Figure 4. Cross-inhibition between Et1p WT and CCR T195V a) CCR WT (1.7 M) was added (after 40 s) to a reaction assay 
containing NADPH and crotonyl‐CoA that was monitored at 340 nm (green trace). After 90 s, Etr1p WT was injected into the 
mixture, leading to the rapid depletion of NADPH. In an equivalent assay, in which CCR T195V was used instead of CCR WT 
(purple trace), addition of Etr1p did not cause NADPH consumption, indicating that Etr1p was inhibited. Data shown are 
representatives of at least three independent experiments. b) Model explaining the observed cross‐inhibition. CCR T195V 
forms the C4‐adduct during catalysis, which leads to a rapid "self‐intoxication" of the enzyme. The C4‐adduct is also able to 
diffuse into other enzyme active sites, to effectively inhibit these enzymes, too. Selection for avoiding C4‐adduct formation 
in NAD(P)H‐dependent enzymes thus acts beyond individual enzyme level. 
 Discussion 
Previous publications on enzymes from the MDR family speculated that T175 might be important for 
puckering of the nicotinamide ring during catalysis20. Here, we provide a surprising alternative 
explanation according to which this residue has specifically evolved to protect Etr1p and other 
NAD(P)H‐dependent reductases from intoxication through formation of a deleterious side product of 
the enzymatic reaction. T175 does not promote catalysis, but serves almost exclusively in controlling 
the catalytic outcome of the enzyme reaction. This is reflected by the fact that the turnover frequency 
of T175V remains essentially unchanged, while the error rate of the reaction is increased by more than 
six orders of magnitude in the same variant. The reason for this dramatic loss of catalytic control 
apparently lies in surprisingly subtle changes in the geometry structure of the active site. Our results 
indicate that the hydroxyl group of T175 alone is responsible for guiding the enzyme reaction with high 
precision. To our knowledge there is no current example – and now simple explanation – how a single 
hydroxyl group could have such a strong effect on the catalytic outcome of a reaction. 
On a more general note, our results demonstrate that the active site of enzymes can feature catalytic 
residues of distinct functionality. Residues such as Y79 that promote catalysis, and residues such as 
T175 that control the catalytic outcome of a given enzyme by actively suppressing unwanted side 
reactions. Although the existence of active site residues that guide enzyme reactions has been 
proposed more than 25 years ago7, the discovery that T175 almost exclusively serves such a function 
is – to our knowledge – the first direct experimental evidence of this hypothesis.  
Our finding that residues promoting enzyme reactions (positive catalysis) and residues directing 
enzyme reactions (‘negative catalysis’) can function independent from each other at the active site 
challenges the common understanding of enzyme catalysis, according to which these two traits are 
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inherently linked with each other. For coenzyme B12‐dependent methylmalonyl‐CoA mutase it was 
shown that an arginine is essential in suppressing an inactivating side reaction31. However, mutation 
of this arginine also affected kcat by a factor of 104. Another example are pyridoxal phosphate (PLP) 
dependent enzymes, which catalyze very different reactions that all originate from a common reaction 
intermediate. It is generally assumed that reaction selectivity in these enzymes is maintained through 
promoting catalysis by stabilization of the favored transition state and/or destabilization of the ground 
state of the favored reaction intermediates32‐33.  
In contrast, our results suggest that binding and promoting productive transition states during catalysis 
is not necessarily sufficient when close, competing transition states can lead to deleterious side 
products. It seems almost a logical consequence that in such cases side reactions need to be actively 
suppressed by the destabilization of competing transition states to give rise to a proficient enzyme. In 
this light, the function of active site residues that are conserved but not known to be essential for 
catalysis so far might require a closer (re‐)inspection. An example are histidine 257 and phenylalanine 
200 in human purine nucleoside phosphorylase. Mutation of these residues to glycine affects catalytic 
activity by 20‐ to 40‐fold, but increase an N3‐inosine isomerization side‐reaction by at least 125‐ to 
250‐fold over the level of detection, indicating a potential role in ‘negative catalysis’ for these 
residues34. However, even for active site residues that are apparently essential for catalysis, it remains 
to be tested, whether they confer a positive catalytic function or if they prevent accumulation of 
inhibitory side‐products like in case of Etr1p.  
Taken together, our results emphasize that enzyme catalysis needs to be understood as combination 
of positive and negative constraints on the substrate‐to‐product reaction coordinate. We expect that 
these findings will (i) lead to a reinvestigation of the principles operating during enzymatic catalysis, 
(ii) clarify the role of many conserved active site residues for which no apparent function could be 
assigned, so far, and (iii) be of high relevance for rational enzyme design. Similar to the concept of 
‘negative design’ already used in the de novo design of proteins31, including ‘negative catalysis’ 
elements as a basic design constraint could pave the way to new efficient and precise catalysts in 
biology and chemistry. 
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 Methods 
 Chemicals 
NADP+ and NADPH (as sodium salts) were purchased from Roth AG, crotonic anhydride were 
purchased from Sigma Aldrich AG, coenzyme A from Roche Diagnostics. Crotonyl‐CoA and C2‐ene 
adduct were synthesized and purified as reported earlier8. All salts and solvents were of analytical 
grade. 
 (4R)-[4-2H1]NADPH synthesis 
(4R)‐[4‐2H1]NADPH was synthesized according to previously published protocols28. Synthesis products 
were confirmed by analytical HPLC and comparison to analytical standards of NADPH. The deuterium 
incorporation into (4R)‐[4‐2H1]NADPH was confirmed to be >95% by mass spectrometry. (4R)‐[4‐
2H1]NADPH was dissolved in 0.5 mM NaOH (aq) after lyophilization and stored at ‐80 °C until it was 
used. 
 Cloning and mutagenesis 
The plasmid containing Etr1p WT and Ccr were constructed in previous studies. Plasmids carrying 
desired point mutations were generated using the QuikChange® Site‐Directed Mutagenesis with 60 ng 
of template plasmid, Phusion® DNA polymerase (Thermo Scientific™) and the primers listed in Table 
S1. The resulting mutated plasmids were confirmed by sequencing (Eurofins AG, Germany). Plasmids 
carrying the correct mutations were transformed into E.coli BL21(DE3) (Invitrogen™) for protein 
expression. 
 Protein expression and purification 
Etr1p and variants were expressed according to previously described protocols9 and desalted into 150 
mM NaCl, 20 mM TrisHCl at pH 7.9 (at room temperature) unless otherwise stated. Ccr Wt and T195V 
was expressed according to previously described methods9 and desalted into the same buffer as Etr1p 
and variants. Protein concentrations were determined with a Thermo Scientific™ NanoDrop 2000 and 
extinction coefficients calculated with the ExPASy server (PMID: 10027275). 
 Stopped flow spectroscopy 
Measurements were recorded on a thermo‐stated stopped flow unit (SFM‐20 connected to a MOS‐
200, equipped with a Xe(Hg)‐lamp and a TC‐100/10 cuvette, Bio‐Logic Science Instruments SAS, Claix, 
France) set to 30 C. Syringe 1 contained 320 M NADPH and 240 M crotonyl‐CoA in 20 mM Tris‐HCl, 
150 mM NaCl buffer pH 7.9 and syringe 2 contained 5.0 M of Etr1p WT or T175V in the same buffer. 
Data were collected at 340 nm every 1 ms for the first 0.3 s, every 500 ms till 10 s and every 1 s up to 
a total of 600 s. To estimate initial turnover rates of Etr1p and its variants, the quasi‐linear phase of 
the curve in the first 10 ms was fitted with linear regression to give a lower estimate for the initial rate 
constant. 
 Mass spectrometry 
Kinetic isotope effects on protonation were measured with ultra‐performance liquid chromatography‐
high resolution heated electrospray ionization mass spectrometry (UPLC HR HESI‐MS) analysis a Q‐
Exactive Plus™ mass spectrometer (ThermoFisher Scientiﬁc, San Jose, CA, USA) connected to a 
Ultimate 3000 (Dionex, Sunnyvale, CA, USA) UPLC system. 
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 Isothermal calorimetry 
Proteins were purified as described above and concentrated to about 100 M (±10 M). The final 
concentration was determined in quadruplicate as described above and this value was used for further 
calculations. The ITC cell of a VP‐ITC (GE Healthcare) was loaded with 220 l of a degassed protein 
solution and the syringe was filled with a 1.5 mM degassed NADPH solution (the concentration was 
determined by the absorption at 340 nm with a Thermo Scientific™ NanoDrop 2000 using 340 nm NADPH 
= 6.2 cm‐1 mM‐1) in the same buffer (150 mM NaCl, 20 mM TrisHCl at pH 7.9). The titration was spread 
over 20 injections with one initial dummy injection. The values association constants were determined 
in duplicate. 
 KIE on protonation 
Reactions for the measurement of kinetic isotope effect on protonation in Etr1p WT and variants 
contained 100 mM Na2HPO4 (pH 7.9), 0.25 mM NADPH, 1.25 M crotonyl‐CoA, and a variable amount 
of D2O to give the desired percentage of D2O, between 7 and 80 %. The enzyme was equilibrated with 
the deuterated buffer for at least 120 min (to allow for hydrogen exchange with the buffer) before the 
addition of the last substrate, crotonyl‐CoA, from a stock solution of 187.5 M (to a final volume of 
150 L). Variant enzymes were added at 125 nM and the WT at 25 nM final concentration. Reactions 
were incubated at room temperature for 1 hour before diluting 10 times with 25 mM ammonium 
formate with 2% MeOH (pH 3.5) prior to analysis. Samples were analyzed with ultra‐performance liquid 
chromatography‐high resolution heated electrospray ionization mass spectrometry (UPLC HR HESI‐
MS) analysis on a Q‐Exactive Plus™ mass spectrometer (ThermoFisher Scientiﬁc™, San Jose, CA, USA) 
connected to a Ultimate 3000 (Dionex™, Sunnyvale, CA, USA) UPLC system. Chromatographic 
separation prior to mass analysis was done with a Kinetex® 1,7 m XB C‐18 100 Å, 50 x 2.1 mm column 
(Phenomenex®, Torrance, CA, USA ). Injection volume was 5 L. Reaction products were separated 
using a mobile phase system comprised of  25 mM ammonium formate pH 8.1 (A) and methanol (B). 
Chromatographic separation was carried out using the following gradient condition at a flow rate of  
0.55 mL min‐1: 0 min, 5%; 1.5 min, 5%; 6.5 min, 95%; 7.5 min, 95%; 7.7 min, 5%; 10.5 min 5%. The 
[butyryl‐CoA + H]+ mother ion was isolated (840 ± 3.5 m/z) and fragmented with argon at 25 eV. The 
isotopic pattern on the [butyryl‐pantothenate + H]+ fragment‐ion (331.150 m/z) was measured to 
determine the deuterium incorporation content. 
The kinetic isotope effect on protonation, Dkobs, was determined by fitting the dependence of the ratio 
of product, butyryl‐CoA, with an incorporated deuterium (        ) to product with an incorporated 
hydrogen (        ) versus the ratio of  D2O (fD2O) to H2O (1‐fD2O) in the buffer with the following 
equation: 
        
        
=      ∙
    
      
    
The         /         ratio was calculated by comparing the isotopologue distributions of different 
samples against a sample with a natural abundance isotopologue distribution as reference. The 
        /        	ratio of a sample was the calculated with the following equation from the 
integrated traces of the specific ions: 
        
        
=
[  + 1] − [  + 0] ∙ (
[  + 1]
[  + 0]
)
[  + 0]
 
[M+0] and [M+1] represent the integrals of the [M+0] and [M+1] peaks and ([M+1]/[M+0]) reference 
represents the ratio of [M+0]/[M+1] in the reference sample with a natural abundance isotopologue 
distribution. All data was analyzed with idms_quan‐0.0.9‐py2‐none‐any.whl package 
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(www.emzed.ethz.ch) that was especially developed to standardize and automatize the data analysis 
of kinetic isotope data with EmZed32 using the equations specified above. Measurements were 
performed in duplicate.  
 Detection of C4-adduct 
To a reaction mixture of 1 l 500 mM Na2HPO4 (pH 7.9), 1 l 200 mM NADPH and 1 l 200 mM crotonyl‐
CoA; 1 l 60 M (3.7 · 10‐4 equivalents) of Etr1p WT or T175V (in 150 mM NaCl, 20 mM TrisHCl pH 7.9) 
was added. The assays for Ccr WT and Ccr T195V contained 1 µl of 30 mM enzyme, 1 µl 60 µM crotonic 
anhydrase and additionally 1µL of 200 mM KHCO3. The assay was reacted for 2 minutes on ice before 
being quenched with 4 l acetonitrile and immediately injected for analysis. 
The calibration curve for the C4‐adduct was made with a dilution series made with pure C4‐adduct 
isolated as previously described16. A stock of 12 M of C4‐adduct was made by dissolving the 
lyophilized C4‐adduct into 100 mM Na2HPO4 (pH 7.9). This stock was diluted to 3.0 M, 0.60 M, 0.125 
M and 0.025 M and dilutions were kept on liquid nitrogen till between diluting and injecting into 
the UPLC‐MS. C4‐adduct eluted at 3.1 min with the employed gradient (see below). The extracted ion 
chromatogram of m/z = 791.123 ± 0.005 (calc. mass m/z =791.1235, the mass difference of 1ppm is 
within the mass accuracy of the MS) was smoothed with the default algorithm (Gaussian) of 
MassHunter Qualitative Analysis software (Agilent Technologies Inc. Santa Clara, CA, USA).   
Samples were measured on a 6550 iFunnel Q‐TOF mass spectrometer (Agilent Technologies Inc. Santa 
Clara, CA, USA) equipped with an electrospray ionization source set to positive ionization mode 
through a 1290 Infinity UPLC (Agilent Technologies Inc. Santa Clara, CA, USA). Chromatographic 
separation was carried out on a RP‐18 column (50 mm x 2.1 mm, particle size 1.7 µm, Kinetex XB‐C18, 
Phenomenex) using a mobile phase system comprised of 50 mM ammonium formate pH 8.1 (A) and 
methanol (B) with following gradient at a flow rate of 250 µl/min: 0 min 0% B; 1 min 0% B, 6 min 80% 
B; 8 min 80% B; 8.5 min 0 %B.  
Capillary voltage was set at 3.5 kV and nitrogen gas was used as nebulizing (20 psig), drying (13 l/min, 
225 °C) and sheath gas (12 l/min, 350°C). MS data were acquired with a scan range of 500‐1200 m/z.  
Targeted MS/MS was carried out on 791 m/z (z=2) with an isolation width of approximately 4 m/z and 
a collision energy of 20 eV with an acquisition time of 1000 ms/spectrum.   
LC‐MS and LC‐MS/MS data were analyzed using MassHunter Qualitative Analysis software (Agilent 
Technologies).  
 Spectrophotometric enzyme assays 
Assays were carried out on a Carry‐60 UV/Vis spectrometer (Agilent Technologies Inc. Santa Clara, CA, 
USA) at 30 C using quartz cuvettes (10‐mm path‐length; Hellma® (Germany)). All assays were carried 
out in 100 mM Na2HPO4, pH 7.9. For determination of the kinetic parameters starting from NADPH and 
crotonyl‐CoA assays contained 200 M crotonyl‐CoA and were started by adding enzyme to the 
following end concentrations: 3 nM Etr1p WT, 5 nM Etr1p S70A, 5 nM Etr1p T324A, 10 nM Etr1p S70A 
T324A, 6.8 M Etr1p Y79F or 1.1 · 102 nM Etr1p T175V. Kinetic parameters were determined by varying 
the NADPH or (4R)‐[4‐2H1]NADPH concentration (between 1 and 64 M) and following disappearance 
of NADPH at 340 nm using an absorption coefficient of 340 nm = 6.2 cm‐1 mM‐1 35. For each concentration 
chosen, at least triplicate measurements were performed. For Etr1p Y79F D340 nm = 2.5 cm‐1 mM‐1 
(340 nm NADPH = 6.2 cm‐1 mM‐1, D 340 nm C4‐adduct = 3.7 cm‐1 mM‐1 was used. Assays for determination of 
kinetic parameters on C2‐ene adduct were by directly adding lyophilized, purified C2‐ene adduct and 
following its disappearance at 370 nm using an extinction coefficient of  370 nm = 6.9 cm‐1 mM‐1 9. Kinetic 
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parameters with the C2‐ene adduct were determined from at least 18 independent measurements at 
varying concentrations. The KIEs on hydride transfer were calculated from Hkcat/Dkcat and (Hkcat · Km 
D)/(DKcat · Km H) ratios. For all kinetic parameters determined, the corresponding errors are given as 95% 
confidence intervals. 
To investigate whether the C4‐adducts formed in Ccr T195V could inhibit Etr1p WT, a reaction with 
200 M NADPH and 200 M crotonyl‐CoA in 100 mM Na2HPO4 (pH 7.9) was started by 1 volume 
percent of either 0.5 M Ccr WT stock 170 M Ccr T195V stock. The reaction was allowed to develop 
for 30 s before adding 1 volume percent of a 50 M Etr1p WT stock.  
 Protein crystallization and structural analysis 
The purified enzymes were crystallized in sitting drops. Etr1p was crystallized at 15 mg/mL with 5 mM 
NADP and 5 mM of crotonyl‐CoA in the gel filtration buffer (100 mM NaCl, 20 mM TrisHCl pH 7.9). In 
most experiments, 1 µl of enzyme solution and 1 µl of reservoir solution were mixed in the wells of a 
crystallization plate (CombiClover Junior Plate, Jena Bioscience). Two different crystalline forms 
appeared after one week at 25°C. Cubic crystal belonging to the trigonal form appears in 2.0 M 
(NH4)2SO4, 100 mM N‐(2‐acetamido)‐2‐iminodiacetic acid (ADA)/NaOH (pH 6.4). Rod shape crystal 
belonging to the monoclinic form appears in 1.85 M (NH4)2SO4, 100 mM ADA pH 6.4 using streak 
seeding to enhance crystals size. Crystals were immersed in a solution containing 30% (v/v) glycerol, 
2.0 M (NH4)2SO4, 100 mM ADA pH 6.4 prior to freezing in liquid nitrogen to prevent water‐crystal 
formation. 
Data were collected at the X10SA beamline from the Swiss Light Synchrotron (Villigen) on a Pilatus 6M 
(Dectris AG, Switzerland). Datasets were processed with XDS36 and scaled with SCALA from the ccp4 
suite37. Both crystal structures were solved by molecular replacement with Phaser from PHENIX 
package38 using the PDB: 4WAS as a template. The starting models for molecular replacement were 
first refined with REFMAC539. All models were then manually rebuilt with COOT40 and further refined 
with PHENIX38. For both structure restraints for non‐crystallographic symmetry (NCS) and a 
translation–liberation–screw‐rotation (TLS) were applied. Final models were validated through the 
MolProbity server41 (http://molprobity.biochem.duke.edu). Data collection and refinement statistics 
are reported in Table S2. Figures were generated and rendered with PyMOL (Schrödinger, LLC). The 
standard deviations between the structures were calculated with the Superpose program of the ccp4 
suite 
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 Supplementary Information 
 
Figure S1. Active site of Etr1p. Distances from Y79 (3.2 Å) and T175 (6.7 Å) to the C of crotonyl‐CoA, the protonation site. 
The distance from T175 to the C of crotonyl‐CoA is too large to be directly involved in the protonation step. 
 
Figure S2. Linearity of the burst phase in Etr1p T175V with amount of enzyme. A) Stopped flow traces of the burst phase 
with the indicated amount of enzyme. B) The amount of NADPH that is consumed in the first 2 seconds of the reaction plotted 
versus the amount of enzyme. The slope of the line is 3.27± 0.07.µM NADPH per µM enzyme, indicating multiple turnovers 
takes place before the enzyme is inhibited. 
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Figure S3. Difference spectroscopy demonstrates C4-adduct formation in the Etr1p T175V mutant. Spectrum of pure C4‐ 
adduct (purple) and difference spectrum (blue dotted lines) of two assays containing either 4 µM Etr1p WT or 4 µM T175V. 
Both assays contained 40 µM NADPH and 50 µM crotonyl‐CoA in 100mM Na2HPO4 pH 7.9. Spectra were taken after both 
reactions depleted NADPH (within manual mixing time). 
 
Figure S4. Circular dichroism spectra of Etr1p WT and mutants employed in this study. Each measurement was performed 
with 10 µM of protein and was performed in triplicate to yield the mean representative scans. Molar ellipticity was subtracted 
from a control buffer scan. The spectra were collected on a JASCO 815 CD spectrometer scanned from 200–260 nm in a 1 mm 
quartz cuvette. 
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Figure S5. Stereo image of the active site of apo-Etr1p WT and T175V. Most of the water network in the active site 
superimposes between the WT and T175, only the crystal water in direct contact with position 175 is shifted in the mutant. 
 
Figure S6. Superimposition of NADP+ and amino acid residue 175 for Etr1p WT (PDB 4W99) and the T175V variant (PDB: 
5LBX) including electron densities. Overlay of NADP+ and the amino acid residue 175 in comparison to electron density maps. 
A) 2Fo-Fc electron density map contoured at 1.5 σ, as well as ball and stick representation of the WT in green, with the T175V 
variant overlaid as ball and stick in purple. B) 2Fo-Fc electron density map contoured at 1.5 σ, as well as ball and stick 
representation for the T175V variant in purple, with the WT overlaid only as ball and stick in green. 
 
Figure S7. 2Fo-Fc electron density maps for NADP+ and crotonyl-CoA bound at T175V after and before refinement. A) 2Fo-Fc 
electron density map for the T175V variant with NADP+ and crotonyl‐CoA contoured at 1.0 σ. B) Fo-Fc electron density map 
with NADP+ and crotonyl‐CoA omitted prior to refinement. The difference map is contoured at 3.0 σ. 
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Figure S8. Picture of the A) trigonal and B) monoclinic crystalline forms (see Table S2). 
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Figure S9. Weblogo analysis of conserved residues in the MDR enzyme superfamily. Sequence logo of A) the residues around 
the conserved threonine 175 (red arrow) and B) the complete sequence alignment. The sequence numbering is shifted due 
to gaps in the alignment and the presence of a histidine‐tag in the crystal structure that is used for the numbering throughout 
the paper. S70 is at position 54, Y79 at position 64, T175 at position 221, T324 at position 421. Sequences from referenceX 
were aligned with MAFFT v7.273 (with iterative refinement method E‐INS‐i) and the sequence logo was created with the 
Weblogo 3.4 server 42. Columns with many gaps or unknown residues are narrow. 
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Figure S10. Detection of C4-adduct in the Ccr T195V variant and WT. A) UPLC‐MS analysis of Ccr WT (green) and Ccr T195V 
variant (purple) containing 1 µl 30µM enzyme, 1 µl 500 mM Na2HPO4 (pH 7.9), 1 µl 200 mM NADPH, 1 µl 200 mM crotonyl‐
CoA, 1 µl 60 µM crotonic anhydrase and 1µL of 200 mM KHCO3. The T195V variant shows accumulation of a C4‐adduct, while 
the Ccr WT did not accumulate detectable amounts of the C4‐adduct. Both variants show accumulation of the catalytically 
competent C2‐adduct. B) UPLC‐MS analysis of authentic standards for the C2 adduct (blue) and the C4 adduct (orange). Data 
shown are representatives of at least three independent experiments. 
Table S1. List of primers used to generate Etr1p and Ccr variants 
Enzyme variant Primer Name Sequence 
Etr1p S70A Etr1p S70A fwd CCGGTCAACCCGGCCGACATCAACCAG 
Etr1p S70A rev CTGGTTGATGTCGGCCGGGTTGACCGG 
Etr1p T324A Etr1p T324A fwd GGGCTTCTGGGTGGCCGAGCTGCTCAAG 
Etr1p T324A rev CTTGAGCAGCTCGGCCACCCAGAAGCCC 
Etr1p Y79F Etr1p Y79F fwd GATCCAGGGCGTCTTTCCGAGCAAGCCG 
Etr1p Y79F rev CGGCTTGCTCGGAAAGACGCCCTGGATC 
Etr1p T175V Etr1p T175V fwd CATCTCGGTCAATCCCCTGGTGGCCTACCTCATGCTCAC 
Etr1p T175V rev GTGAGCATGAGGTAGGCCACCAGGGGATTGACCGAGATG 
Ccr T195V Ccr T195V fwd GCTGACGCTCGCCGTCGCCTACCGCATGC 
Ccr T195V rev GCATGCGGTAGGCGACGGCGAGCGTCAGC 
 
  
A B
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Supplementary Table 3. Etr1p T175V data collection and refinement statistics for both, the monoclinic and trigonal crystalline 
forms (see Figure S8).  
 
 Etr1p T175V monoclinic form  Etr1p T175V trigonal form  
Data collection    
  Wavelength (Å)  1.73913  1.73913  
  Space group  P21  P312  
  Resolution (Å) 49.47 – 2.10 (2.21 – 2.10)  47.04 – 2.50 (2.64 – 2.50)  
  Cell dimensions    
     a, b, c (Å)  67.42, 101.86, 81.59  93.50, 93.50, 231.20  
        (°)  90, 101, 90  90, 90, 120  
  R
merge
 (%)
a
 5.9 (43.0)  12.4 (151.1)  
  R
pim
 (%)
 a
  3.9 (28.6)  4.4 (55.7)  
  I/
I
a
 
 11.8 (2.5)  12.2 (1.5)  
  CC
1/2
  99.6 (80.8)  99.7 (67.7)  
  Completeness (%)
 a
  96.2 (91.5)  100.0 (100.0)  
  Redundancy
a
  3.3 (3.1)  8.6 (7.7)  
   
Refinement    
  Resolution (Å)  49.47 – 2.10  43.34  –  2.5  
  Number of reflections  60553  41370  
  R
work
/R
free
b
 (%)  15.85 / 19.70  19.16 / 21.96  
  Number of atoms    
     Protein  5610  5586  
     Ligands/ions  137  209  
     Solvent  525  157  
  Average B-factors (Å
2
)  40.42  53.04  
  Molprobity clash score, all atoms  1.93 (100th percentile)  2.8 (100th percentile) 
  Ramachandran plot    
    Favoured regions (%) 97.94  96.69  
    Outlier regions (%) 0  0  
  rmsd
c
 bond lengths (Å) 0.009  0.004  
  rmsd
c
 bond angles (°) 1.097  0.787  
PDB code 5LB9 5LBX 
 
a Values relative to the highest resolution shell are within parantheses. b Rfree was calculated as the Rwork for 5% of the reflections that were 
not included in the refinement. c msd, root mean square deviation. 
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4. InhA, the enoyl-thioester reductase from M. tuberculosis forms a 
covalent reaction intermediate 
 Abstract 
The enoyl thioester reductase InhA catalyzes an essential step in fatty acid biosynthesis of 
Mycobacterium tuberculosis and is a key target of anti‐tuberculosis drugs. Here we use enzyme 
mutagenesis, NMR, stopped flow spectroscopy and LC‐MS to show that a covalent reaction 
intermediate is formed during catalysis by InhA. The reaction intermediate is a labile (2S)‐C2‐ene 
adduct between the NADH cofactor and the CoA thioester substrate. We isolated and used the adduct 
as a “molecular probe” to directly access the second half reaction of the catalytic cycle of InhA (i.e., 
the proton transfer), independent from the first half reaction (i.e., the initial hydride transfer). 
Molecular probing allowed us to interrogate the individual contributions of the conserved active site 
residues tyrosine 158 and threonine 196 to either half reaction. The natural tendency of InhA to form 
covalent C2‐ene adduct at the active site calls for a careful reconsideration of the enzyme’s reaction 
mechanism and provides the basis for the development of novel tools to study, manipulate and inhibit 
the catalytic cycle of InhA. 
 Introduction 
Tuberculosis remains one of the deadliest infectious diseases 1. With increasing multidrug resistant 
strains of M. tuberculosis, the cause of the disease, the need for next generation treatments increases 
1. The enoyl‐acyl carrier protein (enoyl‐ACP) reductase InhA is a major target for the clinically relevant 
antibiotics isoniazid and ethionamide 2. In the light of emerging multidrug‐resistant M. tuberculosis 
strains InhA remains a prime candidate for drug design 3. Therefore, the recent decade has seen 
intensive research focusing on developing new inhibitors against this enzyme 4. 
InhA catalyzes the NADH‐dependent reduction of enoyl‐ACP in the biosynthesis of fatty and mycolic 
acids, which form an essential component of the membrane and cell wall of M. tuberculosis, 
respectively 5‐6. The reaction mechanism is postulated to start with a direct hydride transfer from the 
C4 of NADH to the β‐carbon of the enoyl‐ACP, followed by formation of an enolate anion, which is 
subsequently protonated stereospecifically to the pro‐(2R) position of the α‐carbon 3, 7. The source of 
the proton however remains unknown and was suggested to originate from a solvent water due to the 
lack of any protic amino acid residues positioned close enough to serve as proton donor 7. Tyrosine 
158 one of the only protic groups in the active site of InhA was shown by mutagenesis studies to be 
involved in catalysis. When mutated to phenylalanine (Y158F) the enzyme is reported to lose about 
one order of magnitude in catalytic efficiency. The hydroxyl group of Tyrosine 158 was proposed to 
provide electrophilic stabilization of the transition state(s) by hydrogen bonding to the carbonyl of the 
substrate (Figure 1) 8. However, the Y158F variant did not show a significantly different solvent kinetic 
isotope effect (D2OV) in comparison to the wild type (WT) enzyme (WT: D2OV = 1.5±0.2; Y158F 
D2OV = 1.4±0.2)7. 
Here we show that the Y158F variant forms and accumulates a previously overlooked covalent C2‐ene 
adduct between the NADH cofactor and the CoA thioester substrate during catalysis. We use the 
isolated adduct as “molecular probe” to demonstrate that Tyr158 is not deficient in hydride transfer, 
but directly affected in the protonation step. Using stopped‐flow spectroscopy and HPLC‐MS we show 
that InhA WT forms the same intermediate also in its native catalytic cycle. The detection of the C2‐
ene adduct in the catalytic cycle of InhA calls for a careful reconsideration of the reaction mechanism 
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of InhA and related NAD(P)H dependent oxidoreductases. In addition, we describe novel tools to study 
the catalytic cycle of InhA and potential new avenues to eventually inhibit this important drug target. 
 Results 
 Tyrosine 158 and Threonine 196 are involved in catalysis 
Analysis of a crystal structure containing the cofactor NAD+ and a 16C‐acyl‐SNAC substrate analogue 
suggested a water molecule bound by Threonine 196 that could be involved in catalysis and particularly 
in proton donation (Figure 1) 3. We therefore characterized active site variants of T196 as well as the 
previously suggested variants of Y158 using octenoyl‐CoA as a substrate for the reaction (Table 1). The 
Y158F variant retained only 1.8 % of the wild type (WT) kcat with a two‐fold increase of the Km for 
octenoyl‐CoA, which corresponds well with previous studies 7. For an Y158S mutant, contrary to a 
previously report 7, we saw an even stronger decrease in kcat to only 0.11% of WT activity. The T196 
variants on the other hand also showed a strong effect on catalysis. T196A retained 1.0 % and the 
larger, isosteric T196V variant retained 0.15 % of WT kcat. The Km for octenoyl‐CoA was increased by 
more than 5‐fold in both mutants while the Km for NADH did not change significantly compared to WT. 
In summary, our kinetic characterization showed that both Y158 and T196 are involved in catalysis. 
 
Figure 1. Active site architecture of InhA in tripartite structure containing NAD+ (cyan) and C‐16 acyl‐substrate analogue (dark 
cyan) (PDB 1BVR3). Tyrosine 158 (green) is positioned for hydrogen bonding with the carbonyl of the acyl‐thioester and the 
hydroxyl group of the NAD+ ribose. Threonine 196 (green) is positioned below the carboxamide of NAD+ and within hydrogen 
bond distance to the ‐phosphate and a water molecule, which is positioned below the C of the substrate 
 Tyrosine 158 is essential for stereospecificity of protonation 
To assess the function of Y158 and T196 in more detail we next used isotopic labeling to determine the 
protonation stereochemistry of InhA WT and its variants. We performed enzyme reactions in 
deuterated buffer and used a stereospecific oxidase Acx4 from Arabidopsis thaliana to quantify the 
incorporation pattern of deuterium at the 2 position (Figure S1). InhA WT incorporated the deuteron 
with an efficiency of 99 ± 1 % specifically into the 2R position, which is in line with previous data 9. The 
Y158F variant incorporated deuterium with an efficiency of 57 ± 2 % into the 2R position, which 
indicated that this variant lost stereospecificity of proton donation. Both variants T196A and T196V 
showed only a partial loss in stereospecificity, incorporating the deuteron into the 2R position with 91 
± 1 % and 77 ± 1 %, respectively (Table S1). These results suggested that Y158 contributes stronger to 
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the stereospecificity of proton donation than T196. We next aimed at determining the kinetic isotopic 
effects (KIE) of protonation in Y158F variant.  
 
Table 1 Kinetic parameters of InhA WT and variants.  
For the assays of the kinetics with octenoyl‐CoA, NADH was kept constant at 400 µM, for the ones with NADH octenoyl‐CoA 
was kept at 4 mM. 
 KIE measurements confirm that Tyrosine 158 is directly involved in protonation 
Parikh et al. had reported almost identical KIEs on protonation for InhA WT and Y158F (WT: D2OV= 1.51; 
YF: D2OV = 1.39) 7. These KIEs were measured indirectly by following the consumption of the co‐
substrate NADH in H2O or D2O, assuming that reduction and protonation are coupled. NADH 
consumption, however, does not necessarily remain coupled to protonation in the different enzyme 
variants, so that the intrinsic KIE on protonation might become masked when indirect measurements 
are used 10. Therefore, we decided to apply an alternative method that would allow us to directly 
measure the intrinsic KIE on protonation (Dkobs) 11‐13. Here, the intrinsic Dkobs on protonation is 
determined by running assays in buffers with different H2O and D2O contents and fitting the isotopic 
composition of the products to equation 1: 
        
        
=        ∙
    
    
       equation 112 
Using this direct method, we measured a Dkobs of 1.74 ± 0.06 for InhA WT with hexenoyl‐CoA as 
substrate. The Dkobs decreased with increasing chain length of the substrate to 1.14 ± 0.01 for 
dodecenoyl‐CoA (Table 2) indicating an increasing commitment factor with increasing chain length. 
Compared to WT InhA, the Y158F variant showed a significantly increased Dkobs (Table 2). The Dkobs 
decreased with substrate length from 3.9 ± 0.3 with hexenoyl‐CoA to 2.4 ± 0.1 with dodecenoyl‐CoA. 
The strong difference in Dkobs between WT and Y158F clearly demonstrated that the Y158 variant is 
directly affected in the protonation step. At the same time, the apparent differences observed in 
Enzyme Substrate kcat,app [s-1] Km,app [mM] 
InhA WT octenoyl‐CoA 4.9 ± 0.2 0.8 ± 0.1 
 NADH 3.5 ± 0.2 0.09 ± 0.01 
 C2‐ene adduct 3.0 ± 0.2 0.011 ± 0.002 
InhA Y158F octenoyl‐CoA 0.088 ± 0.005 2.0 ± 0.3 
 NADH 0.079 ± 0.001 0.01 ± 0.001 
InhA Y158S octenoyl‐CoA 0.0055 ± 0.0002 0.9 ± 0.1 
 NADH 0.0090 ± 0.0004 0.056 ± 0.009 
InhA T196A octenoyl‐CoA 0.050 ± 0.003 7.6 ± 0.7 
 NADH 0.012 ± 0.0007 0.059 ± 0.011 
 C2‐ene adduct 0.077 ± 0.008 0.01 ± 0.003 
InhA T196V octenoyl‐CoA 0.0073 ± 0.0008 4.3 ± 1.0 
 NADH 0.0051 ± 0.0003 0.11 ± 0.02 
 C2‐ene adduct 0.056 ± 0.003 0.022 ± 0.003 
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intrinsic KIEs between the NADH consumption and the deuterium incorporation method strongly 
suggested that the reduction and protonation steps become (partially) uncoupled in the Y158F variant. 
 
 
Table 2. Dkobs of InhA WT and Y158F 
Substrate InhA WT InhA Y158F 
hexenoyl‐CoA 1.74 ± 0.14 3.9 ± 0.3 
octenoyl‐CoA 1.28 ± 0.04 3.4 ± 0.1 
dodecenoyl‐CoA 1.14 ± 0.03 2.4 ± 0.1 
The Dkobs was measured by quantifying the discrimination between H and D addition at enoyl‐CoA concentrations 
that were 20‐fold below Km to keep the commitment factor low and a NADH concentration of 10 mM, more than 
100‐fold over Km, to avoid a change in the commitment factor due to a change in NADH concentration 
 Y158F variant accumulates a covalent intermediate between crotonyl-CoA and NADH 
To investigate the uncoupling of the reduction and protonation steps in the Y158F variant, we 
characterized the enzyme’s reaction in more detail. Spectrophotometric analysis of the Y158F reaction 
showed a transient increase of absorbance with a maximum at 375 nm, reminiscent of the formation 
of transient reaction intermediates that were observed recently in the enoyl‐reductase Etr1p and other 
enzymes from the medium chain dehydrogenase superfamily (Figure 2A) 14‐16. This observation 
strongly indicated that the reaction of the Y158F variant proceeded stepwise via accumulation of an 
intermediate species. We next isolated the intermediate species via preparative HPLC and 
characterized it further by UV/Vis spectroscopy (Figure S2A) and high resolution mass spectrometry.  
The isolated species was labile (see below) and had a mass‐to‐charge ratio (m/z) of 779.1717, which 
matched the expected mass of a double charged direct adduct between NADH and octenoyl‐CoA 
(Figure S3). Two dimensional (COSY) NMR confirmed CoA and NADH substructures in the intermediate 
and identified a covalent bond between the C2 proton of the NADH nicotinamide ring and the α‐proton 
of the octenoyl‐CoA (Figure S4). In summary, these experiments showed that a covalent C2‐ene 
intermediate accumulates in solution in the Y158F variant during catalysis. However, in contrast to 
similar C2‐ene adducts previously reported for enzymes of the medium chain 
dehydrogenase/reductase family 14‐16, the adduct from InhA Y158F is proposed to feature the opposite 
stereochemistry at the α‐carbon (i.e. (2S)‐C2), due to the binding geometry of the NADH cofactor and 
the substrate at the active site. 
The isolated (2S)‐C2‐ene adduct decayed uncatalyzed in solution into the products octanoyl‐CoA and 
NAD+ with a decay constant of 0.186 ± 0.001 min‐1 (Figure S2B). This uncatalyzed decay into the final 
reaction products provides an explanation for the only partial loss of activity that is observed upon 
mutation of Y158F. Although the Y158F is affected in the protonation step, the enzyme can still form 
the (2S)‐C2‐ene adduct, which then decomposes into the final products in solution. The spontaneous 
decay of the intermediate in solution explains the lack of stereospecificity of deuterium incorporation 
into octanoyl‐CoA produced by Y158F. To rule out that the Y158F mutation caused major changes to 
the active site we co‐crystallized Y158F with NAD+. Analysis of the crystal structure confirmed that the 
active site geometry was not perturbed compared to WT (Figure S5, PDB 6EP8, Table S2). 
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 The C2-ene adduct is also formed in the WT enzyme 
The detection of the (2S)‐C2‐ene adduct in Y158F prompted the question, whether this covalent 
intermediate is only formed in this variant, or whether the (2S)‐C2‐ene adduct is a true intermediate 
in the catalytic cycle of the WT. Using stopped‐flow spectroscopy on the WT enzyme, we observed an 
increase of absorption at 385 nm, the wavelength at which the extinction coefficients of NADH and the 
(2S)‐C2‐ene adduct differ most. The increase appeared in the first turnover within the first 50 ms and 
corresponded to approximately 4 µM (2S)‐C2‐ene adduct, which in turn corresponded to 8% of the 
total active sites of enzyme in the assay (Figure 2B). This result suggested that the (2S)‐C2‐ene adduct 
is formed in the catalytic cycle of the WT enzyme. Our finding was confirmed by directly injecting an 
enzyme assay with WT InhA during steady state catalysis into an HPLC‐ESI‐MS, which demonstrated 
existence of the (2S)‐C2‐ene adduct also under steady‐state conditions (Figure 2C). In summary, these 
results suggest that the (2S)‐C2‐ene adduct is formed during the catalytic cycle of InhA WT and not 
simply as an artifact of the Y158F mutation. 
 
Figure 2. Detection of C2‐ene adduct in InhA Y158F and WT A) Production of C2‐ene adduct by InhA Y158F. The assay 
contained 15.4 mM octenoyl‐CoA, 23.6 mM NADH and 92µM InhA Y158F. C2‐ene adduct production was followed at 385 nm 
(big graph) and 420 nm (small graph). The assay was quenched when C2‐ene formation plateaued after 32 min and directly 
injected into the HPLC for purification and further characterization B) Stopped flow analysis of InhA WT at 385 nm; Syringe 1 
contained 100 µM InhA WT (blue line), Syringe 2 contained 4 mM octenoyl‐CoA and 1 mM NADH all in 30 mM PIPES pH 6.8, 
150 mM NaCl buffer. In the control Syringe 1 contained only buffer without enzyme (black line). Data shown is the average 
of a triplicate for each condition. B) LCMS analysis of InhA. The assay was directly injected after 60s incubation at room 
temperature during steady‐state catalysis and contained 50µM InhA WT, 250mM NADH and 50mM octenoyl‐CoA. In a control 
experiment containing 250mM NAD+ instead of NADH, no C2‐ene adduct was detected. 
 (2S)-C2-ene adduct as a “molecular probe” confirms role of Tyrosine 158 in protonation 
The (2S)‐C2‐ene adduct represents an intermediary state of catalysis: In the covalent adduct the 
reduction has already taken place, while the protonation has not. This specific feature allows to use 
the (2S)‐C2‐ene adduct as a “molecular probe” to test protonation independent of the (preceeding) 
reduction step 14. Indeed, purified (2S)‐C2‐ene adduct was catalytically competent and served as bona 
fide substrate for InhA WT at a kcat of 3.5 ± 0.2 s‐1 and at a Km of 11 ± 2 µM (Table 1). 
We next used (2S)‐C2‐ene adduct to specifically probe the protonation step of InhA WT and different 
variants. WT converted the adduct to the products octanoyl‐CoA and NAD+ as judged from the uniform 
decrease of the adduct peak in the UV‐Vis spectrum (Figure S6). In contrast, in the Y158F variant, the 
peak maximum shifted to 340 nm, which indicated formation of NADH, and thus partial resolution of 
the (2S)‐C2‐ene adduct back into the two substrates. From the absorbance increase, we estimated that 
most of the (2S)‐C2‐ene adduct was converted back to octenoyl‐CoA and NADH. Thus, the Y158F 
variant catalyzed mainly the back reaction. This result is in line with the fact that the protonation step 
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– and thus product formation from the (2S)‐C2‐ene adduct – is impaired by the Y158F mutation (Figure 
S6).  
Compared to the Y158F variant, the T196V and T196A variants were fully able to convert the (2S)‐C2‐
ene adduct further into the products, indicating that these variants are not affected in catalyzing the 
protonation step (Figure S6). Notably, both T196 variants showed an increased kcat and a decreased Km 
for the (2S)‐C2‐ene adduct compared to either NADH or octenoyl‐CoA. This clearly demonstrated that 
T196 is not directly involved in the protonation reaction, and suggested that T196 is rather involved in 
the initial reaction steps of the catalytic cycle leading to the (2S)‐C2‐ene adduct, probably the transfer 
of the hydride (Table 1). 
 Discussion 
Understanding the mechanism of enzymes is a prerequisite to be able to manipulate their function 17. 
Here we provide new insights into the catalytic cycle of the enoyl‐CoA reductase InhA, the major drug 
target of M. tuberculosis. Our data suggest that InhA forms a covalent intermediate adduct between 
the nicotinamide cofactor and the enoyl‐CoA substrate during catalysis. Pre‐steady‐state as well as 
steady‐state measurements show that a significant amount of the active sites of InhA WT are occupied 
by the (2S)‐C2‐ene adduct. Intriguingly, similar dihydropyridine‐substrate adducts were observed 
recently in chemical model reactions 18, the biosynthesis of the natural product sanguinarine 19, and 
the catalytic cycle of enoyl‐CoA reductases of the medium chain dehydrogenases (MDR) superfamily 
15‐16. The detection of the (2S)‐C2‐ene adduct in InhA, an enzyme from the short chain dehydrogenases 
(SDR) superfamily, adds to these recent observations, and suggests that the formation of such 
intermediates is not a singularity of one enzyme or one enzyme family, but eventually a more general 
catalytic principle at the active site of oxidoreductases.  
How is the covalent adduct formed and why?. Based on their studies with model compounds, Libby 
and Mehl suggested the alignment of the reactants in an ene‐like transition state (Figure 3) 18. The 
character and position of the reactants, as well as the electronic environment (e.g., the active site of 
the catalysts) will strongly influence the way the hydride is transferred. One (extreme) possibility is 
that hydride transfer proceeds in a pericyclic fashion resulting in the direct formation of the (2S)‐C2‐
ene adduct. The (2S)‐C2‐ene adduct would then be resolved via the enolate to the final products in 
subsequent steps. Alternatively, the hydride is transferred to the C of the enoyl‐CoA ester according 
to the more canonical mechanism directly forming the enolate. The enolate can either react further to 
the reaction product (e.g., by protonation) or re‐attack the nicotinamide cofactor in a Michael type 
addition to form the (2S)‐C2‐ene adduct (Figure 3). We note that the lack of good electron acceptors 
in proximity to the C of the enolate would favor such a Michael addition, as for instance is the case 
in enoyl‐CoA carboxylase/reductases when CO2 is omitted 16 or Etr1p when the proton donor is 
mutated 14.  
In available crystal structures of InhA with cofactor and product, no obvious proton donor is positioned 
close to the Cα 3, indicating that the formation and accumulation of the (2S)‐C2‐ene adduct might be 
a logical consequence of the active site geometry of InhA. Formation of the (2S)‐C2‐ene adduct could 
also provide an explanation for the puzzling stereochemistry of protonation, which proceeds from the 
same side as the hydride is transferred in InhA, although an obvious proton donor in is absent from 
this side 8. Note that bond formation between the enoyl‐CoA and NADH would induce a change in 
hybridization of the Cα of enoyl‐CoA from sp2 to sp3, which would bring the Cα closer to the phenolic 
hydroxy group of Y158. This re‐positioning could put Y158 into the position for a proton transfer after 
decomposition of the (2S)‐C2‐ene adduct back into the enolate and NAD+ (Figure S7).   
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Figure 3. Proposed reaction pathways for InhA and related oxidoreductases. In a first step the substrates enoyl‐CoA and NADH 
form an ene‐shaped transition state. The observed C2‐ene adduct can then be formed either directly through a pericyclic ene 
reaction or via a enolate formed from direct hydride transfer through a Michael‐addition reaction. The C2‐ene adduct can 
then be resolved through an elimination reaction and the enolate abstracts a proton to form the reduced acyl‐CoA product. 
Besides mechanistic implications, the discovery of a covalent adduct in the catalytic cycle of InhA 
provides the basis to prepare new tools to interrogate and eventually interfere with the mechanism of 
InhA. Using the (2S)‐C2‐ene intermediate as molecular probe allowed us to assess the function of 
individual amino acid residues at the active site of InhA. At the same time, the (2S)‐C2‐ene adduct 
could inspire the design of a new class of mechanistic inhibitors of InhA and related NAD(P)H 
dependent oxidoreductases. Note that compounds that are able to trap substrates at the covalent 
intermediate stage are expected to be high affinity binders of these enzymes. Such compounds could 
act in analogy to finasteride, a mechanism based inhibitor of 5α‐reductase that forms a similar covalent 
adduct between the C4 of NADH and the prodrug within the active site of the enzyme 20. Thus, 
exploiting the natural tendency of InhA to form covalent adducts with NADH might prove to be a 
convenient way to inhibit this key target of M. tuberculosis 
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 Materials and Methods 
 Chemicals 
Hexenoic‐ and octenoic‐acid (synthesis grade) were purchased from Sigma Aldrich AG, coenzyme A 
and DNaseI from Roche Diagnostics, Na2NADH (98%) was purchased from Carl Roth GmbH. All salts 
and solvents were of analytical grade or better. Dodecenoic acid was synthesized from decanal via 
Knoevenagel condensation with malonic acid according to a previously described protocol 21. Enoyl‐
CoAs where synthesized using the mixed anhydride method adapted from a previously described 
protocol 21‐22. The unsaturated acid (156 μmol) and triethylamine (156 μmol) were dissolved in CH2Cl2 
(3 ml) and stirred at 23°C for 30 min. The reaction was cooled to 4 °C and ethylchloroformate (156 
μmol) was added. After 2 h the solvent was evaporated, the crude product dissolved in DMF (4.5 ml) 
and added to a stirring solution of CoA‐trilithium salt (76 μmol) in 0.4 M KHCO3 (4.5 ml). The reaction 
procedure was monitored by mixing 5 μl of reaction mixture with 35 μl of an aqueous 5,5’‐dithiobis‐2‐
nitrobenzoic acid (DTNB, Ellman’s reagent) solution. Upon completion the reaction was acidified to pH 
= 3‐4 with formic acid, diluted to 50 ml with H2O and lyophilized. The product was resuspended in H2O 
and purified by reverse phase HPLC over a Gemini 10 μm NX‐C18 110 Å, 100 x 21.2 mm, AXIA packed 
column (Phenomenex) using a gradient from 5% to 65% (hexenoyl‐CoA) and to 95% (octenoyl‐, 
dodecenoyl‐CoA) over 15 min with 25 mM ammoniumformate pH=8.1 as the aqueous phase. Fractions 
containing the product were pooled, lyophilized and stored at ‐20 °C. 
 Cloning and mutagenesis 
The InhA WT gene from Mycobacterium tuberculosis present in plasmid pET15b (gift from Prof. John 
Blanchard, Albert Einstein College of Medicine, NY, USA) was used as received to express InhA WT. 
InhA variants were generated with the QuikChange® Site‐Directed Mutagenesis Kit (Stratagene, La 
Jolla, USA) using 60 ng of template plasmid and the following primer pairs:  
Y158F: CGATGCCGGCCTTCAACTGGATGAC and GTCATCCAGTTGAAGGCCGGCATCG;  
Y158S: CGATGCCGGCCTCCAACTGGATGAC and GTCATCCAGTTGGAGGCCGGCATCG;  
T196A: CAGGCCCTATCCGGGCGCTGGCGATGAGTG and CACTCATCGCCAGCGCCCGGATAGGGCCTG; 
T196V: GGCCCTATCCGGGTGCTGGCGATGAG and CTCATCGCCAGCACCCGGATAGGGCC 
 Protein expression and purification 
The his‐tagged proteins were expressed in E. coli BL21 (DE3) or E. coli BL21‐AI™ (DE3) in terrific broth 
by inducing at OD600 = 1.5 with 0.5 mM Isopropyl‐beta‐D‐thiogalactoside and 2.5 mM  arabinose when 
using E. coli BL21‐AI™ (DE3) at 25 °C for 12‐16 hours. Harvested cells were lysed in 2.5 ml lysis buffer 
per gram cells: lysis buffer 500mM NaCl, 20 mM Tris HCl, 10% (v/v) glycerol pH 7.9 with 1 mM MgCl2 
and DNaseI at 1 µg/ml. Cells were lysed by sonication and subsequently centrifuged at 50’000 x g for 
at least 30 minutes at 4°C. The clear supernatant was applied to a 1ml HisTrap FF column and washed 
with 24% buffer B for 30‐40 column volumes, until the UV 280 nm absorbance did not decrease 
anymore. The protein was eluted with 100 % buffer B. Buffer A: 500mM NaCl, 20 mM Tris HCl pH 7.9, 
Buffer B was identical to buffer A with the addition of 250 mM imidazole. The eluted protein was 
desalted into 30 mM piperazine‐N,N′‐bis(2‐ethanesulfonic acid), 150 mM NaCl, pH 6.8 within 30 
minutes from eluting, as previous reports mention that the protein can precipitate in the elution buffer 
7. The enzyme was kept in this buffer at 4 °C until it was used. 
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 Determining the stereochemistry of protonation 
Isotopic label incorporation experiments were done analogous to a previously described method (see 
reaction scheme in Figure S1) 14. The protein storage buffer of InhA WT and variants was exchanged 
using three subsequent ultracentrifugation steps (Amicon Ultra‐ 0.5mL Centrifugal Filters, Merck 
Milipore) diluting the original buffer over 10,000 x with deuterated 30 mM PIPES, 150 mM NaCl buffer 
pD 6.8. A 200 µL assay contained 400 µM NADH and 300 µM octenoyl‐CoA in deuterated 30 mM PIPES, 
150 mM NaCl buffer pD 6.8 and were started with 12.5 µM InhA WT, 22.6 µM InhA Y158F, 70.3 µM 
Y158S, 23.9 µM InhA T196V, 40 µM InhA T196A. The reactions were followed spectrophotometrically 
at 360 nm and run at 30 °C until complete consumption of NADH (ca. 1 min for WT, 3h for Y158F, Y158S 
and T196A) except for the assay containing T196V, which was stopped after 7h after approximately 
50% of NADH was consumed. 20 µL of 50% formic acid was added to quench the reaction. The 
octanoyl‐CoA was purified by HPLC, lyophilized and resuspended in 100 mM Tris HCl pH 8.0. Label 
incorporation was checked by HPLC‐ESI‐MS. 7.9 µM Acx4 was added to the samples and the reaction 
mixtures were incubated for 10 min at 30°C, quenched by adding 5% formic acid and analyzed by HPLC‐
ESI‐MS (Table S1). To make sure that the oxidase Acx4 does not unspecifically scramble the signal in 
the α position an assay containing 300 µM octanoyl‐CoA, 0.13 µM Acx4 was run in deuterated 100 mM 
TrisDCl pD 8.0 quenching the assay at different time points by adding 5% formic acid. Over the time 
course of 90 min no incorporation of a deuterium signal in either octanoyl‐CoA or octenoyl‐CoA could 
be detected. 
 KIE measurements 
Reactions for the measurement of the KIEs in InhA WT and Y158F contained 30 mM PIPES buffer pH 
6.8, 150 mM NaCl, 10 mM NADH, 260 μM hexenoyl‐CoA, 26 μM octenoyl‐CoA or 4.6 μM dodecenoyl‐
CoA. H2O and D2O were added according to the desired percentage of D2O; between 10 and 70 % (v/v). 
The enzymes were equilibrated with the partially deuterated buffer for at least 2 hours before the 
assay was started with the addition of the enoyl‐CoA substrate (Enoyl‐CoA substrates were dissolved 
as 25‐fold stock solutions in 50% DMSO). Hexenoyl‐CoA and octenoyl‐CoA assays contained 147 nM of 
InhA WT or InhA Y158F, the dodecanoyl‐CoA assays contained 29 nM of either enzyme. Assays with 
InhA WT were quenched by addition of 5% formic acid after 4 min for octenoyl‐CoA and dodecanoyl‐
CoA and after 20 min for hexanoyl‐CoA. Assays with InhA Y158F were quenched after 150 min for all 
three substrates. 
 C2-ene adduct purification and characterization 
A mixture containing 15.5 mM octenoyl‐CoA, 23.7 mM NADH and 92.5 μM InhA Y158F in 200 mM Tris 
HCl (pH=7, 4 ml) was reacted at 4°C until the absorption at 400 nm reached a maximum. The reaction 
was purified on an Agilent HPLC system using a flow rate of 25 ml min‐1 and using a Gemini 10 μm NX‐
C18 110 Å, 100 × 21.2 mm, AXIA packed column (Phenomenex). The elution of the intermediate was 
followed at 370 nm and collected directly into liquid nitrogen. Upon lyophilization (0.01 mbar, ‐55°C) 
the compound appeared as an intense yellow powder that was stored at ‐80°C. For 
spectrophotometric analysis C2‐ene adduct was dissolved in 30 mM PIPES buffer pH 6.8, 150 mM NaCl. 
The absorption spectrum of the C2‐ene adduct (Figure S2A) and the uncatalyzed decay of C2‐ene 
adduct at 30°C (Figure S2B) was determined on a Cary‐60 UV/Vis spectrometer (Agilent) using quartz 
cuvettes (1‐, 3‐ or 10‐mm diameter; Hellma). For NMR spectroscopy the C2‐ene adduct was dissolved 
in D2O 25 mM Na2DPO4 pH=7.9 and measured at 4°C at 600 MHz (Figure S3). 
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 Stopped-flow spectroscopy 
Measurements were recorded on a thermo‐stated stopped flow unit (SFM‐20 connected to a MOS‐
200, equipped with a Xe(Hg)‐lamp and a TC‐100/10 cuvette, Bio‐Logic Science Instruments SAS, Claix, 
France) set to 30 °C. Syringe 1 contained 1 mM NADH and 4 mM octenoyl‐CoA in 30 mM PIPES, 150 
mM NaCl buffer pH 6.8 and syringe 2 contained 100 µM of InhA WT in the same buffer. For the controls 
either the syringe 1 or syringe 2 contained only buffer. Data was collected at 385 nm every 0.5 ms for 
the first 4 s and then every 0.5 s up to a total of 90 s. Each assay and control was repeated at least 4 
times and the resulting traces were averaged to reduce noise. 
 Protein crystallization 
For protein crystallization the HisTrap purified InhA was incubated with thrombin to cleave off the His‐
tag (120 U thrombin/8 mg InhA) for 2h at room temperature. The solution was then passed through a 
HisTrap column equilibrated in 30 mM PIPES, 150 mM NaCl pH 6.8. The flow through was injected onto 
a Ge HiLoad 16/600 Superdex 200pg column running on 30 mM PIPES, 150 mM NaCl pH 6.8 buffer. 
Crystallization of poly‐histidine tag cleaved InhA from M. tuberculosis was performed under air at 14‐
20°C with a protein concentration of 10 mg/ml. For all crystallization experiment, 3 to 10 mM of NADH 
was added to the protein solution and the protein sample was filtered through 0.2 μm filter. The 24‐
well crystal plate, Combiclover Junior (Jena Bioscience), was used for sitting drop and the crystallization 
conditions from Chollet A. et al was reproduced.23 The best crystals appeared in drops of 2 μl of enzyme 
solution, 1 μl of the reservoir solution and 1 μl of distilled water. The reservoir solution contained 100 
mM HEPES/NaOH pH 7.5, 50 mM sodium citrate pH 6.5, 7‐9 % 2‐methyl‐2,4‐pentanediol. Bi‐pyramidal 
shaped crystals appeared typically within two to three weeks in this condition.  
 Structural analysis 
The crystals were cryo‐protected by soaking with 25 % glycerol (v/v) in the crystallization solution for 
3‐5 seconds prior freezing in liquid nitrogen. The diffraction experiments were performed at 100 K on 
beamline BM30A (FIP) at the ESRF (Grenoble) equipped with a CCD detector (ADSC Q315r). The data 
were processed with XDS 24 and scaled with SCALA from the ccp4 suite 25. The structure was 
determined using the InhA wild‐type from M. tuberculosis inhibited with the active metabolite of 
isoniazid (PDB code 4TRO) as a template for MOLREP. The model was manually constructed with COOT 
26 and refined by PHENIX 27 including hydrogens. The final model was validated by using the MolProbity 
server (http://molprobity.biochem.duke.edu) 28 and deposited without hydrogens. Data collection and 
refinement statistics of the model are listed in Table S2. The figures were generated and rendered with 
PyMOL (Version 1.5, Schrödinger, LLC). For a comparison of the solved structure of InhA Y158F (PDB 
6EP8) with the previously solved WT structure (PDB 1BVR 3) see Figure S5. 
 Spectrophotometric enzyme assays 
Assays were carried out on a Carry‐4000 UV/Vis spectrometer (Agilent) at 30 °C using quartz cuvettes 
(1‐, 3‐, or 10‐mm path‐length; Hellma). All assays were carried out in 30 mM PIPES, 150 mM NaCl, pH 
6.8 if not noted otherwise. For the determination of the kinetic parameters for NADH, octenoyl‐CoA 
was kept constant at 4 mM; for octenoyl‐CoA kinetics NADH was kept at 400 µM NADH and were 
measured at 340 nm. C2‐ene adduct was measured at 385 nm and the concentration of C2‐ene adduct 
was determined directly within each assay using the extinction coefficient C2,385=7.2 cm‐1mM‐1 
(Figure S2A). All Michaelis‐Menten curves were determined by curve fitting using GraphPad Prism 7.02 
with a minimum of 12 measuring points. Scanning traces of InhA WT and variants using C2‐ene adduct 
as a substrate were monitored between 300 and 500 nm using 2 µM InhA WT, 1.2 µM InhA Y158F, 2 
µM InhA T196V and 2 µM InhA T196A (Figure S6).  
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 Supplementary Information 
 
 
Figure S1 Scheme showing the setup for the isotopic label incorporation experiment. Octenoyl‐CoA is reduced by InhA WT 
and variants in D2O and a deuterium is incorporated into octanoyl‐CoA in either 2R or 2S position depending on the 
stereospecificity of the proton doror. Octanoyl‐CoA is purified via HPLC and then oxidized back to octenoyl‐CoA with the 
stereospecific oxidase Acx4. If the proton was donated into 2R position, the resulting octenoyl‐CoA will be unlabeled. In case 
of 2S donation the resulting octenoyl‐CoA will be once deuterated. 
 
Figure S2 Spectrophotometric characterization of C2‐ene adduct A) Absorption spectrum of C2‐ene adduct. Extinction 
coefficients were calculated assuming the total absorbance of 33.8 cm‐1mM‐1 at 260 nm ([ε260nm NADPH + ε260nm CoA] = 
[16.9 cm‐1mM‐1+ 16.9 cm‐1 mM‐1])29  B) Uncatalyzed decay of C2‐ene adduct in 30 mM PIPES buffer pH 6.8, 150 mM NaCl 
at 30°C was measured at 375nm, concentration was calculated using the extinction coefficient ε375nm= 7.46 cm‐1mM‐1. Data 
was fitted with a first order decay, the decay rate was determined to be 0.186 ± 0.001 min‐1 with a t1/2 of 3.73  ± 0.01 min 
using three independent decay curves. 
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Figure S3 LC‐MS analysis of C2‐ene adduct. The doubly charged ion with a mass‐to‐charge ratio of 779.17 (m/z) corresponds 
to a covalent adduct of NADH and octenoyl‐CoA. The ion with an (m/z) at 664 corresponds to NAD+, the one at 387 
corresponds to the octenoyl‐pantetheine, 428 corresponds to 3´‐phospho‐AMP and the  542 ion corresponds to a loss of 
nicotinamide of the NAD+ ion. 
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Figure S4 Two‐dimensional NMR analysis of the C2‐ene adduct recorded at 600 MHz in D2O 25 mM Na2DPO4 pH=7.9 at 4.0 
°C. A) C2‐ene adduct structure and numbering B) 1H‐NMR‐ C) DQF‐COSY‐ D) HSQC‐ spectra of the C2‐ene adduct. E) 
Assignment table for the C2 ene‐adduct. 
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E 
Position 1H-shift (ppm) 13C-shift (ppm) HMBC DQF-COSY 
α 2.62, 2.161 56, 431 ‐ C2, βa, βb 
βa 1.13, 1.161 28, 251 ‐ Cα 
βb 1.16, 1.161 28, 251 ‐ Cα 
γ‐ζ 0.65‐0.75, 0.801 22,28,28,31,  
22,28,28,311  
‐ Cη 
η 0.40, 0.461 13, 131 ‐ Cγ‐ζ 
2 4.3, 9.01 58, 1401 Cα,C4,C5,C6  Cα 
3 ‐ 1132 C2,C5 ‐ 
4 6.4 8.81 135, 1421 C2,C5,C6 C5 
5 5.0, 8.11 101, 1281 C4 C4, C6 
6 6.4, 8.41 131, 1461 C2,C4,C5 C5 
1’’a 3.21 72 C2’’,C3’’,C4’’,C5’’ C1’’b 
1’’b 3.51 72 C2’’,C3’’,C4’’,C5’’ C1’’a 
2’’ ‐ 38 C1’’,C3’’,C4’’,C5’’ ‐ 
3’’ 0.42  18 C1’’a,C1’’b,C5’’ ‐ 
4’’ 0.57  21 C1’’a,C1’’b,C5’’ ‐ 
5’’ 3.71  73 C1’’a,C1’’b,C2’’,C
3’’C4’’, C5’’,C6’’ 
‐ 
6’’ ‐ 175 C5’’,C6’’, C8’’ ‐ 
7’’ ‐ ‐ ‐ ‐ 
8’’ 3.11  35 C9’’,C10’’,C12’’ C9’’ 
9’’ 2.07 35 C8’’,C10’’ C8’’ 
10’’ ‐ 174 C8’’,C9’’,C12’’ ‐ 
11’’ ‐ ‐ ‐ ‐ 
12’’a 2.51 28 Cα’’, Cβ’’,Cγ‐ζ, 
C8’’, C9’’, C10’’ 
C12’’b, C13’’a, C13’’b 
12’’b 2.58 28 Cα’’, Cβ’’,Cγ‐ζ, 
C8’’, C9’’, C10’’ 
C12’’a, C13’’a, C13’’b 
13’’a 2.95 38 C14’’ C12’’a, C12’’b, C13’’b 
13’’b 2.86 38 C14’’ C12’’a, C12’’b, C13’’a 
14’’ ‐ 205 Cα, Cβ, 
C13’’a,C13’’b 
‐ 
1’ 4.46 96 C2, C2’ C2’ 
2’ 3.66 73 C1’ C1’ 
3’ 3.87 70 ‐ C2’ 
4’ 3.77 82 ‐ ‐ 
5’a 3.91 65 C3’ ‐ 
5’b 3.93 65 C3’ ‐ 
C1’ 5.77 86 CC2’ CC2’ 
C2’ 4.48 74 CC1’,CC4’,CC5’ ‐ 
C3’ 4.43 73 CC4’,CC5’ ‐ 
C4’ 4.26 83 CC3’,CC5’ ‐ 
C5’ 3.94 65 CC3’,CC4’ ‐ 
N1’ 5.65 86 CN2’ CN3’ CN4’ CN2’ 
N2’ 4.43 73 CN1’ CN1’,CN3’ 
N3’ 4.17 70 CN1’ CN2’ 
N4’ 4.04 83 CN1’,CN2’,CN5’ ‐ 
N5’ 3.93 65 CN3’ ‐ 
CA2 7.72 152 ‐ ‐ 
CA8 8.09 139 ‐ ‐ 
NA2 7.72 152 ‐ ‐ 
NA8 8.15 139 ‐ ‐ 
1 Chemical shifts in NADP+ or octanoyl‐CoA 
2 Chemical shift assigned from HMBC 
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Figure S5 Crystal structure of InhA WT (green, PDB 1BVR 3) and Y158F (purple, PDB 6EP8). The two active sites overlay very 
well with the phenylalanine in the Y158F variant slightly twisted compared to the WT tyrosine and the loss of a water molecule 
that is bound by the hydroxyl group of tyrosine in the phenylalanine variant (black circle) 
Figure S6 Scanning traces of InhA WT and variants on C2‐ene adduct. Assays contained C2‐ene adduct in 30mM PIPES pH 6.8, 
150mM NaCl. A) 2µM InhA WT. C2‐ene adduct is depleted fast into the products. B) 1.2µM InhA Y158F. C2‐ene adduct 
competes between back reaction to NADH and octenoyl‐CoA (see shift of extinction maximum towards 340nm over time, 
green arrow) and decay into products in solution. C) 2µM InhA T196V. C2‐ene adduct is slowly consumed similar to WT, no 
significant amount of back reaction is observed. D) 2µM InhA T196A. Similar to T196V reaction is mainly in product direction. 
 
A B
C D
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Figure S7 Possible reaction mechanism for InhA. Substrate and NADH form the C2‐ene adduct via a pericyclic ene‐reaction. 
The rehybridization (sp2 to sp3) of the C of the substrate causes the carbonyl to flip and expose the 2R position for 
protonation by tyrosine 158 upon C2‐decay and enolate formation 
 
Table S1 Label incorporation pattern for InhA WT and variants. Assay conditions are described in Supplementary chapter 4. 
Enzyme variant No label (2R) +1 label (2S) 
InhA WT 99 ± 1 % 1 ± 1 % 
InhA Y158F 57 ± 2 % 43 ± 2 % 
InhA Y158S 79 ± 1 % 21 ± 1 % 
InhA T196A 91 ± 1 % 9 ± 1 % 
InhA T196V 77 ± 1 % 23 ± 1 % 
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Table S2. Statistics of the crystal structure analysis. 
 InhA Y158F with NADH (6EP8) 
Data collection  
  Wavelength (Å) 1.07244 
  Space group P6222 
  Resolution (Å) 46.61 – 1.80 (1.90 – 1.80) 
  Cell dimensions  
    a, b, c (Å) 98.3, 98.3, 139.8 
        (°) 90.0, 90.0, 120.0 
  R
merge
 (%)
a
 6.5 (121.0) 
  Rpim (%)a 1.5 (27.1) 
  CC1/2
 a
 100.0 (92.4) 
  I/
I
a
 35.6 (2.9) 
  Completeness (%)
 a
 
100.0 (100.0) 
 
  Redundancy
a
 20.5 (20.8) 
  Number of unique reflections
 a
 37644 (5382) 
  
Refinement  
  Resolution (Å) 42.55 – 1.80 
  Number of reflections 37562 
  R
work
/R
free
b
 (%) 14.54 / 17.51 
  Number of atoms  
    Protein 2086 
    Ligands/ions 92 
    Solvent 264 
  Mean B-value (Å
2
) 37.1 
  Molprobity clash score, all atoms 2.06 (100th percentile) 
  Ramachandran plot  
    Favored regions (%) 255 (95.9) 
    Outlier regions (%) 1 (0.38) 
  rmsd
c
 bond lengths (Å) 0.009 
  rmsd
c
 bond angles (°) 0.129 
PDB code 6EP8 
  
a Values relative to the highest resolution shell are within parentheses. b Rfree was calculated as the Rwork for 5% of the 
reflections that were not included in the refinement. c rmsd, root mean square deviation. 
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5. Combining promiscuous acyl-CoA oxidase and enoyl-CoA 
carboxylase/reductases for atypical polyketide extender unit 
biosynthesis 
 Abstract 
The incorporation of different extender units generates structural diversity in polyketides natural 
products. There is significant interest in engineering the substrate specificity of polyketide synthases 
(PKS) in order to change the chemical structure of polyketides. However, efforts to change extender 
unit selectivity in PKS are hindered by the lack of simple screening methods, as well as by the lack of 
easily available atypical extender units. Here, we present a chemo‐biosynthetic strategy that employs 
biocatalytic proofreading and allows access to a large variety of extender units. In a first step saturated 
acids are chemically coupled to free CoA. The corresponding acyl‐CoAs are further converted to their 
alkylmalonyl‐CoAs in a ‘one‐pot’ reaction through the combined action of an acyl‐CoA oxidase and an 
enoyl‐CoA carboxylase/reductase (ECR). We synthesized six different extender units and used them in 
competition in vitro screens to investigate active site residues conferring extender unit selectivity of 
PKS. Our results show the importance of an uncharacterized glutamine in extender unit selectivity and 
open the possibility for more comprehensive studies on extender incorporation and processing in PKS. 
 Introduction 
Polyketides are a large class of structurally diverse natural products that exhibit a myriad of biological 
activities ranging from antibacterial, to antifungal, cholesterol lowering, immune system suppressing 
and more 1. Although polyketides show a large structural and functional variety, they are all assembled 
from simple acyl‐ and alkylmalonyl‐thioester building blocks. The building blocks are combined in 
successive Claisen‐condensation reactions catalyzed by large multi‐domain enzymes, so‐called 
polyketide synthases (PKS). Structural diversity in the final polyketide product is achieved by a variety 
of different mechanisms. One important mechanism to generate structural variety in polyketides is the 
use of different acyl‐CoA building blocks (‘starter units’) and their condensation with different 
alkymalonyl‐CoA building blocks (‘extender units’) during biosynthesis 2. While PKS have been 
recognized to accept a variety of different acyl‐CoA starter units 3, the extension of the growing 
polyketide chain was for a long time believed to be restricted to malonyl‐CoA and methylmalonyl‐CoA 
units. However, the growing number of PKS that are able to incorporate atypical alkylmalonyl‐CoA 
extender units, such as ethylmalonyl‐CoA, benzylmalonyl‐CoA or octanoylmalonyl‐CoA, highlights the 
importance of this principle in the generation of structurally and functionally diverse polyketides 2.  
Most of the atypical extender units are provided via the reductive carboxylation of unsaturated acyl‐
CoA precursors by enoyl‐CoA carboxylase/reductases 4‐6. Genes encoding ECRs are often associated 
with the biosynthetic gene cluster (BGC) of the respective PKS that incorporates the atypical extender 
unit. Recent studies on the biochemistry of the ECRs identified active site residues that determine the 
substrate spectrum of these enzymes 7. According to these studies, ECRs can be categorized into two 
subfamilies; the ECR‐1 subfamily that possess a rather narrow substrate spectrum and the ECR‐2 
subfamily that display a more relaxed substrate specificity 4, 7. 
The incorporation of atypical extender units through the targeted reprogramming of PKS has become 
an important focus in bioengineering to create polyketides that show novel properties. Most 
approaches in this direction focus on the manipulation of the acyl‐transferase (AT) domains that are  
part of the PKS biosynthetic machinery. ATs are often described as the “gatekeeper” domains that 
decide which extender units will enter the PKS assembly line. In contrast, the downstream domains of 
Combining promiscuous acyl-CoA oxidase and enoyl-CoA carboxylase/reductases for atypical 
polyketide extender unit biosynthesis 
82 
 
the PKS that perform the actual condensation and modification reactions are believed to be rather 
promiscuous towards unnatural α‐substituents 8‐10. Several different strategies to manipulate the 
specificity of extender unit incorporation have been applied up to date 11‐13. Although it has become 
possible to incorporate atypical extender units, this was mainly achieved by lowering selectivity of ATs 
towards their native extender unit, which is very often accompanied by strongly reduced overall 
activities. An improved specificity by improving the desired selectivity in combination with reducing 
the native selectivity by a point mutation has to our knowledge only been achieved in one case 11. This 
highlights the necessity for more comprehensive screening methods to fully understand the 
contributions of AT and other PKS domains towards extender unit specificity.   
Another difficulty that complicates AT engineering is the limited availability of atypical extender units 
variants that can be used to screen for altered specificities of ATs. Commonly atypical extender units 
are synthesized in situ via enzymatic coupling of malonic acid derivatives and CoA using a promiscuous 
variant of the malonyl‐CoA synthetase MatB from Rhizobium trifolii 14‐15. This synthesis route is 
however restricted by the limited number of commercially available malonic acid derivatives, which 
otherwise have to be laboriously synthesized via the acylation of Meldrum´s acid 16. The recent 
description of promiscuous ECRs has opened up new routes for the chemo‐enzymatic synthesis of 
atypical extender units at preparative scale 7. However, promiscuous ECRs often display a significant 
side reactivity and simply reduce the unsaturated acyl‐CoA precursors instead of carboxylation. As an 
example, AntE, the reductive carboxylase in the antimycin biosynthesis pathway, carboxylates only 
25% of one of its natural substrates cinnamoyl‐CoA, while the rest of the substrate is reduced to 
phenylpropionyl‐CoA (‘dihydrocinnamoyl‐CoA’)17. 
Here we increased the carboxylation yield of promiscuous ECRs by applying the principle of biocatalytic 
proofreading. We successfully coupled promiscuous ECRs with an acyl‐CoA oxidase that is able to 
continuously recycle the reduction reaction side product, pushing the ECR reaction towards the 
carboxylation product. Based on this principle, we further developed a chemo‐biosynthetic route that 
allows for the convenient preparation of atypical alkylmalonyl‐CoA extender units from simple starting 
materials in ‘one pot’ and at high carboxylation yield. We use this route to prepare a set of six different 
alkylmlalonyl‐CoA extender units at preparative scale and high purity and demonstrate with a recently 
established in vitro model system of the DEBS PKS 18 that these extender units can be used to 
systematically screen the extender unit selectivity of PKS.  
 Results and Discussion 
 Screening of ECRs for the production of atypical polyketide extender units from enoyl-CoAs 
To first identify suitable ECRs for the preparative‐scale synthesis of alkylmalonyl‐CoA ester, we tested 
six different homologs with respect to their biosynthetic potential. Our screen included ECRs that 
either had been described to show relaxed substrate specificity, were part of a cluster described to 
produce a polyketide with atypical extender units or contained an active site motif indicating 
promiscuity (Table S1). Additionally we tested an ECR variant of C. crescentus (CcrCPAG) that was 
recently engineered from a specific into a promiscuous enzyme through three active site mutations 
(C146P, I169A and F373G) 7. The six ECRs were tested on five different enoyl‐CoA thioesters of varying 
chain length and branching patterns; crotonyl‐CoA, hexenoyl‐CoA, 5‐methylhexenoyl‐CoA, octenoyl‐
CoA and cinnamoyl‐CoA. We determined the carboxylation efficiency for each enzyme with each 
substrate by quantifying the percentage yield of carboxylated product (compared to total product 
formed, including reduced side product, Figure 1A). We also measured the kinetics for each enzyme 
with each substrate by following the consumption of NADPH (Figure 1B, Figure S1, Table S2). Based 
on these parameters, we identified CcrCPAG as most suited ECR for our biocatalytic synthesis strategy, 
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because the enzyme showed the highest carboxylation efficiencies as well as favorable catalytic 
activities for all substrates tested, with the exception of cinnamoyl‐CoA. With cinnamoyl‐CoA, CcrCPAG 
showed a reduced carboxylation efficiency (57%), as well as a reduced catalytic activity (< 0.15s‐1). 
Cinnamoyl‐CoA posed also a challenge for other ECRs. While CinF showed higher carboxylation 
efficiencies (74%) compared to CcrCPAG, the enzyme acted even slower on this substrate (kcat < 0.11s‐1). 
AntE and Ndas_0488 on the other hand displayed two fold higher turnover rates with cinnamoyl‐CoA 
compared to CcrCPAG, albeit at reduced carboxylation efficiency. 
 
Figure 1 Characterization of ECR variants for their substrate promiscuity. A) Percentage of carboxylation product of 
promiscuous ECRs dependent on the substrate compared to the reduction side reaction. Assays contained 100 mM TrisHCl 
pH 8, 100 mM KHCO3, 10 µgmL‐1 carbonic anhydrase, 150  µM NADPH, 75 µM substrate and 1.5 µg of the respective ECR, 
quenched with 5 % formic acid and analyzed by HPLC MS. B) kcat of ECRs for all the substrates tested. 
 Biocatalytic proofreading improved atypical extender unit biosynthesis 
The low carboxylation yields and reduced catalytic activities of ECRs with cinnamoyl‐CoA posed a 
problem for the preparative‐scale production of benzylmalonyl‐CoA. Due to the pronounced reduction 
side reaction of ECRs with cinnamoyl‐CoA, most of the substrate is converted into phenylpropinoyl‐
CoA, which represents a ‘dead‐end’ product. Thus, we sought to employ the concept of biocatalytic 
proofreading  to our biosynthetic strategy19. We reasoned that an efficient regeneration of 
phenylpropinoyl‐CoA back into the substrate cinnamoyl‐CoA should increase the yield of the 
carboxylation reaction in the synthesis assay. Therefore we tested whether the recently described acyl‐
CoA oxidase Acx4 from Arabidopsis thaliana 20 is able to oxidize phenylpropinoyl‐CoA into cinnamoyl‐
CoA. A detailed kinetic characterization of Acx4 showed that the enzyme is not only active with 
phenlypropionyl‐CoA, but accepts many different acyl‐CoAs, including the ones that are relevant to 
this study (butyanoyl‐, hexanoyl, octanoyl‐, and 5‐methylhexanoyl‐CoA Table S3). In the following we 
tested the effect of Acx4 onto the AntE‐dependent carboxylation of cinnamoyl‐CoA (Figure 2A). While 
the control reaction without proofreading enzyme produced only 19 % of benzylmalonyl‐CoA (Figure 
2B), the assay containing Acx4 yielded 73 % benzylmalonyl‐CoA (Figure 2C). The addition of catalase 
to remove the potentially harmful H2O2 produced by Acx4 did not alter the yield of the reaction and 
was therefore not used in further experiments. These results demonstrated that Acx4 can be directly 
added as proofreading enzyme to our biosynthetic assays and that biocatalytic proofreading by Acx4 
increases carboxylation product yields by almost a factor of four. In the following we used this route 
to produce benzylmalonyl‐CoA at the preparative scale and high purity (Figure S3A). 
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Figure 2 Cinnamoyl-CoA carboxylation using the oxidase Acx4 as a proofreading enzyme to recycle the side product 
dihydrocinnamoyl-CoA allows for efficient benzylmalonyl-CoA biosynthesis. A) Scheme of the benzylmalonyl‐CoA synthesis 
reaction containing the proofreading oxidase Acx4. B) HPLC analysis of an assay containing 100 mM NaPO4 buffer pH 8, 
100 mM KHCO3, 100 µM cinnamoyl‐CoA, 2 mM NADPH and 5.3 µM AntE. Without proofreading the assay produces mainly 
the reduced side product dihydrocinnamoyl‐CoA C) HPLC assay analogue to B containing additionally 2.6 µM of the 
proofreading enzyme Acx4. Using the proofreading oxidase the assay now mainly yields benzylmalonyl CoA.  
 A convenient one-pot, preparative-scale biosynthesis of atypical extender units  
Acx4 was not only useful for biocatalytic proof reading, but also opened a new route to the synthesis 
of atypical extender units. We noticed that when promiscuous Acx4 and promiscuous CcrCPAG are 
combined, it becomes possible to synthesize alkylmalonyl‐CoAs directly from the corresponding 
saturated acyl‐CoAs. Acyl‐CoAs are chemically easily accessible from free CoA and the respective 
saturated acids 21‐22, which are commercially more available and cheaper than their desaturated 
counterparts. We demonstrated the new chemo‐biocatalytic route in the following. First, we 
chemically coupled free CoA with butanoyl‐tschüssikovski bruuuuudiiiiiiiiiii, hexanoyl, 5‐
methylhexanoyl‐ and phenylpropinoyl‐CoA in preparative scale 21. Then, the individual synthesis assays 
were lyophilized, resolved in buffer (100 mM TrisHCl pH 7.5, 100 mM KHCO3) to approx. 1 mM acyl‐
CoA, and incubated with Acx4 (2.4 µM), CcrCPAG (0.8 µM) as well as NADPH (10 mM) for 120 min at 
30 °C (see Figure S2). Progress of the individual reactions was followed by HPLC MS (Figure 3), assays 
were quenched after 120 min, CoA esters were purified via HPLC, lyophilized and yields were 
determined (Table S4). Butylmalonyl‐, hexylmalonyl‐, and 3‐methylbutylmalonyl‐CoA were produced 
at yields of >95% from the corresponding acyl‐CoA ester and around 30% from the used CoA after HPLC 
purification. Only the biosynthesis of benzylmalonyl‐CoA did not run to full completion under the 
chosen conditions, even when the concentration of Acx4 and CcrCPAG was increased (Figure 3E. 
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O
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Nevertheless, we could use this new chemo‐biosynthetic route to prepare three alkylmalonyl‐CoA 
extender units in the mg scale and at purity >95%, as judged by HPLC‐MS (Figure S4 and Table S3).  
  
Figure 3 One pot synthesis of atypical polyketide extender units using the acyl-CoA oxidase Acx4 and the reductive 
carboxylase CcrCPAG. A) General reaction scheme. Assays contained contained 100 mM TrisHCl pH 7.5, 100 mM KHCO3, 
10 mM NADPH, approximately 1 mM acyl‐CoA from the CDI reaction mixture, 2.4 µM Acx4 and 0.8 µM CcrCPAG B) HPLC 
analysis of butylmalonyl‐CoA synthesis. C) HPLC analysis of hexylmalonyl‐CoA synthesis. D) HPLC analysis of 
3‐methylbutylmalonyl‐CoA synthesis. E) HPLC analysis of benzylmalonyl‐CoA synthesis using 5 fold increased CcrCPAG and 8 
fold increased Acx4 concentrations compared to the other assays. 
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 Competition assays verify selectivity-conferring active site residues of PKS 
The incorporation behavior of PKS in the presence of a large variety of extender units at the same time 
has been investigated only sparsely so far. This prompted us to utilize our set of six diverse 
alkylmalonyl‐CoAs in PKS competition assays. As model system, we used a modified DEBS PKS in vitro 
model system that produces triketides 18. We first tested substrate specificity of the WT modules of 
the model system in a competition experiment containing 1 mM of all extender unit; the natural 
substrate methylmalonyl‐CoA as well as the unnatural extender units malonyl‐, ethylmalonyl‐, 
butylmalonyl‐, 3‐methylbutylmalonyl‐, and hexylmalonyl‐CoA. Samples were quenched after 60 min 
incubation at 30 °C and triketides were analyzed by HPLC‐ESI‐TOF. While the WT modules showed 
incorporation of ethyl‐ and butylmalonyl‐CoA, they did not accept 3‐methylbutyl‐, hexyl‐ or malonyl‐
CoA (Figure 4A), indicating that slightly larger extender units are able to enter the WT modules of the 
triketide model system when provided at equal concentrations as the natural extender methylmalonyl‐
CoA. This is well in line with earlier reports on the promiscuity of DEBS WT modules tested with 
individual atypical extender units 23. 
Next, we tested competitive incorporation of atypical extender units into a triketide model system 
with altered selectivity of the AT domain of module 2. To that end we targeted Y754 that is located in 
the YASHS motif of the AT domain, which was previously described to confer methylmalonyl‐CoA 
selectivity 24. We substituted Y754 with valine to increase selectivity of the AT towards longer side 
chains 25. The Y745V showed increased incorporation of atypical extender units in the competitive 
assay, again in line with earlier findings (Figure 4B). Having demonstrated that our multi‐substrate 
competition assay can be used to screen extender unit selectivity, we decided to target a, to our 
knowledge, so far uncharacterized glutamine (Q624 in DEBS module 2), which is highly conserved in 
methyl‐ and ethylmalonyl‐CoA incorporating ATs. In AT4 of the reveromycin PKS 26, which displays 
relaxed selectivity towards longer and branched alkylmalonyl‐CoA extender units, this canonical 
glutamine is replaced with histidine. The Q624H variant showed increased incorporation of atypical 
extender units in the competitive assay, indicating the importance of this residue for substrate 
selectivity (Figure 4C).  
Taken together our results demonstrate the potential of the newly developed synthesis route to 
prepare a set of atypical alkylmalonyl‐CoA extender units that can be used for in vitro screening and 
site directed mutagenesis of PKS to assess their substrate selectivity. Our chemo‐biosynthetic route 
can be easily extended for the synthesis of a large library of atypical extender units. Along with recently 
established in vitro polyketide systems, this will open the way to characterize large libraries of mutants 
in the AT domain, eventually leading to a detailed understanding of the function of active site residues 
that contribute to substrate selectivity in PKS. 
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Figure 4 In vitro extender unit promiscuity screen for triketide biosynthesis of the DEBS polyketide synthase. The WT 
systems production was compared to two variants that were altered in the AT domain of module 2. Assays contained 1 mM 
each of the natural extender unit methylmalonyl‐CoA (1) and of the atypical malonyl‐CoA (2), ethylmalonyl‐CoA (3), 
butylmalonyl‐CoA (4), 3‐methylbutylmalonyl‐CoA (5) and hexylmalonyl‐CoA (6). Assays were incubated for 60 minutes and 
quenched with 5 % formic acid. A) Triketides produced by the WT modules of the in vitro DEBS triketide system. B) Triketides 
produced by the Y754V variant of the AT of module 2 of the DEBS triketide system. C) Triketides produced by the 
Q624H variant of the AT of module 2. Both variants additionally incorporate 3‐methylbutylmalonyl‐CoA (5) and 
hexylmalonyl‐CoA (6). D) Scheme of the produced triketides. E) Model of the AT active site of DEBS module 2 generated with 
SWISS‐MODEL (Bienert et al. 2017) with the [KS3][AT3] didomain crystal structure (2QO3) as template (Tang et al. 2007). 
Highlighted in purple are Serine 652 that carries the malonyl‐CoA extender unit, as well as Tyrosine 754 and Glutamine 624 
that line the alkylmalonyl‐CoA binding pocket and that were targeted by site directed mutagenesis in this study. F) Model of 
the promiscuous AT4 from the reveromycine PKS using the same template. Highlighted is the conserved serine that carries 
the malonyl‐CoA extender unit, as well as the histidine which replaces the conserved glutamine of methyl‐ and ethylmalonyl‐
CoA specific ATs (i.e., Q624 of DEBS AT2). 
 Materials and Methods 
 Plasmid construction 
The expression plasmid for CinF was a generous gift from Rolf Müller 27. The expression plasmid for 
CcrCPAG was previously cloned into pTE‐16b using NdeI and BamHI, mutations were introduced using 
the QuickChange Site‐Directed Mutagenesis Kit (Stratagene, La Jolla, USA)7. The antE, divR, Ndas_0488 
and KSE_65530 were codon optimized and synthesized by the DOE Joint Genome Intitute adding an N‐
terminal 10x His tag and cloned into the backbone pET16b using NcoI and XhoI (see Table S4 for 
complete DNA and protein sequences). 
 ECR and Acx4 preparation 
E.coli BL21 (DE3) (for Acx4 E.coli BL21 AI (DE3)) were transformed with the respective expression 
plasmid and plated on LB‐Agar containing 100 µg/ml Ampicilin (50 µg/ml Kanamycin for CinF). Pooled 
colonies of overnight inoculated petri dishes were used to inoculate 1 L of TB containing the respective 
antibiotic. The expression culture was incubated at 37 °C until an OD600 of 0.8 was reached. Cultures 
for ECR expressions were cooled down to 20 °C and induced with 0.25 mM IPTG and incubated over 
night. Acx4 expression cultures were cooled to 30 °C and induced with 0.25 mM IPTG and 2 ‰ L‐
arabinose and incubated for four hours. Cells were harvested, resuspended in 50 ml Buffer A (50 mM 
TrisHCl pH 7.9, 500 mM NaCl) and lysed by sonication. Lysates were centrifuged at 42,000 g at 4 °C for 
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45 min. The supernatant was then loaded onto a pre‐equilibrated 1 mL HisTrap column (GE Healthcare) 
and washed with 15 % Buffer B (50 mM TrisHCl pH 7.9, 500 mM NaCl, 500 mM imidazole) and eluted 
with 100 % Buffer B. The buffer of the purified proteins was exchanged into the protein storage buffer 
(30 % glycerol, 150 mM NaCl, 25 mM TrisHCl pH 7.9). Protein purity was checked by SDS‐gel 
electrophoresis, concentration of proteins were determined spectroscopically at 280 nm using 
calculated extinction coefficients. For Acx4 the FAD concentration was determined at 450 nm and FAD 
was added to reach an equimolar protein to FAD ratio. Proteins were stored at ‐20 °C. 
 DEBS protein preparation 
The expression plasmids for the in vitro triketide model system of DEBS were constructed according to 
a previously described protocol yielding the plasmids pBL12 (here termed pET28b‐LD(4); the N‐
terminal HisTag of pBL12 was exchanged for a StrepTag), pBL13 (pET28b‐(5)Mod1(2)) and pBL16 
(pET28b‐(3)Mod2TE) 18. E. coli BAP1 was transformed with expression plasmid, 1L of TB expression 
culture was grown to an OD600 of 0.7, cooled down to 18°C, induced with 0.25 mM IPTG and incubated 
over night at 18°C. Cells producing module 1 and module 2 were harvested, resuspended in Buffer C 
(50 mM NaH2PO4 pH 7.6, 450 mM NaCl, 20% glycerol), lysed by sonification and centrifuged at 42,000g 
at 4°C for 45 min. The supernatant was incubated with pre‐equilibrated Protino Ni‐NTA beads (1 mL 
resin) for 1h. The beads were washed with 5% Buffer D (75 mM NaH2PO4 pH 7.6, 500 mM imidazole, 
20 mM NaCl, 10% glycerol) and then eluted with 100%. The elusion was loaded onto a with Buffer E 
(50 mM NaH2PO4 pH 7.6, 10% glycerol) pre‐equilibrated HiTrap Q anion exchange column and eluted 
in a 50 mL NaCl gradient with a final concentration of 500 nM NaCl. Cells expressing the plasmid 
yielding the loading domain were resupended in Buffer C, processed as described above and purified 
over a pre‐equilibrated 1 mL StrepTrap column (GE Healthcare), using 2 mM d‐Desthiobiotin (Sigma‐
Aldrich) for elution. Fractions were tested on an SDS‐PAGE gel, pooled and concentrated with an 
Amicon Ultra‐4 100 kDa (50 kDa for LD(4)) centrifugal filter. A final concentration of 20% glycerol was 
added to the concentrated proteins, their concentration was determined spectroscopically at 280 nm 
and they were stored at ‐80°C. 
 Chemical CDI coupling 
CDI (1,1′‐carbonyldiimidazole) coupling of carboxylic acids to CoA was done according to a previously 
described protocol 21. 42 mg CDI (0.27 mmol, 4 eq.) was dissolved in 2 mL THF and the acid was added 
(0.31 mmol, 4.8 eq.; hexanoic acid: 38.9 µl, octanoic acid: 49.2 µl, dihydrocinnamic acid: 46.5 µl and 
5‐methylhexanoic acid: 43,5 µl). The reactions were stirred for 1 h at 22 °C. 50 mg CoA was dissolved 
in 500 µL 1 mL KHCO3 and added to the reaction. The reaction was stirred for another 45 min and 
tested for remaining free thiols using DTNB, then flash frozen in liquid N2 and lyophilized overnight. 
Samples were then dissolved in 1  mL H2O and used for HPLC‐purification or used for desaturation by 
Acx4 or for direct one‐pot biosynthesis of the extender units. 
 Synthesis of cinnamoyl-CoA using ethylchloroformate coupling 
Synthesis of cinnamoyl‐CoA was done by chemically coupling cinnamic acid to CoA according to a 
previously described protocol21. 37 mg trans‐cinnamic acid (0.25  mmol, 2  eq.) was dissolved in 2 mL 
DCM, 37 µl trimethylamine (0.26 mmol, 2.1  eq) was added and the reaction was stirred at 20°C for 30 
min. The mixture was cooled on ice and 24 µl ethylchloroformate (0.25 mmol, 2 eq.) was added. The 
mixture was stirred on ice for 2h. The DCM was evaporated at room temperature and resuspended in 
2 mL DMF. 100mg CoA (0.125 mmol, 1 eq.) was dissolved in 300µL 1 M KHCO3 and added to the 
mixture at 20 °C. Completion of the reaction was tested using DTNB, the reaction mixture was 
quenched by adding 500 µL of 50 % formic acid, frozen in liquid N2 and lyophilized overnight. The 
sample was dissolved in 2 mL H2O and used for HPLC purification. 
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 Synthesis of malonyl-, methylmalonal- and ethylmalonyl-CoA 
Synthesis of malonyl‐ and methylmalonyl‐CoA was done according to a previously described protocol 
21. 20 mg CoA (1 eq.), 13.2 mg malonic acid (5 eq.) or 15.2 mg methylmalonic acid (5 eq.) and 70.4 mg 
ATP (4 eq.) were dissolved in 5 mL of 200 mM KHCO3 containing 15 mM MgCl2 and 3.2 µM MatB. The 
reaction was incubated at 30°C and completion confirmed with DTNB. The mixture was quenched with 
5% formic acid and directly used for HPLC purification. Ethylmalonyl‐CoA was synthesized by chemical 
coupling of crotonic anhydride with CoA followed by the addition of a CcrCPAG, NADPH and KHCO3. 
10  mg CoA was dissolved in 1 mL 1 M KHCO3.The mixture was cooled on ice and 3.2  µl of crotonic 
anhydride was added and stirred on ice for 30 min. Completion of the reaction was tested using DTNB. 
The reaction mixture was then added to 8 mL of 250 mM TrisHCl pH 7.5 containing 30 mM NADPH, 
250 mM KHCO3 and 100 nM CcrCc IA/CP/FG. The reaction was incubated for 30 min at 30 °C, quenched 
with final concentration 5 % formic acid and directly used for HPLC purification. 
 One pot biosynthesis of extender units 
The enzymatic desaturation with Acx4 as well as the reductive carboxylation was then done using this 
lyophilized reaction mixture without any purification in between. The lyophilized CDI reaction mixture 
(see above) was resuspended in 1 mL of H2O and used directly for the biosynthesis of the extender 
units. A 10 mL assay for extender unit biosynthesis contained 2 mL of 0.5 M TrisHCl pH 7.5 (final 
concentration 100 mM), 1 mL of 1M KHCO3 (100 mM), 500 µL of 200mM NADPH (10 mM), 300 µl of 
the dissolved CDI reaction mixture (theoretical maximum of 50 mM, resulting in an approximate final 
concentration of 1 mM in the assay), 500 µl of 48 µM Acx4 (2.4 µM) and 200 µl of 39 µM CcrCPAG 
(0.8 µM). The mixture was shaken at 200 rpm in a buffled Erlenmeyer flask at 30 °C for 120 min. To 
follow progress of the reaction, 30 µl of the reaction mixture were quenched at various time points 
with the addition of 3 µl of 50 % formic acid and analyzed by analytical HPLC‐MS (Figure 3). The 
reaction was quenched after 120 min with the addition of 1 mL of 50 % formic acid, centrifuged for 10 
min at 17000 g to remove precipitated protein and then purified via HPLC. The purified product was 
lyophilized, resuspended in water and the final yield of the overall reaction and purification was 
determined by determining the extender unit concentration via UV/Vis absorption at 260 nm 
(calculated as (mol product)/(mol CoA) Table S3). 
 HPLC purification of acyl-CoA esters 
All synthesized CoA‐thioesters were purified using a 1260 Infinity LC system (Agilent) using a Gemini 
10 µm NX‐C18 110 Å, 100 x 21.2 mm, AXOA packed column (Phenomenex). The general protocol used 
a flow rate of 25 ml*min‐1 starting with 5  min of 5 % MeOH in 50  mM NH4HCO2 pH  8.2, followed by 
a gradient from 5 % to 40 % MeOH in 15 min, a 2 min washing step at 95 % MeOH and a re‐equilibration 
step of 3  min at 5 % MeOH. Purified CoA‐esters were lyophilized and the purity was checked using 
analytical HPLC‐MS according to the protocol described for the carboxylation vs. reduction assays. 
 Determination of carboxylation vs. reduction ratio of ECR variants 
Assays for the determination of carboxylaton vs. reduction contained 100 mM TrisHCl pH 8, 100 mM 
KHCO3, 10 µgmL‐1 carbonic anhydrase, 150 µM NADPH, 75 µM substrate and 1.5 µg of the respective 
ECR. The reaction was followed on a Cary‐60 UV/Vis spectrometer and quenched upon completion 
with final concentration 5 % formic acid. Assays were then analyzed on a 1260 Infinity LC system 
(Agilent) with attached with a 6130 Quadrupole LC/MS detector (Agilent) using a Luna 3 µm C18(2) 
100 Å, 150 x 2 mm (Phenomenex) column with a flow rate of 0.3 ml*min‐1. For malonyl‐, 
methylmalonyl‐ and ethylmalonyl‐CoA a gradient starting with 3  min of 5 % MeOH in 50  mM NH4HCO2 
pH  8.2, followed by a gradient from 5 % to 25 % MeOH over 20  min, a 2  min washing step at 95 % 
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MeOH and a 3 min re‐equilibration step at 5 % MeOH. All other samples were run using a gradient 
starting with 3  min of 5 % MeCN in 50 mM NH4HCO2 pH 8.2, followed by a gradient from 5 % to 35 % 
MeCN over 20 min, a 2 min washing step at 95 % MeCN and a 3  min re‐equilibration step at 5 % CN. 
 Spectrophotometric enzyme assays 
Enzyme assays were carried out on a Cary‐60 UV/Vis spectrometer (Agilent) using quartz cuvettes (1‐ 
and 10 mm diameter, Hellma). Acx4 characterization was done using 10 mm cuvettes in 100 mM 
TrisHCl pH 8 buffer following double bond formation at 290  nm (D290 = 2.26  mM‐1cm‐1) for all 
substrates except for phenylpropionyl‐CoA (dihydrocinnamoyl‐CoA), which was measured at 308 nm 
(D308.=16.4 mM‐1cm‐1, Figure S2B). ECR characterization for all substrates was in 1‐mM cuvettes 
following NADPH consumption at 360 nm in 100 mM TrisHCl pH8 buffer containing 100 mM KHCO3 
and 500µM NADPH (Figure S4). 
 Extender unit incorporation assays 
Competition assays to test incorporation of extender units into triketides were run at 30°C in 200 mM 
NaH2PO4 with 2 mM NADPH, 4 µM epimerase, 0.2 mM propionyl‐CoA, 1 mM of each extender unit and 
1 µM of LD(4), (5)Mod1(2) and one of the (3)Mod2TE variants. Assays were quenched with 5% formic 
acid after 60 min and analyzed via HPLC‐ESI‐TOF on a 6550 iFunnel Q‐TOF LC‐MS (Agilent) using a 
1.8 µm Zorbax SB‐C18 column, 50 x 2.1 mm (Agilent) using H2O (A) and MeCN (B) both containing 0.1% 
formic acid. The gradient condition were as follows: 0 min 5 % B; 1 min 5  % B; 6 min 95 % B,6.5 min 
95 % B, 7 min 5 % B with a flow rate of 250 µl/min. Capillary voltage was set at 3.5 kV and nitrogen gas 
was used as nebulizing (20 psig), drying (13 l/min,225 °C) and sheath gas (12 l/min, 40°C). MS data 
were acquired with a scan range of 100‐1000 m/z. Data were analyzed using MassHunter Qualitative 
Analysis software (Agilent) and eMZed 28. 
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 Supplementary Information 
Table S1 (related to Figure 1); Overview of the selected promiscuous ECRs 
Enzyme Phylum Family Organism Promiscuity motif Accession code Source 
         
CcrCPAG Proteobacteria Caulobacteriaceae Caulobacter crescentus P A G WP_010920921 Peter D. (10.1002/anie.201505282) 
CinF Actinobacteria Streptomycetaceae Streptomyces sp. JS360 P A G WP_067247071.1 Huo L. (10.1038/nchembio.734) 
AntE Actinobacteria Streptomycetaceae Streptomyces sp. NRRL2288 A V V AGG37751.1 synthesized DOE‐JGI (this work) 
Ndas_0488 Actinobacteria Nocardiopsaceae Nocardiopsis dassonvillei P V F WP_013151542.1 synthesized DOE‐JGI (this work) 
KSE_65530 Actinobacteria Streptomycetaceae Kitasatospora setae T A G YP_004908268.1 synthesized DOE‐JGI (this work) 
DivR Actinobacteria Streptomycetaceae Streptomyces sp. HKI0576 A A V CCA30183 synthesized DOE‐JGI (this work) 
 
Table S2 (related to Figure 1); kcat and Km of the ECR variants towards the tested substrates, Values with yellow background 
were fitted using substrate inhibition. ND = not determinable, errors are given as standard error. 
kcat [s-1]      
 crotonyl‐CoA hexenoyl‐CoA 5‐methylhexenoyl‐CoA octenoyl‐CoA cinnamoyl‐CoA 
CcrCPAG 1.5 ± 0.1 1.4 ± 0.1 0.9 ± 0.1 17 ± 1 0.15 ± 0.01 
CinF 1.84 ± 0.03 1.10 ± 0.04 0.32 ± 0.03 3.5 ± 0.7 0.113 ± 0.003 
AntE 0.81 ± 0.04 1.7 ± 0.1 3.0 ± 0.1 3.1 ± 0.2 0.27 ± 0.01 
Ndas_0488 2.9 ± 0.5 2.8 ± 0.5 1.5 ± 0.1 0.33 ± 0.01 0.28 ± 0.02 
KSE_65530 1.78 ±  0.05 0.50 ± 0.02 0.6 ± 0.1 1.0 ± 0.4 0.03 ± 0.003 
DivR 0.089 ± 0.003 1.0 ± 0.2 0.17 ± 0.01 ND ND 
      
Km [µM]      
 crotonyl‐CoA hexenoyl‐CoA 5‐methylhexenoyl‐CoA octenoyl‐CoA cinnamoyl‐CoA 
CcrCPAG 525 ± 85 74 ± 10 153 ± 45 75 ± 15 3 ± 2 
CinF 154 ± 10 16 ± 2 53 ± 11 11 ±4 52 ± 6 
AntE 218 ± 31 103 ± 18 125 ± 18 133 ± 18 42 ± 6 
Ndas_0488 38 ± 17 58 ± 17 30 ± 5 45 ± 6 160 ± 35 
KSE_65530 111 ± 8 33 ± 5 36 ± 17 100 ± 60 ND 
DivR 10 ± 2 96 ± 30 56 ± 9 ND ND 
 
Table S3 (related to Figure 2) Kinetic characterization of the acyl-CoA oxidase Acx4 
Substrate kcat [s-1] Km [µM] kcat/Km [s-1M-1] 
butyryl‐CoA 30 ± 1.1 66 ± 9 (4.5 ± 0.8)·105 
hexanoyl‐CoA 66 ± 2.1 31 ± 3 (2.2 ± 0.3)·106 
octanoyl‐CoA 2.8 ± 0.3 33 ± 5 (8.5 ± 1.3)·104 
5‐methylhexanoyl‐CoA 7.2 ± 0.3 32 ± 7 (2.3 ± 0.5)·105 
phenylpropionyl‐CoA 0.21 ± 0.01 12 ± 2 (1.8 ± 0.3)·104 
Assays for butyryl‐Coa, hexanoyl‐CoA, octanoyl‐CoA and 5‐methylhexanoyl‐CoA were measured at 290 nm following the 
double bond formation using D290 = 2.26 cm‐1mM‐1. The assay for phenylpropionyl‐CoA was measured at 308 nm using D290 
= 16.6 cm‐1mM‐1 as determined from the spectra of purified phenylpropionyl‐CoA and cinnamoyl‐CoA (Figure S2)  
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Table S4 (related to Figure 3); Yields of extender unit biosynthesis 
Type of acyl-CoA Yield for chemical coupling Yield of one pot synthesis Overall yield after HPLC purification 
    
butylmalonyl‐CoA 57% 99% 27% 
3‐methylbutylmalonyl‐CoA 50% 100% 36% 
hexylmalonyl‐CoA 72% 93% 28% 
benzylmalonyl‐CoA 49% 27% ‐ 
 
benzylmalonyl‐CoA 
(one pot from cinnamoyl‐CoA 
without proofreading) 
 
‐ 8% ‐ 
benzylmalonyl‐CoA 
(one pot from cinnamoyl‐CoA) 
‐ 73% 37% 
 
 
Table S5 (related to Figure 1); Sequences of enzymes used in this study 
CcrCPAG 
DNA 
ATGGGCCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCATATCGAAGGTCGTCATATGACGATTCAGACGCTTGAGACCACCGC
GCTGAAGGACCTGTACGAGATCGGTGAGATCCCGCCGGCCTTCCACGTGCCGAAAACCATGTACGCCTGGAGCATCCGCAAGGAGCGCCA
CGGCAAGCCGACCCAGGCCATGCAGGTCGAGGTGGTGCCCACCTGGGAGATCGGCGAGGACGAGGTGCTGGTGCTCGTGATGGCCGCC
GGCGTCAATTACAACGGGGTCTGGGCCGCTCTGGGCGAGCCGATCAGCCCGCTGGACGGCCACAAGCAGCCTTTCCACATCGCCGGGTCC
GACGCCTCGGGCATCGTCTGGAAGGTCGGCGCCAAGGTGAAGCGGTGGAAGCTGGGCGACGAGGTCGTCATCCACCCGAACCAGGACG
ACGGCGACGACGAGGAGTGCAACGGCGGCGACCCGATGTTCTCGTCCAGCCAGCGCGCGTGGGGCTACGAGACGCCGGACGGCAGCTTC
GCCCAGTTCTGCCGGGTGCAGTCGCGCCAGCTGCTGCCGCGCCCCAAGCACCTGACCTGGGAAGAGAGCGCCTGCTACACCCTGACCCTG
GCCACCGCCTACCGCATGCTGTTCGGCCACAAGCCGCATGAGCTGAAGCCCGGCCAGAACGTGCTGGTCTGGGGCGCCTCGGGCGGTCTT
GGCGTCTTCGCCACCCAGCTGGCCGCCGTGGCCGGCGCCAACGCCATCGGCGTGGTGTCCTCCGAGGATAAGCGCGAGTTCGTGCTGTCG
ATGGGCGCCAAGGCGGTGCTGAACCGGGGCGAGTTCAACTGCTGGGGCCAGCTGCCGAAGGTCAACGGCCCCGAGTTCAACGACTACAT
GAAGGAGAGCCGCAAGTTCGGCAAAGCCATCTGGCAGATCACCGGAAACAAGGACGTCGACATGGTGTTCGAGCACCCTGGCGAGCAGA
CCTTCCCGGTGTCGGTGTTCCTGGTCAAGCGCGGCGGCATGGTGGTGATCTGCGCCGGCACGACGGGCTTCAACCTGACCATGGACGCCC
GCTTCCTGTGGATGCGCCAGAAGCGCGTGCAAGGGTCGCACGGCGCCAACCTGATGCAGGCCAGCGCCGCCAACCAGCTGGTCATCGACC
GCCGCGTCGATCCCTGCCTGTCGGAAGTCTTCCCCTGGGACCAGATCCCGGCGGCCCACGAGAAGATGCTGGCCAACCAGCACCTGCCGG
GGAACATGGCCGTGCTGGTCTGCGCCCAGCGCCCCGGCCTGCGCACCTTCGAGGAAGTGCAGGAGCTGAGCGGGGCGCCATAG 
Protein 
MGHHHHHHHHHHSSGHIEGRHMTIQTLETTALKDLYEIGEIPPAFHVPKTMYAWSIRKERHGKPTQAMQVEVVPTWEIGEDEVLVLVMAAGV
NYNGVWAALGEPISPLDGHKQPFHIAGSDASGIVWKVGAKVKRWKLGDEVVIHPNQDDGDDEECNGGDPMFSSSQRAWGYETPDGSFAQF
CRVQSRQLLPRPKHLTWEESACYTLTLATAYRMLFGHKPHELKPGQNVLVWGASGGLGVFATQLAAVAGANAIGVVSSEDKREFVLSMGAKAV
LNRGEFNCWGQLPKVNGPEFNDYMKESRKFGKAIWQITGNKDVDMVFEHPGEQTFPVSVFLVKRGGMVVICAGTTGFNLTMDARFLWMRQ
KRVQGSHGANLMQASAANQLVIDRRVDPCLSEVFPWDQIPAAHEKMLANQHLPGNMAVLVCAQRPGLRTFEEVQELSGAP 
AntE 
DNA 
ATGGGCCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCATATCGAAGGTCGTCATATGACTAAAGACCTGTACGAACTGGGCG
ACGCTCCGCCACTGGGTACTGCGCCGAAACAGATGTATGCTTCCCTTATCCGCCAGGAGCGTTATGGCCGTCCGGTTGACGCTTTCCGTACC
GAAGTAGTGGATGTACCGCCGGTTGGTCCGGGTCAGGTACTGGTTAAAGTAATGGCAGCTGGCGTAAACTACAACAACGTGTGGGCGGC
ACTGGGTGAGCCACTGGACGTAATTGCAGCGCGCCAGAAACAGGGCGCTACCGAAGACTTTCATATCGGCGGTTCAGACCTGTCTGGCAT
TGTATGGGCGGTTGGTGACGGGGTACGTCTGAAACCGGGTGCAGAGGTTGTGGTTCTGGCTTGTCGTTGGGACGAATCTGCACAGGACAT
CCGCCTGGGCGCTGACCCGGTTACCTCTTCTACTCAGCGTGTATGGGGCTATGAAGAAAACTACGGTTCTTTCGCTCAGTTTGCAGTTGTAG
ACGAATATATGTGCCACCCGAAACCGCAGCGCCTGAGCTGGGCTGCGGCTTCTTGCTACATGGCCACCGCCGCGACCGCCTATCGTCAGCT
GTTCGGCTGGGAACCGCACACTGTTCGTCCGGGTGACCCGGTTCTGATCTGGGGCGGTGCAGGTGGTCTGGGCTCCATCGCGATCCAGCT
GGTACGTCACGTTGGTGGCATCCCGGTAGCTGTGGTGAGCTCCGAAGAACGTGGTGAATTCTGTATGCGCCTGGGCGCGAAAGGTTGGAT
CGACCGTCGTGAATTCGACCACTGGGGTCGTCTGCCGGACACCACTGACGAGGAAGCTATGAAACAGTGGCTGGACGGCGCGCGCGCTTT
CGGTCGTCGTTTCTGGGAAGTTCTGGGTGAACGCCGTGCGCCGCGTATCGTTCTGGAACACTCTGGTGCTGACACCATCCCGACTTCCATCT
ATATGGCTGACAACGCCGGTATGGTGGTTATCTGCGGTGGCACGACTGGCTATAACGGTGACGTTGACCTGCGTTTCCTGTGGATGCGTCA
AAAGCGCCTGCAGGGTAGTCACGTAGCTTCTGCACGCGAAGCACGTGAAATCACTCGCCTGATCGACCAAGGTGCAATCGACCCGTGCCT
GTCCCGTACCTTCGGTTTCGAAGAGATCGGCCTGGCTCACCAGCTGATCCACGATAACCAGCACCCGTCTGGTAACATGGCTGTTCTGGTTA
ACGCAACGGAGTAA 
Protein 
MGHHHHHHHHHHSSGHIEGRHMTKDLYELGDAPPLGTAPKQMYASLIRQERYGRPVDAFRTEVVDVPPVGPGQVLVKVMAAGVNYNNVW
AALGEPLDVIAARQKQGATEDFHIGGSDLSGIVWAVGDGVRLKPGAEVVVLACRWDESAQDIRLGADPVTSSTQRVWGYEENYGSFAQFAVV
DEYMCHPKPQRLSWAAASCYMATAATAYRQLFGWEPHTVRPGDPVLIWGGAGGLGSIAIQLVRHVGGIPVAVVSSEERGEFCMRLGAKGWI
DRREFDHWGRLPDTTDEEAMKQWLDGARAFGRRFWEVLGERRAPRIVLEHSGADTIPTSIYMADNAGMVVICGGTTGYNGDVDLRFLWMR
QKRLQGSHVASAREAREITRLIDQGAIDPCLSRTFGFEEIGLAHQLIHDNQHPSGNMAVLVNATE 
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Ndas_0488 
DNA 
ATGGGCCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCATATCGAAGGTCGTCATATGCCGAAAGACCTGTACGACCTCGGCG
AAGTTCCGCCGCTGGGTCACGTTCCGGCACGTATGCATGCTTTCACTCTGCGTCGCGAACGTTACGGTCAGCCGCGTGAAGCCTTCGCTCG
TGAGGTAGTTCCGGTCCCGCGTCTGGAACCGGGTCACGTACTGGTTTACACCATGAGCGCGGGCATTAACTATAACAACGTATGGGCTGCA
ATGGGTCACCCGGTTGACGTAATCGCAATGCGTGAAAAGGTGGGTGCGGCTGAAGAGTACCACATCGGCGGTTCTGACGGTGCCGGTGT
TGTGTGGGCTGTTGGTGAAGGTGTGCGCGGTGTTGAGGTTGGTGACCACGTAATCATCGCACCGGGCCAGTGGGATGAATCCGCTGACG
ACATTCGTATGGGTCGCGACCCGATCGCATCCCAGTCTATGCGTGTTTGGGGTTACGAGAACAACTTTGGCTCCTTCGGTCAGTTCACTCTG
GTACGTGACATCCAGTGTCACCGCAAACCGGAAAACCTCCCGTGGGACGTTGCAGGCGGTTTCCTGGTATCTGCTGCCACCGCTTACCGTC
AGCTGTTCGGTTGGGAACCGAACGTTGTACGCCCGGGTGACCCGGTTCTGATCTGGGGTGGTGCTGGTGGTCTGGGCACATCCGCAATCC
AGCTGGCTCGTCAAGTTGGTGGCAAGCCGGTAGCTGTGGTTTCCACCGAAGACAAAGCTCGTATGTGCCGTGAACTGGGCGCAGTAGGCG
TTATCCAGCGTACTGAATTCGACCATTGGGGTCGTGTGCCGGACGAGGGCGACACACAGGCTTACGCATCCTGGATGCGTGGTGTGCGCG
CATTCGGCAAGCGCTTCTGGGAAGAACTGGGCGAGCGTCGTGCACCACGTATCGTTTTCGAACACACTGGTGCAGACACTCTGCCGACTTC
TCTGTACCTGTGCGACAATGCTGGCATGGTTGTACTGTGCGGTGCAACCTCTGGTTTCCAGGCAGACGTTGATCTGCGCTTCCTGTGGATGC
GTCTGAAACGCCTGCAGGGTTCCCACTTCGCATCTCCGGCTCAGTGCCGCATGGTAATCGACCTGGTAGCAGGTGGCCAGCTGGATCCGTG
TGTTACTCGTATCGTGGAGTTCGACGAAATTGGTGAAGCGCATCAGCTGATCCGCGACAACGCTCAGCCGCCGGGCAACATGTCTGCTCTG
GTAAACGCACGTGCAGGCCAGACTGGTCTGGACGTTTAA 
Protein 
MGHHHHHHHHHHSSGHIEGRHMPKDLYDLGEVPPLGHVPARMHAFTLRRERYGQPREAFAREVVPVPRLEPGHVLVYTMSAGINYNNVWA
AMGHPVDVIAMREKVGAAEEYHIGGSDGAGVVWAVGEGVRGVEVGDHVIIAPGQWDESADDIRMGRDPIASQSMRVWGYENNFGSFGQF
TLVRDIQCHRKPENLPWDVAGGFLVSAATAYRQLFGWEPNVVRPGDPVLIWGGAGGLGTSAIQLARQVGGKPVAVVSTEDKARMCRELGAV
GVIQRTEFDHWGRVPDEGDTQAYASWMRGVRAFGKRFWEELGERRAPRIVFEHTGADTLPTSLYLCDNAGMVVLCGATSGFQADVDLRFLW
MRLKRLQGSHFASPAQCRMVIDLVAGGQLDPCVTRIVEFDEIGEAHQLIRDNAQPPGNMSALVNARAGQTGLDV 
KSE_65530 
DNA 
ATGGGCCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCATATCGAAGGTCGTCATATGCAGATGGACGAACTGACAGAAGCGG
TTCTGCGTGACGCTCCGCCGGAGGAACTGTCTCGTCTGCCGCTGCCGAAAGACTATACCGCAGCACACCTGCTGCGCCAGGACGTAGAAAT
GTTCCATGGCGTGGCTGATAAAGACGTTCGCCGCAGCCTGCATGTTGGTCGCGTACCGCTGCCGGAACTGGCTCCGGACGAAGTGCTCGT
TGCTGTTATGGCGTCTTCCGTTAACTACAACACCGTATGGTCTGCAACTTTCGAGCCGGTTTCCACCTTCGACGCTCTGCGTCGTTACGCTCG
CAGCGGTGGCTGGCAGGCACGCCACGATCAGCCGCACCAGGTAATCGGCTCTGACGCAGCTGGTGTTATCGTACGTACGGGCGCTGGCGT
ACGCCGTTGGCAGGTAGGTGATCATGTTGCGGTATCTACCGCTGTGGTGGACGACCAGGACCCAGTTACTCACACTGACGGCATGCTGGG
TGCAGATCAGAAGGCATGGGGTTACGAAACCAACTTCGGCGGCTTGGCTCACTACACTGTTGTTCGTGCGTCTCAGCTGATCGCTAAACCG
CCACACCTGACCTGGGAAGAAACTGCTAGCATCCCGCTGTGCGGTGGCACAGCATACCGTATGTTAGTTTCTGAAAAAGGTGCTCGTATCA
AACAGGGTGACATCGTACTTATCTGGGGTGCGTCCGGTGGTCTGGGTGCATTCGCTGTTCAGCTGGTTAAGAACGGTGGTGGTATTCCGG
TAGGTGTTGTAAACTCTGAACGTAAAGCAGAACTTGTACGTCGTCTGGGCTGTGACGTAGTTATCAACCGTGAAGAAATTGGTATCGGTAA
AGCACCGGAAAGCCCGCAGGAAACTGTTGAACTGGCTAAGCGCCTGGGTCGTGCCATCCGTTCTCAGGTTGGTGAAGACCCGCACATCGT
ATTCGACCATGTAGGTAAAGCAACCTTTGGCATCAGCGTTATCGTTGCGCGTCGTGGTGGTACCGTTGTAACTTGCGGCTCTTCCACCGGCT
ACCAGCACACCTTCGATAACCGTTACTTCTGGATGAACCTGAAGCGTATCGTAGGTTCTCATGGTATGAACCTGGGCGAGGCTGCTGAAAT
GATGCGTCTGTACAAACTGGGTCTGCTGGCACCGGTTGTTTCTCGCACTTACCCACTGGCAGAAGTTGGCGAAGCGGCTCGTCTGGTTCAA
AACAACCAGCACACCGGCAAAATCGGTGTGCTGTGTCTGGCAGACCAACCGGGTCTGGGTGTTACCGACCCGGCAACTCGCGCTCGTCTG
GGCGAGGACTGGCTGCGTCCGCTGGCAGAGGACCGTGTTCCGGCTCTGGCTGGCTAA 
Protein 
MGHHHHHHHHHHSSGHIEGRHMQMDELTEAVLRDAPPEELSRLPLPKDYTAAHLLRQDVEMFHGVADKDVRRSLHVGRVPLPELAPDEVLV
AVMASSVNYNTVWSATFEPVSTFDALRRYARSGGWQARHDQPHQVIGSDAAGVIVRTGAGVRRWQVGDHVAVSTAVVDDQDPVTHTDGM
LGADQKAWGYETNFGGLAHYTVVRASQLIAKPPHLTWEETASIPLCGGTAYRMLVSEKGARIKQGDIVLIWGASGGLGAFAVQLVKNGGGIPV
GVVNSERKAELVRRLGCDVVINREEIGIGKAPESPQETVELAKRLGRAIRSQVGEDPHIVFDHVGKATFGISVIVARRGGTVVTCGSSTGYQHTFD
NRYFWMNLKRIVGSHGMNLGEAAEMMRLYKLGLLAPVVSRTYPLAEVGEAARLVQNNQHTGKIGVLCLADQPGLGVTDPATRARLGEDWLR
PLAEDRVPALAG 
DivR 
DNA 
ATGGGCCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCATATCGAAGGTCGTCATATGGCGGTGGGTTCTCTGACCGATGCACC
GGCAGACGCAGTTTCTGCTGAAGAAAACGTTGGTGCAGACCTGCCGGCAGAATTCCGTGCAGTACATATCTGCGCGGAAGACGAAGCAAT
GTTCTCCGACCTGTCTGATAAAGACGTACGTAAATCCCTGCGCGTTGGCCCGGTTGCTATGCCAGAACTGGCTCCGGACGAAGTTCTGATC
GCAGTTATGGCATCTTCTGTTAACTACAACACCGTATGGAGCGCTCAGTTCGCACCGGTGTCTCCGTTTCGCTTCCTGGAGAAATTCGGTCG
TCGTGGTGGCTGGGCTGCACGTCACGACCTGCCGCACCAGGTTCTGGGTTCTGACGCTGCTGGCGTAGTAGTGCGTACTGGTTCCGGTGTT
CGCCGCTGGCGTGTAGGTGATCACGTTGTAGTTAGCGCCGCATACGTAGACGAACAGGACCCGGGTACGCACGCAGATGGTATGATCGGT
GAAGACCAGCTGGCATGGGGCTACGAAACTAACTTCGGTGGCATGGCTGACTATGCGGTTGCTCGCGCAAGCCAGCTGATCCCGAAACCG
CCGCACCTGACCTGGGAAGAAGCTGCATCTAACACTGCATGCGCATCTACCGCGTACCGTATGCTAGTAGGTGAGCGCGGTGCTCGTATGA
AACAGGGTGACGTAGTTCTGGTATGGGGTGCAGCTGGCGGTCTCGGCTCCTACGGTGTTCAGCTGGTTCGTAACGGTGGTGGCGTACCGG
TGGCAGTAGTGTCTTCCGCTCGCAAAGCTGAAGCAGTTCGTCGTCTGGGTTGTGATATTGTAGTTGACCGCGCTGAGATCGGTCTGACTGA
CGATCCGACCGACGACCCGGATGAGGTAATTCGTATCGGTAAACGCCTGGGTGCAATCATCCGTGAACGTACCGGTCGCGACCCGGACAT
CGTATTCGAGCACATCGGTCGTGCTACCTTCGGCGTATCTGTTTTCGTTGTACGTCGCGGTGGTGTAGTAGTTACTTGTGGTAGCTCTACCG
GTTACCAGCATGTATTCGATAACCGTTATCTGTGGATGAAACTAAAACGTGTAGTAGGCTCTCACGTTGCAAACCTGCAGGAAGCGTGGGA
CTGCAACCGCCTGTTTGAATTGGGTGCAATCGTACCGACTGTTAGTGCAGTATTCCCGATGGACGAGGTGGGCGAGGCTGTTCGCATCGTG
CAGAACAACCGCCACATTGGCAAAATCGCGGTACTGTGTCAGGCTGACCGCCCTGGTCTGGGTGTTACCGACCCGGAACTGCGTGCTCGT
GTAGGTGGCGACGATCGCCTGAACCCGCTGCGTGGGATGACTGCGGTAGGCGAAGGTGAATAA 
Protein 
MGHHHHHHHHHHSSGHIEGRHMAVGSLTDAPADAVSAEENVGADLPAEFRAVHICAEDEAMFSDLSDKDVRKSLRVGPVAMPELAPDEVLIA
VMASSVNYNTVWSAQFAPVSPFRFLEKFGRRGGWAARHDLPHQVLGSDAAGVVVRTGSGVRRWRVGDHVVVSAAYVDEQDPGTHADGMI
GEDQLAWGYETNFGGMADYAVARASQLIPKPPHLTWEEAASNTACASTAYRMLVGERGARMKQGDVVLVWGAAGGLGSYGVQLVRNGGG
VPVAVVSSARKAEAVRRLGCDIVVDRAEIGLTDDPTDDPDEVIRIGKRLGAIIRERTGRDPDIVFEHIGRATFGVSVFVVRRGGVVVTCGSSTGYQH
VFDNRYLWMKLKRVVGSHVANLQEAWDCNRLFELGAIVPTVSAVFPMDEVGEAVRIVQNNRHIGKIAVLCQADRPGLGVTDPELRARVGGDD
RLNPLRGMTAVGEGE 
Acx4 DNA 
ATGGGCCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCATATCGAAGGTCGTCATATGGCAGTGTTATCGTCAGCGGATCGTGC
GTCTAACGAAAAGAAAGTGAAATCCAGCTATTTCGATCTTCCGCCTATGGAGATGTCTGTGGCCTTTCCACAAGCAACACCAGCCAGCACTT
TTCCACCGTGTACGAGCGATTACTATCACTTCAACGATCTGCTCACCCCGGAAGAACAGGCGATCCGCAAGAAAGTGCGCGAATGCATGGA
AAAGGAAGTAGCTCCGATCATGACAGAGTACTGGGAGAAAGCCGAATTTCCGTTTCACATTACCCCGAAACTGGGTGCAATGGGAGTGGC
TGGTGGGAGCATCAAAGGCTATGGATGCCCCGGCTTGTCGATTACCGCGAATGCTATTGCCACCGCAGAGATTGCACGCGTTGATGCCAG
TTGCTCAACGTTCATTCTGGTCCATTCAAGCCTGGGTATGCTGACCATCGCTTTGTGTGGCTCTGAAGCGCAGAAAGAGAAATACTTACCGT
CCTTGGCGCAACTGAACACTGTAGCGTGTTGGGCCCTGACGGAACCGGATAACGGCTCTGACGCGTCGGGTCTGGGTACCACAGCAACCA
AAGTTGAAGGCGGTTGGAAAATCAATGGTCAGAAACGCTGGATTGGCAATAGCACGTTTGCGGATCTGCTCATTATCTTTGCCCGTAATAC
GACGACTAACCAGATTAACGGCTTTATCGTGAAGAAGGATGCTCCAGGCCTGAAAGCGACCAAGATTCCGAACAAAATCGGTCTGCGCAT
GGTTCAGAATGGCGACATTCTTCTGCAGAACGTGTTCGTTCCGGATGAGGATCGCTTGCCCGGCGTCAACTCCTTCCAAGACACCAGTAAA
GTGTTAGCCGTTAGCCGTGTCATGGTTGCCTGGCAACCTATCGGAATTTCGATGGGCATCTACGACATGTGTCATCGCTATCTGAAAGAAC
GGAAACAGTTTGGTGCTCCTTTAGCGGCCTTCCAGCTGAATCAACAGAAACTTGTGCAGATGCTGGGGAATGTACAAGCGATGTTTCTTAT
GGGCTGGCGTCTGTGCAAACTCTATGAAACGGGCCAGATGACTCCCGGACAGGCTTCGCTGGGGAAGGCATGGATTAGTTCCAAAGCCCG
TGAAACCGCGTCATTAGGTCGTGAACTGCTGGGCGGCAATGGGATTCTGGCAGACTTTCTGGTCGCCAAAGCGTTCTGCGATTTGGAACC
GATCTATACCTATGAGGGGACTTACGACATTAACACCCTCGTAACCGGTCGCGAAGTCACGGGTATTGCGAGTTTCAAACCGGCAACACGC
AGCCGGCTGTAA 
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Protein 
MGHHHHHHHHHHSSGHIEGRHMAVLSSADRASNEKKVKSSYFDLPPMEMSVAFPQATPASTFPPCTSDYYHFNDLLTPEEQAIRKKVRECMEK
EVAPIMTEYWEKAEFPFHITPKLGAMGVAGGSIKGYGCPGLSITANAIATAEIARVDASCSTFILVHSSLGMLTIALCGSEAQKEKYLPSLAQLNTVA
CWALTEPDNGSDASGLGTTATKVEGGWKINGQKRWIGNSTFADLLIIFARNTTTNQINGFIVKKDAPGLKATKIPNKIGLRMVQNGDILLQNVFV
PDEDRLPGVNSFQDTSKVLAVSRVMVAWQPIGISMGIYDMCHRYLKERKQFGAPLAAFQLNQQKLVQMLGNVQAMFLMGWRLCKLYETGQ
MTPGQASLGKAWISSKARETASLGRELLGGNGILADFLVAKAFCDLEPIYTYEGTYDINTLVTGREVTGIASFKPATRSRL 
 
 
 
Figure S1 (related to Figure 1 and Table S2) Michaelis-Menten plots of characterized ECR variants as well as Acx4. 
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Figure S2 (related to Figure 3) HPLC traces of every step in the synthesis of butylmalonyl-CoA. A) HPLC trace after chemical 
coupling. Amount of hexanoyl‐CoA was assessed by comparing the absorption of hexanoyl‐CoA at 260nm to all other 
absorbing species in the mixture at this wavelength. B) HPLC trace after oxidation and carboxylation of hexanoyl‐CoA. Purity 
was assessed by the absorption of butylmalonyl‐CoA compaired to all other absorbing species except of the NADPH/NADP+ 
peak at 260 nm. C) HPLC trace of the purified butylmalonyl‐CoA. 
  
A
B
C
Combining promiscuous acyl-CoA oxidase and enoyl-CoA carboxylase/reductases for atypical 
polyketide extender unit biosynthesis 
97 
 
 
Figure S3 (related to Figure 3) Progress of up-scaled benzylmalonyl-CoA synthesis from cinnamoyl-CoA. A) The assay 
contained 100 mM TrisHCl pH 8, 100 mM KHCO3, 1 mM cinnamoyl‐CoA, 20 mM NADPH, 40 µgmL‐1 carbonic anhydrase, 20 
Acx4 and 2.1 µM CcrCPAG. B) Extinction coefficients of cinnamoyl‐CoA, dihydrocinnamoyl‐CoA and benzylmalonyl‐CoA.  
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Figure S4 (related to Figure 3) Purity of all synthesized extender units assessed by HPLC-MS (left panel; HPLC trace at 260 
nm, right panel; m/z of the elution peak) 
 
 99 
 
  
 100 
 
 
 
 
 
 
 
CHAPTER VI 
Trifunctional propionyl-CoA synthase: A self-
organizing, multi-catalytic ‘pico’-compartment 
that sequesters a reactive intermediate 
 
Authors:  
Iria Bernhardsgrütter*, Bastian Vögeli*, Tristan Wagner, Dominik M. Peter, Niña 
Socorro Cortina, Gert Bange, Sylvain Engilberge, Eric Girard, François Riobé, 
Olivier Maury, Seigo Shima, Jan Zarzycki, Tobias J. Erb 
 
 
* These authors contributed equally to this work 
 
 
 
Submitted to:  
Science 
 
Author contributions:  
I.B, B.V, D.M.P, J.Z, and T.J.E conceived the project. I.B, B.V, T.W., J.Z, and T.J.E 
designed and performed experiments and analyzed the data. E.G, F.R, and O.M 
designed and prepared the phasing compound Tb‐Xo4. I.B, B.V, S.E, E.G, T.W and 
J.Z collected X‐ray data sets, T.W and J.Z solved crystal structures. E.G, G.B, and 
S.S oversaw crystallography and SAXS experiments, provided equipment and 
beam‐time. N.S.C. performed mass spectrometry and analyzed the data. I.B, B.V, 
T.W, J.Z, and T.J.E wrote the manuscript with contributions from all other 
authors. 
Trifunctional propionyl-CoA synthase: A self-organizing, multi-catalytic ‘pico’-compartment that 
sequesters a reactive intermediate 
 
101 
 
6. Trifunctional propionyl-CoA synthase: A self-organizing, multi-
catalytic ‘pico’-compartment that sequesters a reactive intermediate 
 Abstract 
Cells need to cope with toxic or reactive intermediates formed during metabolism. One strategy is to 
sequester reactions that produce such intermediates within specialized compartments. Here we show that 
propionyl‐CoA synthase (PCS), a dimeric 400 kDa three‐domain fusion protein and the key enzyme of the 3‐
hydroxypropionate bi‐cycle for CO2‐fixation, forms a self‐assembling, multi‐catalytic compartment to 
sequester the reactive intermediate acrylyl‐CoA. Structural analysis revealed protomer mimicking as core 
building principle of PCS. Kinetic analysis suggests that compartment access and catalysis are synchronized 
by sophisticated interdomain communication. The reaction chamber of PCS features three active sites and 
has a volume of only 33 nm³. This is three orders of magnitude smaller than average bacterial 
microcompartments and more than two orders of magnitude smaller than other proteinaceous 
nanocompartments. Thus, PCS represents the smallest multi‐reaction chamber described in biology to date 
that could inspire the engineering of a new class of dynamically regulated nanoreactors. 
 Introduction 
Biological systems face the challenging task to efficiently catalyze hundreds to thousands of different 
chemical reactions in one 'pot', the cytoplasm. Diffusion is relatively fast compared to biochemical reactions, 
which leads to uniform concentrations of metabolites in the cytoplasm, in particular when considering the 
size of microbial cells 1. This can result in 'cross‐talk' between metabolic pathways and cause cross‐inhibition, 
inactivation or even irreparable damage to metabolism, especially when the respective intermediates are 
instable or reactive 2. Nature has evolved several strategies to ensure that problematic pathway 
intermediates are not released into the cytoplasm, but directly transferred to the next enzyme or active site. 
These strategies include encapsulation of intermediates in membrane or protein delimited organelles 
(compartmentalization), covalent linking of intermediates to multi‐domain enzyme complexes or carrier 
proteins, electrostatic guidance of intermediates from one active site to the next, or formation of 
intramolecular tunnels between two active sites 3.  
Here, we report on the enzyme reaction cascade from 3‐hydroxypropionate to propionyl‐CoA, which is the 
key sequence in the 3‐hydroxypropionate bi‐cycle for autotrophic CO2 assimilation 4‐5. The overall sequence 
comprises three enzymatic steps, during which a highly reactive, toxic and unstable intermediate, acrylyl‐
CoA, is formed. In autotrophic Sulfolobales the three reactions are catalyzed by individual enzymes 6‐7. 
However, in several phyla (e.g. Proteobacteria and Chloroflexi, Figure S1) the three reactions are catalyzed 
by a fusion enzyme of about 1850 amino acids, that comprises three catalytic domains, the propionyl‐CoA 
synthase (PCS, Figure 1a, Figure S2) 4. We wondered if PCS specifically evolved as a fusion enzyme to 
overcome free diffusion of reactive acrylyl‐CoA. Therefore, we overproduced PCS from Erythrobacter sp. 
NAP1 (GenBank accession no. EAQ29651) and studied how this multi‐domain enzyme copes with its reactive 
intermediate, acrylyl‐CoA.  
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 Results 
 HPLC analysis of PCS reaction indicates that acrylyl-CoA is sequestered 
When we followed the overall reaction of PCS, we could not detect acrylyl‐CoA in the assay mixture, while 3‐
hydroxypropionyl‐CoA and propionyl‐CoA accumulated (Figure 1b). Only when we increased the 
concentration of the enzyme, acrylyl‐CoA was detectable, albeit at very low levels (Figure 1c). The 
concentration of acrylyl‐CoA corresponded to 1.8 ± 0.1 % of PCS monomers and stayed constant during 
steady state. This demonstrated that acrylyl‐CoA was formed in situ by the dehydratase domain, but 
presumably stayed sequestered within PCS being quickly consumed by the reductase domain. Notably, when 
the reduction reaction was prevented (by omitting NADPH), acrylyl‐CoA did not accumulate, while 3‐
hydroxypropionyl‐CoA still did (Figure 1d). This indicated that even when interrupting the catalytic sequence, 
acrylyl‐CoA remains sequestered within PCS.  
 The overall structure of PCS 
To understand the structural basis of acrylyl‐CoA sequestration, we solved the crystal structure of PCS in the 
presence of CoA, NADP+ and an ATP analog (phosphomethylphosphonic acid adenylate ester) using a new 
phasing compound 8 (PDB 6EQO, Table S1 and Figure S3). PCS forms a dimer (of 400 kDa) around a central 
core of reductase domains (Figure 1a). The ligase and dehydratase domains extend to both sides, enclosing 
spherical compartments (‘reaction chambers’) that each feature three internal active sites (Figure 2). The 
active sites are interconnected through positively charged surfaces, suggesting electrostatic guidance of the 
CoA intermediates during catalysis. Escape of intermediates from the reaction chamber is prevented by 
negative charges surrounding any small openings. The inner diameter of the reaction chamber is between 
3.5 – 5.5 nm with a volume of 33 nm³. This volume is between three and six orders of magnitude smaller 
than that of bacterial microcompartments 9, for example carboxysomes (12 × 103 to ~10 × 107 nm3, calculated 
from inner diameters ranging from 30 to 600 nm) 10, two orders of magnitude smaller than of described 
nanocompartments, such as encapsulins (5 × 103 nm3, calculated from inner diameter of 22 nm) 11, and even 
half of that of proteasomes (59 and 84 nm3) 12. Thus, PCS forms the smallest multi‐catalytic reaction chamber 
observed in Nature, a ‘pico’‐compartment.  
 Molecular mimicry and organization of the reaction chamber 
The active sites of the individual domains of PCS align well with the ones of lone‐standing homologues (acyl‐
CoA ligase, dehydratase and reductase Figure S4, S5 and S6). These lone‐standing homologues are organized 
as homo‐oligomers that require contributions from neighboring protomers 13‐15. In the reaction chamber of 
PCS that is organized as a monomer, there are no neighboring protomeric subunits that could contribute to 
active site formation. Instead, the domains of PCS carry extra extensions to mimic the contributions from the 
other subunit(s) present in the lone‐standing homologues (Figure S7, S8 and S9). As an example, the 
dehydratase domain of PCS features additional helices (Figure S8) containing two highly conserved residues 
(F1220 and K1223 14) that are involved in the stabilization of the CoA‐ester. In case of lone‐standing 
dehydratase homologs, which form homotrimers, these residues usually protrude into the active site of a 
neighboring subunit of the homo‐trimeric complex. Another example is the reductase domain of PCS that 
carries a structural extension that mimics the part of the CoA binding site that is provided by a neighboring 
subunit in lone‐standing enoyl‐CoA reductases/carboxylase homologues, which are organized as 
homotetramers (Figure S9). Furthermore, the ligase domain of PCS carries structural extensions that are 
absent in any lone‐standing acyl‐CoA synthetase homologues (Figure S7), most prominently, an additional 
four helix bundle. This four‐helix bundle appears to be unique to PCS and is exclusively found in PCS 
homologues (based on BLASTP analysis). This four helix bundle caps one side of the reaction chamber. Its 
absence would leave the enzyme compartment wide open (Figure S12). 
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Figure 1. Trifunctional PCS: Structure and catalytic behavior. a, Dimeric structure of PCS from Erythrobacter sp. NAP1 (PDB 6EQO). 
One protomer is depicted in cartoon and one in surface representation. The multi‐domain organization is highlighted by different 
colors: orange, ligase domain; purple, dehydratase domain; cyan, reductase domain; blue sphere, N‐terminus; red sphere, C‐
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terminus. Schematic arrangement of the three domains and their individual reactions are shown using the same color code. b, Time 
course of the overall reaction with 0.1 µM PCS, 800 µM CoA, 500 µM 3‐hydroxypropionate, 800 µM ATP and 300 µM NADPH. 
Production of the 3‐hydroxypropionyl‐CoA intermediate (orange) and the final product propionyl‐CoA (cyan) was observed. In 
contrast no free acrylyl‐CoA was detectable. c, Time course of the reaction containing 10 µM PCS, 5 mM CoA, 5 mM 3‐
hydroxypropionate, 5 mM ATP and 5 mM NADPH. At these high enzyme concentrations acrylyl‐CoA (purple) was detected at 0.18 
µM during steady‐state corresponding to 1.8% occupancy of reductase active sites. 3‐Hydroxypropionyl‐CoA und propionyl‐CoA 
accumulate over time. d, as in ab, but without NADPH. Again, formation of 3‐hydroxypropionyl‐CoA was observed, but not of free 
acrylyl‐CoA. e, Isotopic labeling competition experiment containing unlabeled 3‐hydroxypropionate and either 13C‐labeled 3‐
hydroxypropionyl‐CoA (experiment 1) or acrylyl‐CoA (experiment 2). The reaction was started by the addition of PCS. Products were 
analyzed by LC‐MS (see Table S4 for detailed assay conditions). f, Results of the isotopic labeling competition experiment. Only 0.8 ± 
0.4 % of propionyl‐CoA was produced from exogenous 13C‐labeled 3‐hydroxypropionyl‐CoA during steady state (experiment 1). 
Approximately every fifth propionyl‐CoA (21 ± 15%) was formed from exogenous 13C‐labeled acrylyl‐CoA during steady‐state 
(experiment 2). b – d, data of a representative single experiment. f, data mean ± s.d. (n=3). 
 Biochemical characterization of PCS 
How is the sequence of reactions orchestrated within the compartment? The three enzyme reactions of PCS 
can be measured individually, when the appropriate substrates and cofactors are provided, demonstrating 
that all active sites are in principle accessible 4. We determined the kinetic parameters for the overall reaction 
of PCS as well as for each catalytic domain. While the ligase and the dehydratase domain had apparent 
turnover frequencies (kcat) comparable to the overall reaction of PCS, the kcat of the reductase domain was 
almost 30‐fold higher (Figure S10, Table S2 and S3). This suggests that acrylyl‐CoA is immediately consumed 
upon its formation in situ. To study whether externally provided intermediates can access the reaction 
chamber of PCS during steady‐state, we performed an isotopic labeling competition experiment 16‐17. When 
starting from 3‐hydroxypropionate, PCS preferentially catalyzed the overall reaction. Externally added 3‐
hydroxypropionyl‐CoA or acrylyl‐CoA were used only to a small extent by PCS under these conditions (Figure 
1e, 1f and Table S4). In other words: despite the high catalytic efficiency of the reductase domain, almost no 
externally added acrylyl‐CoA was reduced by PCS in the steady‐state. Note that the formed 13C labelled 
propionyl‐CoA (21 ± 15 %) corresponds with the amount that the reductase is able toform by incorporation 
of external acrylyl‐CoA within the first 0.6 s and thus before steady‐state of the overall reaction is reached. 
These results demonstrated that catalysis in PCS is consecutive, and that internally produced 3‐
hydroxypropionyl‐CoA and acrylyl‐CoA are channeled within the enzyme. 
 Interdomain communication in PCS 
Apparently, external acrylyl‐CoA is prevented from entering the reaction chamber of PCS indicating that the 
enzyme assumes a ‘closed state’ during catalysis. Therefore, we wondered, if any of the substrates (CoA, ATP, 
3‐hydroxypropionate) or products (AMP) would restrict access of exogenous acrylyl‐CoA to the reductase 
domain during steady‐state. Indeed, CoA had a strong effect on both the KM and the kcat of acrylyl‐CoA 
consumption by the reductase domain. To measure the influence of CoA on the reduction reaction, we used 
the E1027Q variant that is unable to hydrate acrylyl‐CoA and added different concentrations of CoA. At low 
concentrations (0.3 mM), CoA acted as competitive inhibitor of the reduction reaction (Figure S11), 
suggesting that free CoA directly competes with acrylyl‐CoA at the active site of the reductase domain. At 
higher concentrations (3.0 mM), free CoA additionally acted as non‐competitive inhibitor, indicating that a 
second CoA binding site outside of the reductase domain influenced the reduction reaction. We speculated 
that this binding site was located in the ligase domain. We substituted a conserved lysine (K783) in the ligase 
domain that directly interacts with CoA by methionine in the E1027Q variant (Figure S12). The interaction 
between K783 and CoA is suggested to stabilize the closed conformation of PCS. The K783M mutation 
rendered the ligase as well as the reductase domains still functional. Notably the non‐competitive inhibition 
of CoA on the reductase domain was completely removed in this variant (Figure S11). Thus, we concluded 
that the ligase domain and the reductase domain act not independently from each other and that the K783 
plays an important role in communication between the two domains. The hypothesis that the domains in 
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PCS act in a synchronized fashion was additionally supported by the observation that NADPH (the co‐
substrate of the third reaction) in turn had a strong effect on the kinetic parameters of the first reaction. The 
ligase reaction alone had an apparent Michaelis‐Menten constant for CoA (KM,CoA) of 6 ± 3 mM. However, 
when we added NADPH to the reaction mixture, KM,CoA decreased by a factor of 30 to 0.22 ± 0.05 mM 
(Figure S11, Table S2). To test whether the effect of NADPH onto the ligase reaction was independent from 
an active reductase domain, we repeated the same assay with a dehydratase mutant of PCS (E1027Q). In this 
enzyme variant, the reductase domain is still functional, but is not provided with substrate because of the 
inactive dehydratase domain. In the E1027Q variant KM,CoA dropped even below that of wt PCS to 0.019 ± 
0.003 mM (Figure S11, Table S2). These results clearly confirmed that the individual domains of PCS are 
coupled with each other and that interdomain communication in PCS works in both directions (Figure S10, 
Table S2). 
 Opening and closing of the reaction chamber 
The kinetic characterization demonstrates a functional coupling of the last reaction step in PCS to the first 
one and vice versa. Apparently, PCS undergoes synchronized conformational changes during catalysis 
allowing substrates and products to enter and leave the reaction chamber. The gatekeeper to the reaction 
chamber of PCS is presumably the ligase domain. Stand‐alone CoA ligases undergo significant conformational 
changes between ‘open’ and ‘closed’ states during catalysis 13, 18. When we superposed a ‘closed‐state’ 
Salmonella enterica ligase (PDB 2P2F) 13 with the PCS ligase domain, the structures aligned almost perfectly 
(rmsd of 0.932 Å over 441 Cα‐atoms) with the exception of a four‐helix bundle extension only present in PCS 
(Figure S7). The N‐terminus of an ‘open‐state’ ligase of Saccharomyces cerevisiae (PDB 1RY2) 18 still aligned 
well to the PCS ligase domain (rmsd of 0.955 Å over 374 Cα‐atoms), whereas the C‐terminal domain (~130 
residues) was rotated outwards. Modelling a corresponding conformational change onto PCS results in the 
exposure of a ‘hole’ that provides access to the interior of an ‘open state’ compartment (Figure S12). Upon 
binding of CoA and formation of 3‐hydroxypropionyl‐CoA by the ligase domain, the reaction chamber 
becomes shut, keeping the intermediates enclosed. 
We performed limited proteolysis on PCS with trypsin in the absence and presence of different substrates 
and products to directly test for conformational changes (Figure S13). When incubated in the presence of 
CoA, which restricts access to the active site of the reductase (see above), PCS was fragmented within 90 
min. In contrast, the simultaneous addition of 3‐hydroxypropionate, NADP+ and ATP protected PCS from total 
proteolysis (Figure S14). This confirmed that the enzyme assumed different conformations depending on the 
presence of different substrates or products, orchestrating and synchronizing catalysis. SAXS analyses of PCS 
in the presence of different substrates support this conclusion (Table S5). 
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Figure 2. Multi-catalytic reaction chamber of PCS. Volume filling representation19 of the reaction chambers enclosed by PCS. The 
central catalytic reaction chamber of each protomer is formed through the contribution of all three domains. Orange, contribution 
of the ligase domain; purple, contribution of the dehydratase domain; cyan, contribution of the reductase domain. The close up 
shows a cross section through the reaction chamber. Electrostatic charge distribution is shown as a gradient from red – negatively 
charged to blue – positively charged. The three active sites are well connected within the reaction chamber. Large positively charged 
patches may guide the CoA‐ester intermediates or help retaining them inside during catalysis. Negative charges around the small 
openings may also prevent leakage of the negatively charged CoA‐derivatives. The PCS structure co‐crystalized with CoA (no density), 
an ATP analog and NADP+ is depicted in cartoon showing the ligase domain in orange, the dehydratase domain in purple and the 
reductase domain in cyan. CoA binding sites have been modelled based on the superposition of the structures of lone‐standing CoA 
ligase (PDB 2P2F) 13, dehydratase (PDB 5JBX) 14 and reductase (PDB 4A0S) 15 onto PCS (compare Figure S4, S5 and S6). Distances 
between the active sites have been determined by measuring the distance between sulfur atoms of modelled CoA moieties to be: 
ligase ‐ dehydratase 42.5 Ǻ, dehydratase – reductase 33.7 Ǻ, ligase – reductase 63.5 Ǻ. 
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 The catalytic cycle of PCS 
Taken all our results together we propose the following catalytic mechanism (Figure 3). First the ligase forms 
the 3‐hydroxypropionyl‐AMP from ATP and 3‐hydroxypropionate in the open conformation. Binding of CoA 
then closes the reaction chamber. NADPH facilitates the binding of CoA, which is consistent with the lowered 
KM,CoA observed upon NADPH addition and would ensure that the enzyme contains all necessary cofactors to 
catalyze the complete reaction sequence upon closing the chamber. The formed 3‐hydroxypropionyl‐CoA is 
subsequently dehydrated to acrylyl‐CoA within the closed reaction chamber, isolated from the external 
environment. The final reduction reaction would trigger the re‐opening of the reaction chamber for product 
release and prepare the enzyme for the next catalytic cycle. This mechanism fits well with the observation 
that the kcat of the ligase reaction alone drops significantly in presence of NADPH, indicating that NADPH 
stabilizes the closed conformation and limits the catalytic rate of the ligase domain. The conformational 
changes are supported by limited proteolysis experiments, which indicate that the enzyme features at least 
two different states depending on the substrates available (Figure S13 and S14). Notably, the peptides that 
appear more prominent in the sample of closed PCS are corresponding to the flexible cap in the ligase domain 
that is exposed in the closed conformation but hidden within the PCS structure in the open conformation. In 
summary the enzyme displays a synchronized reaction mechanism to sequester and channel the toxic acrylyl‐
CoA between active sites. 
 
Figure 3. Proposed catalytic cycle of PCS. In the open conformation 3‐hydroxypropionate (3OHP) and ATP are converted to 3‐
hydroxypropionyl‐AMP (3OHP‐AMP) through the ligase domain (orange). The binding of CoA induces closing of the enzyme and the 
formation of 3‐hydroxypropionyl‐CoA (3OHP‐CoA). 3OHP‐CoA is released into the reaction chamber, where it is converted by the 
dehydratase domain (purple) to acrylyl‐CoA. Acrylyl‐CoA then enters the active site of the reductase domain (cyan). The reduction of 
acrylyl‐CoA to propionyl‐CoA causes the re‐opening of the reaction chamber. Propionyl‐CoA is released, which leaves PCS ready for 
the next catalytic cycle. 
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 Discussion 
In summary, PCS, a key enzyme in the 3‐hydroxypropionate bi‐cycle for CO2 fixation, is not a simple fusion 
protein of three individual enzymes, but represents a sophisticated structural arrangement of three domains 
enclosing a reaction chamber, which connects all three active sites. This novel strategy of substrate 
channeling combines the mechanisms of compartmentalization with the allosteric gating in enzyme channels. 
However, key features distinct PCS from either of the two substrate channeling mechanisms. The volume of 
the PCS reaction chamber is several orders of magnitude smaller than those of known bacterial micro‐ or 
nanocompartments. Usually, such compartments consist of self‐assembling shell proteins that encapsulate 
enzymes 20‐23. Compared to these, PCS is to our knowledge the first self‐organizing compartment in central 
carbon metabolism where just one polypeptide fulfills the structural role of forming the reaction chamber, 
as well as the catalytic role of driving the multi‐reaction sequence. The orchestration of the three‐reaction 
sequence in PCS is guaranteed through interdomain communication (Figure 3) and conformational changes, 
similar as described in other channeling complexes24‐26. Conformational change of the PCS ligase domain 
controls the only entry and exit site to the three active sites buried within the 33 nm3 reaction chamber. 
Other channeling enzymes in contrast, connect two active sites through a narrow channel where the 
conformational change of single residues suffice to gate the separate entry and exit sites. Channeling in other 
CoA‐ester metabolic enzymes requires covalent attachment of the CoA‐ester or a shared binding site of the 
CoA moiety between two active sites27‐29. Thus, the channeling mechanism of PCS is not only a novelty in 
CoA‐ester metabolic enzymes but also generally represents an unprecedented principle for directing 
intermediates along a defined multi‐reaction sequence.  
PCS is able to catalyze three very fundamental chemical reactions in CoA‐ester biochemistry and retain 
intermediates within its reaction chamber. As such, the enzyme employs an intriguingly ‘simple’ principle to 
catalyze a consecutive reaction sequence within a controlled environment. This notably comes at minimal 
biosynthetic cost, because no additional proteins are required. The natural example of a minimal self‐
assembling nanoreactor that is dynamically regulated could serve as a model for the engineering of spatially 
and temporally controlled reaction sequences 30‐35, especially such that proceed via toxic, reactive or unstable 
intermediates. 
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 Materials and Methods 
 Chemicals 
Chemicals were obtained from Sigma‐Aldrich (Munich, Germany) and CARL ROTH GmbH (Karlsruhe, 
Germany). 3‐hydroxypropionate was bought from TCI Deutschland GmbH (Eschborn, Germany). Coenzyme 
A was purchased from Roche Diagnostics. 1‐13C‐propionate sodium salt was purchased from Cambridge 
Isotope Laboratories Inc. (Tewksbury, USA). Biochemicals and materials for cloning and expression were 
obtained from Thermo Fisher Scientific (St. Leon‐Rot, Germany), New England Biolabs GmbH (Frankfurt am 
Main, Germany) and Macherey‐Nagel GmbH (Düren, Germany). Carbonic anhydrase was bought from MP 
Biomedicals (Illkirch, France). Primers or synthesized genes were obtained from Eurofins MWG GmbH 
(Ebersberg, Germany) or the DOE Joint Genome Institute (California, USA), respectively. Materials and 
equipments for protein purification were obtained from GE Healthcare (Freiburg, Germany), Bio Rad 
(Munich, Germany) or Merck Millipore GmbH (Schwalbach, Germany). 
 Synthesis of 3-hydroxypropionyl-CoA, 13C-acrylyl-CoA and 13C-3-hydroxypropionyl-CoA 
For the synthesis of unlabeled 3‐hydroxypropionyl‐CoA a previously described method using 
carbonyldiimidazole coupling of the precursor acid with coenzyme A was used 36. Unlabeled acrylyl‐CoA was 
synthesized using a previously described mixed anhydride coupling 36. 13C‐acrylyl‐CoA and 13C‐3‐
hydroxypropionyl‐CoA were synthesized in two steps from 13C‐propionate. In the first step the CDI coupling 
method was adapted for the synthesis of 13C‐propionyl‐CoA by a protonation step. 13C‐propionate (0.156 
mmol, 4.8 eq.) was dissolved into 1 mL THF containing pTsOH (0.156 mmol, 4.8 eq.) for 15 min, the mixture 
was centrifuged and CDI (0.130 mmol, 4 eq.) added to the supernatant. The mixture was stirred at RT for 1 
h. CoA (0.0325 mmol, 1 eq.) dissolved in 250 µL 0.5M NaHCO3 was added and stirred for 1h. The mixture was 
lyophilized, HPLC purified and again lyophilized. 13C‐acrylyl‐CoA was synthesized enzymatically using the acyl‐
CoA oxidase Acx4 from Arabidopsis thaliana 37. A 1 mL assay contained 100 µL 1 M KHPO4 200 µL 30 mM 13C‐
propiony‐CoA and 600 µL 1mg/mL Acx4. The reaction was quenched after 1 h by adding 20 µL 50% formic 
acid and directly injected into the HPLC‐MS for purification using a previously described purification protocol 
36. In case of 13C‐3‐hydroxypropionyl‐CoA the assay contained additionally 50 µL of the dehydratase PhaJ from 
Pseudomonas aeruginosa for direct hydration of the in situ generated acrlyl‐CoA. 
 Bacterial strains and growth conditions 
E. coli DH5α (Thermo Scientific™) strains were used for cloning and grown in LB medium 38. For protein 
expression E. coli BL21‐AI™ (Invitrogen) or Arctic‐Express (DE3) RIL (Agilent Technologies) were grown in TB 
medium39. Incubation temperature was 37°C. Antibiotics for selection purposes were used accordingly: 100 
µg/ml ampicillin, 15 µg/ml gentamycin. 
Cloning. All in silico cloning was performed with Clone Manager 9 (Scientific & Educational Software). For 
purification, preparation, cloning, transformation and amplification of DNA, standard protocols were used 40. 
Plasmid isolation and PCR product purification was performed with kits from Macherey Nagel (Düren, 
Germany) according to the manufacturer’s protocols.  
The PCS gene with an N‐terminal 10x His tag was synthesized by the DOE Joint Genome Institue. The construct 
was cloned into the expression backbone pET‐16b by restriction cloning, resulting in the plasmid pTE1005. 
Point mutants were generated by QuickChange® Site‐Directed mutagenesis (Stratagene, La Jolla, USA). 
Following primers were used: forward primer (5’‐CGT TTC GGT CAA CCA CAA ATC AAT CTT CGC‐3’) and 
reverse primer (5’‐GCG AAG ATT GAT TTG TGG TTG ACC GAA ACG‐3’) for the E1027Q variant; forward primer 
(5’‐CGG AAA TTT TTG GCA CAG CGC TGT GCA ATG CTT ATG AG‐3’) and reverse primer (5’‐CTC ATA AGC ATT 
GCA CAG CGC TGT GCC AAA AAT TTC CG‐3’) for the H1769A variant; forward primer (5’‐CCT CAC AGC CAG 
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ATG GGT GTA ACT CC‐3’) and reverse primer (5’‐GGA GTT ACA CCC ATC TGG CTG TGA GG‐3’) for the K783M 
variant. 
 Expression and purification of PCS 
PCS was expressed from the plasmid pTE1005 using E.coli ArcticExpress (DE3) RIL as expression host. The 
cells were transformed with the expression plasmid and plated on LB agar containing selective antibiotic and 
grown overnight. The colonies were used to inoculate 1 L TB medium. The expression culture was incubated 
at 37°C while shaking at 110 rpm until an OD600 of 0.7 – 0.9 was reached. The E.coli ArcticExpress (DE3) RIL 
culture was cooled down to 14°C before induction. Expression was induced by adding 0.25 mM IPTG. The 
culture was incubated for 16‐20 h. The cells were harvested by centrifugation at 5000 x g for 10 min. The 
pellet was stored at ‐20°C, optionally. Cells were resuspended in a 1:3 ratio (w/w) in Buffer A (50 mM Tris‐
HCl pH 7.9, 500 mM NaCl) containing SIGMAFAST™ protease inhibitor (Sigma‐Aldrich, Munich, Germany) and 
lysed by ultrasonication. The lysate was cleared by ultracentrifugation at 50’000 x g for 45 min at 4°C 
followed by filtration through a 0.45 μm syringe filter. The lysate was loaded onto a 1 mL His‐Trap (GE 
Healthcare). Unspecifically bound proteins were washed off with 15 mL of 5 % Buffer B (50 mM Tris‐HCl pH 
7.9, 500 mM NaCl, 500 mM imidazole). To wash away the E.coli ArcticExpress (DE3) RIL Cpn60 chaperone, an 
additional wash step was performed with 15 mL removal buffer (50 mM Tris‐HCl pH 7.5, 50 mM KCl, 20 mM 
MgCl2, 5 mM ATP). PCS was eluted with 100% buffer B and applied to a pre‐equilibrated HiLoad 16/60 200 
pg superdex (GE Life Science) column (150 mM NaCl, 20 mM Tris HCl pH 7.9). The purity of the PCS was tested 
by SDS‐PAGE.  
 
Purification of PCS using a HisTrap and Gelfiltration column 
 Kinetic characterization of PCS 
Spectrophotometric assays were set up to measure the activity of PCS. The assays were performed in 10 mm 
quartz cuvettes (Hellma Analytics) on a Cary‐60 UV/Vis spectrometer (Agilent Technologies Inc. Santa Clara, 
CA, USA). The assay temperature was set to 30 °C. The parameters for the CoA ligase domain alone were 
measured using a coupling assay via myokinase (purified from ASKA JW1375), pyruvate kinase and lactate 
dehydrogenase (SigmaAldrich P02694). To probe the influence of acrylyl‐CoA on the ligase reaction, the assay 
was repeated using the PCS E1027Q variant deficient in the enoyl‐CoA hydratase reaction to avoid back 
reaction of acrylyl‐CoA to 3‐hydroxypropionyl‐CoA. In this assay PCS and acrylyl‐CoA were added to the 
reaction and incubated for 5 min at 30°C before starting the reaction with the addition of CoA. The effect of 
NADPH on the ligase reaction was also tested with the PCS E1027Q variant to avoid overall reaction. The 
reaction catalyzed by the dehydratase domain was assayed using the PCS H1769A variant that is deficient in 
the reductase reaction. Acrylyl‐CoA formation was coupled to its reduction by a stand‐alone reductase (Etr1p 
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from Saccharomyces cerevisiae). The PCS reductase reaction was measured using the E1027Q variant that is 
deficient in the enoyl‐CoA hydratase reaction to avoid the back reaction of acrylyl‐CoA to 3‐
hydroxypropionyl‐CoA. The assay was repeated in presence of different concentrations of free CoA. PCS and 
CoA were added to the reaction mixture and incubated for 10 min at 30°C before starting the reaction with 
the addition of acrylyl‐CoA. 
All reactions were measured by following the consumption of NADPH or NADH (ligase coupling assay) at 340 
nm (εNAD(P)H = 6.22 mM‐1 cm‐1) or at 365 nm (εNADH = 3.4 mM‐1 cm‐1). The detailed conditions for all assays can 
be found in Table S2.  
 Crystallization of PCS 
All crystallization was performed at 18°C using the sitting drop method in 96‐well 2‐drop MRC Crystallization 
Plates in polystyrene (Molecular Dimensions, Suffolk, UK). Crystallization drops (1.4 – 2 µL) contained PCS at 
10 mg/ml premixed with 2mM of CoA, NADP+ and phosphomethylphosphonic acid adenylate ester each 
mixed with reservoir solution in a 1:1 ratio. First thin needle‐shaped crystals appeared after several weeks in 
100 mM BisTris pH 6.5, 200 mM NaAc, 25 % (w/v) polyethylene glycol (PEG) 3350 supplemented with 3 % 
(w/v) trimethylamine N‐oxide dihydrate as additive (condition 1). These crystals had a C2 symmetry and the 
best resolution obtained was 2.7 Å, which was used for the final structure model. Increasing the additive 
trimethylamine N‐oxide dihydrate to 6 % still lead to crystal formation (condition 2) but exhibited strong 
twinning. Crystals could also be reproduced in the same condition replacing the additive with 100 mM D‐(‐)‐
fructose (condition 3) or 4 % (v/v) tert‐butanol (condition 4). Crystals of the space group P 21 21 2 were 
obtained in the same condition supplemented with 2 % (w/v) benzamidine hydrochloride as additive 
(condition 5). Phasing was achieved by soaking crystals of condition 3 in 100 mM Xo4 8 for 4 minutes. All 
crystals were cryo‐protected with the respective crystallization solution supplemented with 20 – 30 % 
ethylene glycol. 
 X-ray crystallography analysis 
Numerous heavy atom derivatives have been tested attempting to solve the structure of PCS such as: 
Potassium tetrachloroplatinate(II), organic mercury derivatives, 5‐amino‐2,4,6‐triiodoisophthalic acid and 
lanthanide phasing compounds (NatX‐ray SAS, Saint Martin d'Hères, France). These derivatives resulted in 
either very low occupancy of the heavy atoms or a significant decrease in diffraction. A recently developed 
lanthanide complex, Xo4, containing a terbium ion 8 gave the best results with high anomalous signal not 
interfering with diffraction quality for short time soakings. We solved PCS in the C2 crystalline form using the 
single‐wavelength anomalous scattering method. Datasets were collected at beamline Proxima‐2A of the 
SOLEIL synchrotron (Paris, France) at the Tb LIII absorption edge (wavelength of 1.649165 Å) on two different 
crystals (condition 3, see above) soaked in Tb‐Xo4. Merging provided a 3.45 Å resolution data set with high 
redundancy facilitating the location of 18 terbium sites using the SHELX 41 software and PHASER 42. After 
multiple cycles of phasing, electron density modification, and secondary structure building using AUTOSOL 
from the PHENIX package 43, the electron density quality was sufficient to build a model with Buccaneer from 
the CCP4 package 42. The initial model was then used as template for molecular replacement with a dataset 
of a native crystal (condition 1, see above) using PHASER‐MR. The native dataset was collected (wavelength 
of 0.97625 Å) at beamline ID29 of the ESRF (Grenoble, France). Manual extension of the model was done 
using COOT 44. Several rounds of manual and automatic refinements were performed using COOT and 
PHENIX‐Refine. The model (PDB 6EQO) structure was refined with Ramachandran statistics of 94.93 % 
favored, 4.82 % allowed, and 0.25 % outliers. 
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 Limited proteolysis 
PCS at 0.5 mg/mL was forced into a supposedly closed or open state by adding 3 mM CoA or a combination 
of 3.4 mM ATP, 2 mM 3‐hydroxypropionate and 2 mM NADP+, respectively. A zero time sample of 10 μL was 
taken. Trypsin (Promega, diluted in 25 mM Tris‐HCl pH 7.5, 10 mM CaCl2) was added in a protein:protease 
ratio of 200:1. Samples of 10 µL were taken at different time points. The sample was quenched with 10 μL 4x 
SDS buffer and heated at 90°C for 10 min. Samples were applied onto an SDS‐PAGE gel. For peptide 
quantification, the limited proteolysis was repeated as described. However, the samples were quenched by 
adding PMSF protease inhibitor (dissolved in 2‐propanol) to a final concentration of 1 mM. The propylation 
was performed overnight in the dark (at RT) in 100 mM HEPES buffer pH 7.5, 400 mM sodium 
cyanoborohydride and 5 % (v/v) acetone 45. The open state PCS samples were treated with unlabeled acetone 
while the closed state PCS samples were incubated with D6‐labeled acetone. The reaction was stopped with 
0.07 % TFA. Samples were concentrated and dried in a Speedvac. The open and closed state samples of each 
time point were combined and purified over a C18 membrane (cut from EmporeTM SPE disks). Peptides were 
eluted with 0.1 % trifluoroacetic acid (TFA) in 50 % acetonitrile (ACN). Samples were dried in the Speedvac. 
Peptides were resuspended in 50 µl 0.1 % TFA. 1 µl of the peptide sample was mixed with 1 µl solution of 
3 g/L alpha‐Cyano‐4‐hydroxycinnamic acid in 80 % ACN (v/v) containing 0.3 % TFA onto a MALDI plate. The 
dried spots were measured automatically for MS and MSMS in a MALDI TOF/TOF analyzer (Applied 
Biosystems/MDS Sciex, Framingham, MA, USA) and the 4800 Series Explorer Software. 
 Time course assays 
The time course assays with 0.1 µM PCS contained 0.8 mM CoA, 0.5 mM 3‐hydroxypropionate, 0.8 mM ATP, 
4 mM MgCl2, 40 mM KCl, 50 mM KHCO3 and 0.3 mM NADPH, if stated, in 100 mM potassium phosphate 
buffer pH 8. At specific time points 20 µL of the assay were quenched with 20 µL of 50 % formic acid. The 
time course assay with 10 µM PCS contained 5 mM CoA, 5 mM 3‐hydroxypropionate, 5 mM ATP, 6 mM MgCl2, 
60 mM KCl and 2 mM NADPH in 100 mM Tris‐HCl pH 7.8. At specific time points 10 µL of the assay were 
quenched with 10 µL acetonitrile and 10 % formic acid. Standard curves (1 µM to 500 µM) for quantification 
for 3‐hydroxypropionyl‐CoA, acrylyl‐CoA and propionyl‐CoA were prepared in the corresponding buffer 
conditions. The samples were centrifuged at 17´000  × g and frozen in liquid nitrogen. Samples were 
immediately thawed before application to hrLC‐MS.  
 Isotopic labeling competition experiment 
The competition contained 3 mM CoA, 2 mM 3‐hydroxypropionate, 200 µM NADPH, 5 mM ATP, 7.5 mM 
Mg2Cl, 60 mM KCl, 100 mM KHCO3 and 100 mM Tris‐HCl pH 7.8. For the competition either 100 µM 13C‐3‐
hydroxypropionyl‐CoA or 100 µM 13C‐acrylyl‐CoA was added. The assay was started with 2 µL of 1.28 mg/mL 
PCS wt and the reaction monitored photospectrometrically at 340 nm using a Cary‐60 UV/Vis spectrometer 
(Agilent Technologies Inc. Santa Clara, CA, USA) at 30°C using quartz cuvettes (10‐mm path‐length; Hellma® 
(Germany)). The assay was quenched after a ΔAbs of 0.36 that corresponds to a turnover of 60 µM. The 
isotopic pattern of the produced propionyl‐CoA was analyzed by hrLC‐MS. 
 High resolution LC-MS (hrLC-MS) 
3‐hydroxypropionyl‐Coa, acrylyl‐CoA and propionyl‐CoA were analyzed using an Agilent 6550 iFunnel Q‐TOF 
LC‐MS system equipped with an electrospray ionization source set to positive ionization mode through a 
1290 Infinity UPLC (Agilent Technologies Inc. Santa Clara, CA, USA). Compounds were separated on a RP‐18 
column (50 mm x 2.1 mm, particle size 1.7 µm, Kinetex XB‐C18, Phenomenex, Aschaffenburg, Germany) using 
a mobile phase system comprised of 50 mM ammonium formate pH 8.1 (A) and methanol (B). 
Chromatographic separation was carried out using the following gradient condition at a flow rate of 250 
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µl/min: 0 min 0% B; 1 min 0% B, 3 min 2.5% B; 9 min 23% B; 14 min 80 %B; 16 min 80%; 17 min 0 % B; 18 min 
0 % B.  
Capillary voltage was set at 3.5 kV and nitrogen gas was used as nebulizing (20 psig), drying (13 l/min, 225 °C) 
and sheath gas (12 l/min, 400°C). The TOF was calibrated using an ESI‐L Low Concentration Tuning Mix 
(Agilent Technologies Inc. Santa Clara, CA, USA) before measurement (residuals less than 2 ppm for five 
reference ions). MS data were acquired with a scan range of 750‐1200 m/z. 
CoA-thioesters were additionally detected by UV absorbance at 260 nm using a diode array detector (1290 
Infinity II, Agilent Technologies Inc. Santa Clara, CA, USA) 
LC‐MS data were analyzed using MassHunter Qualitative Analysis software (Agilent). 
 SAXS analysis 
PCS was freshly purified as described above two days before SAXS analysis was performed. The protein was 
stored on ice until measurements. Gel filtration buffer for dilutions and blank measurements was treated 
equally. SAXS data were recorded at the European Synchrotron Radiation Facility (Grenoble, France) on 
beamline BM29. The protein was up‐concentrated at the beamline. If stated, cofactors were added to the 
concentrated protein at following concentrations: 3‐hydroxypropionate, 2mM; CoA, 3 mM; ATP, 3.4 mM. 
Two‐fold dilution series (4 mg/mL to 0.125 mg/ml) were prepared by dilution with gel filtration buffer 
containing the corresponding cofactors. The different dilutions were measured to investigate sample quality. 
Sample storage and measurement temperature was set to 20°C. The ESRF BM29 online software was 
employed for primary data reduction. PrimusQt (version 4.8.1 46) was used for data analysis. 
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 Supplementary Information 
 
Figure S1. Maximum likelihood phylogenetic tree of PCS homologues. The evolutionary history was inferred based on the Le-
Gascuel model 47. The scale of the branch lengths is measured in number of substitutions per site. All positions containing gaps and 
missing data were eliminated. Evolutionary analyses were conducted in MEGA7 48. Bootstrap values 49 for confidence limits are given 
at important nodes. The position of the PCS homologue of Eryhrobacter sp. NAP1 is highlighted with a red box. 
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Figure S2. PCS domain distribution. Sequence alignment of Erythrobacter sp. NAP1 PCS (PDB 6EQO) with its closest lone-
standing homologues; the acetyl-CoA ligase of Salmonella enterica (PDB 2P2F) 13, the HMG-CoA dehydratase of Myxococcus xanthus 
(PDB 5JBX) 14 and the enoyl-CoA carboxylase/reductase of Streptomyces sp. JS360 (PDB 4A0S) 15. The secondary structure of PCS 
is represented above the sequence and colored according to their domain contribution; orange - ligase domain, purple – dehydratase 
domain, cyan - reductase domain. 
10 20 30 40 50 60 70 80 90 100 110 120 130 140
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
MIGEGDDIGSSNNLEKQSHGLRISDRDHFQRLREECRSDPGEFHGRLAKREICWLIEGPGGNPAWAFYDDAAETWTGWDASSAAPITLDLPESFEP-WERAFNDDDPPNWRWFEGGLTSTAFNEVDRHVLSGHGDEAAMI
----------------------------------MSQTHKHAIPANIADR--C-LIN-PEQYET-KYKQSINDPDTFWGE--QGKI-LDWITPYQKVKNTSFAPGNVSI-KWYEDGTLNLAANCLDRH-LQENGDRTAII
--------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------------
150 160 170 180 190 200 210 220 230 240 250 260 270 280
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
FEGDRWNMASEGGRGGPVDSEVISRRKLLLESAKCALALKALGLEAGDRIALNMPSIPEQIYWTEGAKRMGIVYTPVFGGFSDKTLSDRIADAGARVVVTADGSYRNAQMVPFKPSYTDPALDNFIAVPVAMELLGQALE
-----W----E-GDDTS-QSKHISYRELHRDVCRFANTLLDLGIKKGDVVAIYMPMVPEAAVAMLACARIGAVHSVIFGGFSPEAVAGRIIDSSSRLVITADEGVRAGRSIPLK--------------------------
--------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------------
290 300 310 320 330 340 350 360 370 380 390 400 410 420
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
DGELVVAPEHAGLIRSEVAGLLDGEVTVERSDVMRGVGKALTAIASGEAAGGAMTPRQAAQLRIAIASALVDSPPRVDAVVVVKHTAQPDLPWNEARDHWSHDLTAAAGEELLKAARDAGFDVADEEALLALSDTEFVRA
----------------K-----N----VDDA--LKNPN-----VTSVEH------------------------------VIVLKRTG-SDIDWQEGRDLWWRDL--------IE---KAS---PEHQPE-AM--------
--------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------------
430 440 450 460 470 480 490 500 510 520 530 540 550 560
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
IWAGAPVLAVDAEYPNFIIYTSGSTGKPKGVVHVHGGYASGVAATMPAAFGAEPGDVMYVVADPGWITGQSYQIAASLLSRVTTVITEGSPVFPHAGRFASIIERYGVNVFKAGVTFLKSVMQNPENLKDIQRYDLSSLK
----------NAEDPLFILYTSGSTGKPKGVLHTTGGYLVYAATTFKYVFDYHPGDIYWCTADVGWVTGHSYLLYGPLACGATTLMFEGVPNWPTPARMCQVVDKHQVNILYTAPTAIRALMAEGD--KAIEGTDRSSLR
--------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------------
570 580 590 600 610 620 630 640 650 660 670 680 690 700
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
VATFCAEPVSPAVQAFAMEHITHRYINSYW---ATEHGGMV--WTHFADADGFPLEADAHTYPLPWIMGDVWVEDADGSSNGPVEYERDTGTGGAPWRVAEDGEKGEIVIALPYPYLTRTIWGDVENFTVEHVGNLARVA
ILGSVGEPINP--------E-A--W-EWYWKKIGKEKCPVVDTWWQ-TETGGF-MI----T-PLP---GAI--ELKAGSATRPF-FGVQPALVDNEGHPQEGATEGNLVITDSWPGQARTL------F-----GD-----
--------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------------
710 720 730 740 750 760 770 780 790 800 810 820 830 840
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
GGWRGDEVRYADTYWRRWKGAWAYTQGDFAMRHPDGSFSLHGRSDDVINVSGHRIGTEEIEGAILRDKALDPNSPVGNVIVIGAPHSQKGVTPIAFVTPVEGRRLTQDDKRRLTDLVRTEKGAVAVPQDFIELSEFPETR
-----HE-RFEQTYFSTFKNM--YFSGDGARRDEDGYYWITGRVDDVLNVSGHRLGTAEIESALV------AHPKIAEAAVVGIPHAIKGQAIYAYVTLNHGEEPSPELYAEVRNWVRKEIGPLATPDVLHWTDSLPKTR
--------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------------
850 860 870 880 890 900 910 920 930 940 950 960 970 980
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
SGKYMRRMVRAVVEGG--EVGDASTLRNPESLDELARAVDGWKRRQSLSDTQALFERYRFFTIQYNLVAPGKRVATVTVK-NPPVNALNERALDELVIIAEHLARKDDVAAVVFTGSGTASFVAGADIRQMLEEVNSVEE
SGKIMRRILRKIAAGDTSNLGDTSTLADPGVVEKL---LEE-KQAIAMPS------------------------------------------------------------------------------------------
----------------------------------------------------------GPHMPEFKVDARG-PIEIWTIDGESRRNAISRAMLKELGELVTRVSSSRDVRAVVITGAGDKAFCAGADLKER-ATMAE-DE
--------------------------------------------------------------------------------------------------------------------------------------------
990 1000 1010 1020 1030 1040 1050 1060 1070 1080 1090 1100 1110 1120
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
AKALPDNAQLAFRTIEEMDKPC--IAAIQGVALGGGMEFALACHYRVAEPKARFGQPEINLRLLPGYGGTQRLPRLLADGGGETGLRDALDLILGGRAIDADAALAVGAVDALADGSDNALSHAHAMVREFVRSGDDSAL
--------------------------------------------------------------------------------------------------------------------------------------------
VRAFLDGLRRTFRAIEKSD--CVFIAAINGAALGGGTELALACDLRVAAPAAELGLTEVKLGIIPGGGGTQRLARLV----G-PG-RAK-DLILTARRINAAEAFSVGLANRLA-PEGHLLAVAYGLA-ESVV--ENAPI
--------------------------------------------------------------------------------------------------------------------------------------------
1130 1140 1150 1160 1170 1180 1190 1200 1210 1220 1230 1240 1250 1260
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
GKAFAARKTQTQSWHEPASIDLDAVLEDEFLQRILNQLEWAGRDKAGERALDAVRTGWTQGMTAGLECEAQRFAEAIIDPEGGKTGIQQFMDKQSPPLPVRRDGVWEDDQHEATKTALIEAGDLLPLGAPFYPGVTAIPP
--------------------------------------------------------------------------------------------------------------------------------------------
--A-VA--TAKHAIDEGTGLELDDALALE-LRKYEEILKTEDR-LEGLRAFAEKRAPVYKGR------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------------------SSLSRA---V-LDGASAAEIEAAPV
1270 1280 1290 1300 1310 1320 1330 1340 1350 1360 1370 1380 1390 1400
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
KQLAFGIARDPDTGAPRF-GPPETHERE---LV-VNTPKPGANEALIYLLSSEVNFNDIW-A-LTGIPVSPF--------D---AHDEDVQITGSGGLALVAALGSELKEEGRLQVGDLVSVYSGTSELLSPLAGDDPMY
--------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------------
PDTYLALHLRAEDAD-MFKGVADKDVRKSLRLGEVPMPELAPDEVLVAVMASSINYNTVWSAMFEPIPTFHFLKQNARQGGWATRHDQPYHVLGSDCSGVVVRTGIGVR---RWKPGDHVIVHPAHVDEQEPATHGDGML
1410 1420 1430 1440 1450 1460 1470 1480 1490 1500 1510 1520 1530 1540
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
AGFAIQ-GYETKTGSHAQFLTVQGPQLHRPPADLTLEQAGAYTLNLGTVARCLFTT--LEIQAGKTAFVEGSATGTGLDALKSSVRTGLAVTGLVSSEDRAEFVKSHGSVGAINRKDPEIADCFTPVPDDPDEARQWEAD
--------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------------
GTEQRAWGFETNFGGLAEYGVVRASQLLPKPAHLTWEEAAVSPLCAGTAYRMLVSDRGAQMKQGDIVLIWGASGGLGSYAIQFVKNGGGIPVAVVSSAQKEAAVRALGCDLVINRAELGITD---DIADDP---RRVVET
1550 1560 1570 1580 1590 1600 1610 1620 1630 1640 1650 1660 1670 1680
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
GEKLLDAYRETNGGKLADYVVSHAGERAFPRSFQLLAEGGRLAFYGASSGYHFSFMGKGGEARPDEMLA-R-ANLRGGESVLLYYGPGSHELADEKGLEMVEAARLMKARMVIVTTSDGQREFLQSLGLEDAVEGIVSIE
--------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------------
GRKLAKLVVE-KAGREPDIVFEHTGRVTFGLSVIVARRGGTVVTCGSSSGYLHTFDNRYLWMKLKKIVGSHGANHEEQQATNRLFESGAVVPAMSAVYPLAEAAE--ACRVVQTSRQVGKVAVL-CMAPEQGL-GVTDPD
1690 1700 1710 1720 1730 1740 1750 1760 1770 1780 1790 1800 1810 1820
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
GLKRRLSDFHWPDTLPRLPDARTDIENFKIGVRAYQQNTMKPFGTAVGKLLRSPGNPRGVPDLVIERAGQDTLGVSTSLVKPFGGRVIYAEEMAGRRYTFYAPQVWTRQRRIYMPSAEIFGTHLCNAYEVTMMNEMVAAG
--------------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------------
-LRARLGE-DRLNPLRGLTATSR---------------------------------------------------------------------------------------------------------------------
1830 1840 1850 1860 1870 1880
....|....|....|....|....|....|....|....|....|....|....|....|....
LLDVTEPTMVPWEGLPEAHQAMWDNRHSGATYVVNHALPAMGLTTKDELLEYWVAAQSDTGETS
----------------------------------------------------------------
----------------------------------------------------------------
----------------------------------------------------------------
A A A A B B C D
DE E F F F G G H
H F F
C I I DDD
D D J J K K K C C
K K L L M M M
N N N N N O O
N NO O N
P P PQ QQ R
R Q Q S S S
S S S S S
S S
T
T S S
Q Q
PCS (6EQO)
Ligase (2P2F)
Dehydratase (5JBX)
Reductase (4A0S)
PCS (6EQO)
Ligase (2P2F)
Dehydratase (5JBX)
Reductase (4A0S)
PCS (6EQO)
Ligase (2P2F)
Dehydratase (5JBX)
Reductase (4A0S)
PCS (6EQO)
Ligase (2P2F)
Dehydratase (5JBX)
Reductase (4A0S)
PCS (6EQO)
Ligase (2P2F)
Dehydratase (5JBX)
Reductase (4A0S)
PCS (6EQO)
Ligase (2P2F)
Dehydratase (5JBX)
Reductase (4A0S)
PCS (6EQO)
Ligase (2P2F)
Dehydratase (5JBX)
Reductase (4A0S)
PCS (6EQO)
Ligase (2P2F)
Dehydratase (5JBX)
Reductase (4A0S)
PCS (6EQO)
Ligase (2P2F)
Dehydratase (5JBX)
Reductase (4A0S)
PCS (6EQO)
Ligase (2P2F)
Dehydratase (5JBX)
Reductase (4A0S)
PCS (6EQO)
Ligase (2P2F)
Dehydratase (5JBX)
Reductase (4A0S)
PCS (6EQO)
Ligase (2P2F)
Dehydratase (5JBX)
Reductase (4A0S)
PCS (6EQO)
Ligase (2P2F)
Dehydratase (5JBX)
Reductase (4A0S)
PCS (6EQO)
Ligase (2P2F)
Dehydratase (5JBX)
Reductase (4A0S)
Trifunctional propionyl-CoA synthase: A self-organizing, multi-catalytic ‘pico’-compartment that 
sequesters a reactive intermediate 
 
118 
 
  
Figure S3. Anomalous map contoured at 6 σ indicating the positions (in orange) of terbium contained in the new phasing compound 
Tb‐Xo4 8. 
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Figure S4. Close-ups of the active sites of the ligase domain of PCS and a close homologue. a, Active site of the PCS ligase domain 
co-crystalized with an ATP analog (green) and with the predicted CoA binding site indicated (green label). The ATP entry site is 
indicated by a black arrow. b, Active site of a lone-standing CoA ligase of Salmonella enterica (PDB 2P2F) 13 co-crystalized with an 
ATP analog and CoA (green).  
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Figure S5. Close-ups of the active sites of the dehydratase domain of PCS and a close homologue. a, Active site of the PCS 
dehydratase domain with the essential active site glutamate E1027. b, Active site of a lone-standing dehydratase of Myxococcus xanthus 
co-crystalized with CoA and malonic acid (green) (PDB 5JBX) 14 with the essential active site glutamate E132.  
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Figure S6. Close-ups of the active sites of the reductase domain of PCS and a close homologue. a, Active site of the PCS reductase 
domain with essential active site histidine H1769 co-crystalized with NADP+ (green). The NADP+ entry site is indicated by a black 
arrow. b, Active site of a lone-standing enoyl-CoA carboxylase/reductase of Streptomyces sp. JS360 co-crystalized with octenoyl-CoA 
and NADP+ (green) (PDB 4A0S) 15 with the essential active site histidine H361.  
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Figure S7. Superposition of the ligase domain with a close homologue, the acetyl‐CoA synthetase of Salmonella enterica (PDB 2P2F) 
13. The blue and red spheres corresponds to the N‐termini and C‐termini of PCS or the homologue, respectively. The pink spheres 
mark the insertion points of the additional secondary structure elements in PCS. a, Superposition of a PCS ligase domain (orange) 
with the monomer of the homologue (gray, rmsd of 0.930 Ǻ over 447 Cα‐atoms). Additional structural elements of the PCS monomer 
are shown in pink. b, Superposition of a PCS ligase domain with the dimer of the homologue (gray and black). The peripheral 
extensions of the PCS ligase domain are not aligning with the second chain of the dimeric homologue. The largest additional structural 
element is a four helix bundle on top of the structure. 
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Figure S8. Superposition of the PCS dehydratase domain with a close homologue, the HMG‐CoA dehydratase of Myxococcus xanthus 
(PDB 5JBX) 14. The blue and red spheres corresponds to the N‐termini and C‐termini of PCS or the homologue, respectively. The pink 
spheres mark the insertion points of the additional secondary structure elements in PCS. a, Superposition of a PCS dehydratase 
domain (purple) with the monomer of the homologue (gray, rmsd of 1.085 Ǻ over 147 Cα‐atoms). Additional structural elements of 
PCS dehydratase domain are shown in pink. b, Superposition of a PCS dehydratase domain with the trimeric homologue (gray, sand 
and black). The additional secondary structure elements in the PCS dehydratase domain partly mimic the neighboring chain of the 
trimeric homologue. 
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Figure S9. Superposition of the PCS reductase domain with a close homologue, the enoyl‐CoA carboxylase/reductase of Streptomyces 
sp. JS360 (PDB 4A0S) 15. The blue and red spheres corresponds to the N‐termini and C‐termini of PCS or the homologue, respectively. 
The pink spheres mark the insertion points of the additional secondary structure elements in PCS. a, Superposition of a PCS reductase 
domain (cyan) with the monomer of the homologue (gray, rmsd of 1.530 Ǻ over 291 Cα‐atoms). Additional structural elements of 
PCS reductase domain are shown in pink. b, Superposition of a PCS reductase domain with the dimer of the homologue (gray and 
black). The additional secondary structure elements in the PCS reductase domain partly mimic the neighboring chain of the 
homologue dimer. 
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Figure S10. Michaelis-Menten plots of the kinetic characterizations of the reactions of PCS from Erythrobacter sp. NAP1. All points 
were measured in triplicates and the 95% confidence intervals are indicated. For kinetic parameters see Table S2, for assay 
compositions see Table S3. a, Overall reaction of PCS dependent on CoA concentration. The curve was fitted excluding values above 
5 mM CoA, which resulted in substrate inhibition. b, Overall reaction of PCS in dependence of ATP concentration. Substrate inhibition 
was observed at 10 mM ATP. c, Overall reaction of PCS in dependence of 3‐hydroxypropionate concentration. d, Overall reaction of 
PCS in dependence of NADPH concentration. e, The coupled dehydratase and reductase reaction depending on the 3‐
hydroxypropionyl‐CoA concentration. f, The ligase reaction alone depending on the CoA concentration in presence or absence of 
NADP+. g, The ligase reaction alone using the PCS E1027Q variant deficient in the dehydratase reaction to test the effect of acrylyl‐
CoA. Substrate inhibition can be observed above 10 mM ATP. The curve was fitted including those values. h, The ligase reaction alone 
using the PCS E1027Q variant deficient in the dehydratase reaction to test the effect of NADPH. i, The ligase reaction alone using the 
PCS E1027Q K783M variant depending on the CoA concentration. j, The dehydratase reaction alone using the H1769A variant 
deficient in the reductase activity to allow coupling to the stand‐alone reductase Etr1p (from Saccharomyces cerevisiae) to monitor 
acrylyl‐CoA formation. k, The reductase reaction alone depending on the acrylyl‐CoA concentration. l, The reductase reaction alone 
using the PCS E1027Q variant depending on the acrylyl‐CoA concentration in presence of different CoA concentrations. m, The 
reductase reaction alone using the PCS E1027Q K783M variant depending on the acrylyl‐CoA concentration in presence of different 
CoA concentrations. 
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 Figure 
S11. Lineweaver‐Burk representation of the effects of CoA on the reductase reaction of PCS. All points were measured in triplicates 
and the 95% confidence intervals are indicated. a, The reductase reaction alone catalyzed by the PCS E1027Q variant depending on 
the acrylyl‐CoA concentration in presence of three different CoA concentrations. b, Detailed view of the data of a,. c, The reductase 
reaction alone catalyzed by the PCS E1027Q K783M variant depending on the acrylyl‐CoA concentration in presence of two different 
CoA concentrations. d, Detailed view of the data of c,. While PCS E1027Q is also non‐competitively inhibited by 3 mM CoA (changes 
in apparent KM, CoA and kcat) PCS E1027Q K783M variant is only inhibited competitively (change in apparent KM, CoA). 
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Figure S12. Hypothetic conformational change of PCS upon CoA binding. The left panel depicts the effect of the plausible 
conformational change on the overall structure by surface representation, while the right panel shows a close up of the ligase domain 
active site in the different conformations with modeled CoA. The modeled open conformation suggests how PCS allows substrates 
to enter the reaction chamber. Our observation of CoA preventing access of intermediates to the reaction chamber can be explained 
by this hypothesis. Note, that the PCS‐specific four‐helix bundle is required to enclose the enzyme compartment. 
a, closed conformation of PCS as it was obtained from the crystal structure in this study. The closed conformation might be stabilized 
by interactions of K783 and R812 of the flexible cap domain with bound CoA. b, open conformation of PCS was modeled by replacing 
the flexible cap subdomain of PCS with the one from the open‐state ligase of Saccharomyces cerevisiae (PDB 1RY2) 18. The size of the 
opening is roughly 13 Ǻ and 24 Ǻ in the two dimensions. A loop corresponding to PCS residues 831‐862 had to be omitted from the 
model because of clashes. The green spheres mark its insertion points. Orange – non‐flexible part of ligase domain, light green – 
flexible cap of ligase domain (defined by comparing PDB 2P2F and 1RY2 [2, 5]), purple – dehydratase domain, cyan and grey – 
reductase domains from both protomers. 
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Figure S13. Limited proteolysis on PCS with different substrates/products. Limited proteolysis of PCS with trypsin (200:1 
protein:protease ratio) analysed by SDS‐PAGE. 1, PCS (0.5mg/ml) apo; 2, with CoA; 3, with CoA, ATP, NADP+; 4, with an ATP analog, 
CoA, 3‐hydroxypropionate; 5, with ATP; 6, with ATP, NADP+; 7, with ATP, 3‐hydroxypropionate; 8, with ATP, 3‐hydroxypropionate, 
NADP+; 9, PCS apo without trypsin. CoA at 3 mM, ATP and analog at 3.4 mM, 3‐hydroxypropionate at 2mM, NADP+ at 2mM.  
 
Figure S14. Limited Proteolysis of PCS in open and closed conformation. a, limited proteolysis of PCS with trypsin (200:1 
protein:protease ratio) analysed by SDS‐PAGE. The closed conformation (left) was induced by addition of 3 mM CoA, while the open 
conformation was stabilized by 2 mM 3HP, 3.4 mM ATP and 2 mM NADP+ (right). b, percent of remaining full‐length PCS over time 
was quantified from the SDS‐PAGE gel. Samples on both gels derive from the same experiment and gels were processed in parallel. 
c, peptides from the closed and open conformation appearing after the first 30 seconds of the limited proteolysis were quantitatively 
compared. Peptides in blue are slightly less prominent in the sample of closed PCS (ratio of peptide in closed sample to open sample: 
0.73 for peptide 866‐890, 0.82 for peptide 714‐724, 0.84 for peptide 1053‐1065, 0.90 for peptide 121‐131) while peptides in red are 
overrepresented in the sample of closed PCS (ratio of peptide in closed sample to open sample: 1.38 for peptide 664‐673, 1.71 for 
peptide 866‐890, 2.05 for peptide 805‐818, 2.3 for peptide 837‐855). Data of a representative single experiment.  
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Table S1. X-ray diffraction data collection and model refinement statistics 
 PCS with NADP+, 
phosphomethylphosphonic acid 
adenylate ester 
(PDB: 6EQO) 
PCS with NADP+, 
phosphomethylphosphonic acid 
adenylate ester, Tb-Xo4 
(SAD data) 
Data collection   
Space group C 1 2 1 C 1 2 1 
Cell dimensions   
    a, b, c (Å) 383.41, 86.74, 133.96 389.68, 88.02, 134.91 
        () 90.00, 108.89, 90.00 90.00, 108.53, 90.00 
Resolution (Å) 46.18 - 2.70 (2.75 - 2.70)* 49.66 - 3.45 (3.54 – 3.45)† 
Rmerge 0.212 (0.886) 0.497 (3.374) 
I / I 4.2 (1.7) 7.5 (1.3) 
CC1/2 (%) 
Completeness (%) 
95.8 (18.9) 
97.9 (94.2) 
98.2 (30.5) 
99.7 (99.0) / ano. 99.7 (98.8) 
Redundancy 3.1 (2.7) 20.2 (16.9) / ano. 10.2 (8.5) 
   
Refinement  Not fully refined 
Resolution (Å) 46.18 - 2.70 (2.75 - 2.70) NA 
No. unique reflections 111918 (5260) NA 
Rwork / Rfree 0.191 / 0.229 NA 
No. atoms 28218 NA 
    Protein 27636 NA 
    Ligands 150 NA 
    Water 432 NA 
B-factors   
    Protein 52.99 NA 
    Ligands 52.86 NA 
    Water 42.07 NA 
R.m.s. deviations   
    Bond lengths (Å) 0.006 NA 
    Bond angles () 0.765 NA 
*The structure was determined from a single crystal. †Phasing was achieved with a merged dataset from two crystals. Values in 
parentheses are for highest-resolution shell. NA, not applicable. 
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Table S2. Kinetic parameters of the reactions of propionyl‐CoA synthase of Erythrobacter sp. NAP1. 
reaction PCS 
variant 
substrate app. KM in mM app. kcat in s-1 
 
overall 
wt CoA 0.22 ± 0.05 4.7 ± 0.3 
wt ATP 0.34 ± 0.14 3.6 ± 0.3 
wt 3OHP 0.20 ± 0.02 4.71 ± 0.12 
wt NADPH 0.020 ± 0.003 5.1 ± 0.2 
dehydratase + 
reductase 
wt 3OHP-CoA 6.6 ± 1.1 11.7 ± 1.0 
ligase alone 
wt CoA 6 ± 3 5.7 ± 1.2  
wt CoA (+ 2 mM NADP+) 3.3 ± 0.5 8.3 ± 0.6 
E1027Q CoA 1.6 ± 0.4 9.1 ± 0.7 
E1027Q CoA (+ 0.2 mM NADPH) 0.019 ± 0.003 1.63 ± 0.06 
E1027Q CoA (+ 0.2 mM acrylyl-CoA) 2.4 ± 0.3 8.6 ± 0.5 
E1027Q 
K783M 
CoA 2.6 ± 0.2 2.77 ± 0.08 
dehydratase alone H1769A 3OHP-CoA 2.4 ± 0.5 5.7 ± 0.4 
reductase alone 
E1027Q acrylyl-CoA 0.014 ± 0.005 137 ± 17 
E1027Q  acrylyl-CoA (+ 0.0 mM CoA) 0.015 ± 0.003 44 ± 3 
E1027Q acrylyl-CoA (+ 0.3 mM CoA) 0.070 ± 0.016 34 ± 3 
E1027Q acrylyl-CoA (+ 3.0 mM CoA) NA NA 
E1027Q 
K783M 
acrylyl-CoA 0.008 ± 0.003 24 ± 2 
E1027Q 
K783M 
acrylyl-CoA (+ 3.0 mM CoA) 0.5 ± 0.4 29 ± 12 
Data are shown as the mean ± 95% confidence intervals, as determined from a non-linear fit of at least 18 data points. Michaelis-
Menten graphs of the original data are shown in Figure S11. NA, not applicable. For detailed reaction compositions, see Table S3. 
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Table S3. Composition of enzyme assays to determine kinetic parameters of PCS. 
 
overall 
 
 
 
(CoA) 
overall 
 
 
 
(ATP) 
overall 
 
 
 
(3OHP) 
overall 
 
 
 
(NADPH
) 
dehydratase 
+ 
reductase 
 
(3OHP-CoA) 
ligase 
 
 
 
(CoA) 
ligase 
+ 
NADP+ 
 
(CoA) 
ligase 
+/- 
NADPH 
 
(CoA) 
ligase 
+/- 
acrylyl-CoA 
 
(CoA) 
dehydratase 
 
 
 
(3OHP-CoA) 
reductase 
 
 
 
(acrylyl-
CoA) 
reductase 
+/- 
CoA 
 
(acrylyl-
CoA) 
Pi buffer pH 8 100 100 100 100 100 100 100 100 100 100 100 100 
KHCO3 50 50 50 50 50      50 50 
3OHP 2.3 1.3 X 2.1  2.3 2.3 2.1 2.1    
CoA X 2 2 1.7  X X X X   X 
ATP 5 X 5 3  5 3 3 3    
3OHP-CoA     X     X   
acrylyl-CoA         0.2 / 0  X X 
NADPH 0.3 0.3 0.3 X 0.3   0.2 / 0   0.3 0.3 
KCl 40 40 40 40 40 40 40 40 40    
MgCl2 4 4 4 10 4 10 10 10 10    
PEP      1 1  1    
NADH      0.3 0.3  0.3    
NADP+       2      
PCS [nM] 32 32 32 47 32 X1 17.3 104.0
2/25.22 22.32 34.23 1.82 X
4 
CA [nM] 67 67 67 67 67      2 2 
Etr1p [µM]          0.5   
PK/LDH [U]      ̴ 4.8/6.9 ̴ 2.4/3.5 ̴ 2.4/3.5 ̴ 2.4/3.5    
Myo [μM]      4.6 2.4 2.9 2.9    
All concentrations given in mM if not stated otherwise. Abbreviations: 3OHP, 3-hydroxypropionate; 3OHP-CoA, 3-hydroxypropionyl-CoA; CA, carbonic anhydrase (Simga-Aldrich C3934); PEP, 
phosphoenolpyruvate; Myo, myokinase; PK/LDH, mixture of pyruvate kinase and lactate dehydrogenase (Sigma-Aldrich P0294) 
1 14 nM of wild type PCS or 68 nM of PCS E1027Q K783M. 
2 PCS E1027Q mutant that is deficient in the dehydratase reaction was used. 
3 
PCS H1769A mutant that is deficient in the reductase reaction was used. 
4 PCS concentration was different depending on CoA concentration in assay. Assay with PCS E1027Q: without CoA, 5 nM PCS; with 0.3 mM CoA, 9 nM PCS; with 3 mM CoA, 17 nM PCS. Assay with 
PCS E1027Q K783M: without CoA, 12 nM PCS; with 3 mM CoA, 22 nM PCS.
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7. Archaeal acetoacetyl-CoA-thiolase/HMG-CoA-synthase complex 
channels the intermediate via a fused CoA-binding site 
 Abstract 
Many reactions within a cell are thermodynamically unfavorable. To efficiently run some of those 
endergonic reactions, nature evolved intermediate‐channeling enzyme complexes, in which the 
products of the first endergonic reactions are immediately consumed by the second exergonic 
reactions. Based on this concept, we studied how archaea overcome the unfavorable first reaction of 
isoprenoid biosynthesis; the condensation of two molecules of acetyl‐CoA to acetoacetyl‐CoA 
catalyzed by acetoacetyl‐CoA thiolases (thiolase). We natively isolated an enzyme complex comprising 
the thiolase and HMG‐CoA synthase (HMGCS) from a fast‐growing methanogenic archaeon 
Methanothermococcus thermolithotrophicus. HMGCS catalyzes the second reaction in the mevalonate 
pathway, the exergonic condensation of acetoacetyl‐CoA and acetyl‐CoA to 3‐hydroxy‐3‐
methylglutaryl‐CoA. The 380‐kDa crystal structure revealed that both enzymes are held together by a 
third protein with so far unknown function (DUF35 protein). The active‐site clefts of thiolase and 
HMGCS form a fused CoA‐binding site, which allows for efficient coupling of the endergonic thiolase 
reaction with the exergonic HMGCS reaction. The tripartite complex is found in almost all archaeal 
genomes and in some bacterial ones. In addition, the DUF35 proteins are also important for 
polyhydroxyalkanoate (PHA) biosynthesis most probably by functioning as a scaffold protein that 
connects thiolase with 3‐ketoacyl‐CoA reductase. This natural and highly conserved enzyme complex 
offers great potential to improve isoprenoid and PHA biosynthesis in biotechnologically relevant 
organisms. 
 Introduction 
Biological systems have evolved to efficiently catalyze a myriad of enzymatic reactions in metabolism. 
Among these reactions, some exhibit extremely unfavorable thermodynamics. One prominent 
example, found in the tricarboxylic acid cycle (TCA), is the oxidation of malate to oxaloacetate that is 
catalyzed by malate dehydrogenase (MDH). Under physiological conditions, the equilibrium constant 
for this reaction in the forward direction is Keq = (2.86 ± 0.12) ×10−5 1; estimated ΔG°’ = +30.3 kJ/mol 
using eQuilibrator 2. If considered as an isolated reaction alone, this unfavorable step would drastically 
reduce the flux through the TCA cycle. However, recent in vivo chemical cross‐linking experiments have 
shown that MDH forms a weakly associated complex with the next enzyme in the TCA cycle, citrate 
synthase (CS) 3‐4. The oxaloacetate produced by MDH is electrostatically guided from the active site of 
the MDH to the active site of the CS, without freely diffusing into the bulk solvent 5‐6. The direct 
substrate channeling from one active site to the other leads to an increased consumption of 
oxaloacetate by CS in a low‐concentration microenvironment and allows high flux through the MDH/CS 
complex despite unfavorable thermodynamics of the first reaction 5. This coupling mechanism 
balances the first endergonic reaction with the second and drives the high rate of citrate formation 
required 4‐5. 
Another example of a reaction with unfavorable thermodynamics in central carbon metabolism is the 
non‐decarboxylative Claisen condensation of two acetyl‐CoA molecules into acetoacetyl‐CoA catalyzed 
by acetoacetyl‐CoA thiolases (thiolase); Keq = (1.1 ± 0.2) ×10−5 7; estimated ΔG°’ = +26.1 kJ/mol using 
eQuilibrator 2. Thiolases operate in all domains of life and are a part of several important metabolic 
pathways. There are two types of thiolases 8. Degradative thiolases are involved in the ‐oxidation of 
fatty acids, where they catalyze the thermodynamically favorable reaction; thiolytic cleavage of a wide 
range of 3‐ketoacyl‐CoAs into shorter acyl‐CoAs and acetyl‐CoA. Biosynthetic thiolases operate in 
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polyhydroxyalkanoate (PHA) and the mevalonate biosynthesis pathways, where they catalyze the 
thermodynamically unfavorable condensation of two molecules of acetyl‐CoA to acetoacetyl‐CoA. 
Both types of thiolases have significant sequence identity and show a similar protein fold 8. In the 
mevalonate pathway, acetoacetyl‐CoA is condensed with a third acetyl‐CoA molecule to form 3‐
hydroxy‐3‐methylglutaryl‐CoA (HMG‐CoA) by HMG‐CoA synthase (HMGCS) and then reduced to 
mevalonate by HMG‐CoA reductase (HMGCR) using NADPH as reductant (Figure 1A). The exergonic 
HMGCS and HMGCR reactions make the total mevalonate biosynthetic reaction thermodynamically 
favorable. 
The mevalonate pathway is found in eukaryotes, archaea as well as some gram positive bacteria, where 
it forms the starting compound of isoprenoid biosynthesis 9. Isoprenoids are one of the largest groups 
of natural products and display a wide variety of biological functions. They serve as hormones, 
photosynthetic pigments, quinones, plant defense compounds and as a component of membranes 10. 
Particularly, archaea require a lot of isoprenoids as building blocks of the membrane lipid‐bilayer. This 
raises the question how archaea realize high flux through the mevalonate pathway despite the 
unfavorable thermodynamics of the thiolase reaction.  
Here, we show that the thiolase and HMGCS of the methanogenic archaeon Methanothermococcus 
thermolithotrophicus form a 380‐kDa enzyme‐complex in combination with a small scaffold protein 
(Pfam family: DUF35), which connects the two enzymes. The crystal structure of the native complex 
revealed a unique, shared CoA‐binding site formed by both the thiolase and HMGCS subunit. Structural 
and biochemical data indicates that the complex uses this shared binding site to couple the endergonic 
non‐decarboxylative Claisen condensation to the exergonic HMG‐CoA forming reaction. This complex 
is conserved in most of archaea and can be found in many bacteria. 
 Results 
 A tripartite complex found by native purification 
We initially identified the presence of the thiolase/HMGCS complex from M. thermolithotrophicus, 
which is a fast growing methanogen with a doubling time of about 30 minutes in a minimum mineral 
medium at 65 °C 11‐12, by the shotgun purification of its proteome (see Supporting Information, Figure 
1B). After identification of the multi‐component enzyme, we purified the thiolase/HMGCS complex 
from the cell lysate by following mevalonate producing activity using a coupled enzyme assay 
containing HMGCR. In the purification steps, the total activity increased to 4.4 fold after the first two 
purification steps, which indicated that there are some inhibitory or regulatory components for the 
reactions in the lysate that were lost during these purification steps. At the end of the five‐step 
purification, the specific activity was increased by 1000‐fold (Table 1). Four protein bands were visible 
on SDS‐PAGE in the final fraction (Figure 1B, Figure S1).  
Multiple crystalline forms were observed in one crystallization drop. We dissolved single crystals and 
tested the enzyme activity (Figure 1B). A type of crystals exhibited the HMG‐CoA‐forming enzyme 
activity from acetyl‐CoA and contained three proteins as shown by SDS‐PAGE; the ratio of the band 
intensities was approximately 1:1:1. By mass spectrometry sequencing, these proteins were annotated 
as the 41.9‐kDa thiolase, the 37.5‐kDa HMGCS, and a 15‐kDa DUF35 family‐protein. The function of 
the DUF35 family proteins was at that point unknown 13. Complexing of the DUF35 protein with 
thiolase and HMGCS, however, was in line with the observation that DUF35 proteins are typically 
encoded within the same transcriptional unit. Other crystals in the crystallization drop, which did not 
exhibit the HMG‐CoA‐forming activity, contained a protein with a molecular mass of 27.9 kDa present 
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in the SDS‐PAGE. This protein was identified by mass spectrometry sequencing as thiazole synthase, 
which is not functionally related to the mevalonate pathway. 
Table 1. Target purification of the thiolase/HMGCS complex.  
Purification step Protein (mg) Total activity (U) Specific activity (U/mg) Purification (‐fold) 
     
Soluble fraction 4000 31 0.008 1 
DEAE Sepharose 2300 99 0.043 5.4 
Q Sepharose 1100 130 0.12 15 
Hydroxyapatite 310 59 0.19 24 
Source 15 Phe 4.3 43 10 1300 
The activity was determined using HMGCR coupled assay. The assays contained 2‐mM acetyl‐CoA, 2‐µM HMGCR, 450‐µM 
NADPH in 100‐mM HEPES‐NaOH pH 7.5. 
 
Figure 1. Mevalonate pathway and purification strategy. (A) Reaction scheme of the three enzymes involved in the 
mevalonate pathway. (B) Workflow applied in this work to identify and analyze the thiolase/HMGCS complex. Proteins in the 
cell extract was isolated by shotgun purification (see SI). Two different crystalline forms appeared (green arrows) from a 
fraction. Crystals were washed and dissolved. The protein bands on SDS‐PAGE of the dissolved crystals were used for mass‐
spectrometry identification. Based on the protein‐sequence analysis, the function of the crystallized proteins was predicted 
and the thiolase/HMGCS activity were measured by the HMGCR‐coupled assay. The thiolase/HMGCS complex was purified 
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again from the cell extract using the enzyme assay (target‐purification) and the purified enzyme complex was enzymologically 
characterized.  
 Architecture of the thiolase/HMGCS complex 
The crystals containing thiolase, HMGCS and the DUF35 protein were used for X‐ray diffraction 
experiments. We solved the structure of this enzyme complex using the newly developed terbium‐
containing phasing‐reagent, Tb‐Xo4 14. Diffraction data of the Tb‐Xo4 soaked crystals were collected at 
the terbium LIII absorption edge and the 16 terbium sites with high occupancy were used to determine 
the structure by means of anomalous phasing (Materials and Methods, Figure S2). The complex 
contained two dimers of thiolase, two dimers of HMGCS and four monomers of the DUF35 family 
protein (Figure 2A). The structure of the thiolase dimer in the complex showed the highest similarity 
to the lone‐standing Scp2 type‐II thiolases from eukaryotic parasites (i.e. Leishmania mexicana, PDB: 
3ZBG, root mean square deviation (rmsd) of 1.0 Å), which are folded as a five‐layered αβαβα catalytic 
domain (Figure S3A) 15‐17. The HMGCS dimer from M. thermolithotrophicus has a very similar fold as 
the HMGCS from eukaryotes (i.e. Homo sapiens, PDB: 2P8U, rmsd 1.8 Å) and gram‐positive bacteria, 
which adopt a five‐layered αβαβα catalytic fold (Figure S3B) 18‐19. However, the HMGCS from M. 
thermolithotrophicus is reduced in size and lacks a C‐terminal extension of about 50‐100 amino acids 
compared to HMGCS from eukaryotes and gram positive bacteria.  
The third component of the complex, the DUF35 protein, has high similarity with a homolog from 
Sulfolobus solfataricus, whose structure has been solved by a structural genomics initiative (PDB: 3IRB, 
rmsd 2.9 Å) (Figure S3C and S3D) 13. A role in lipid and polyketide antibiotic biosynthesis was proposed 
for this homologue 13. The DUF35‐encoding genes are also found in operons containing sterol‐carrier 
protein X related thiolases 20‐22. In the crystal structure of the S. solfataricus DUF35 homolog, the N‐
terminal helix is bound to the hydrophobic core of the protein and also bound to another DUF35 
monomer 13. This helix was speculated to serve as a scaffold for binding other proteins. In contrast, in 
the DUF35 protein from the thiolase/HMGCS complex, the hydrophobic core of the DUF35 protein 
binds to the thiolase dimer and its N‐terminal segment interacts with one thiolase subunit (Figure S3C). 
A Zn(II) ion is coordinated in its rubredoxin domain and the rubredoxin binds to the second thiolase 
subunit. Furthermore, the core of the DUF35 protein displays multiple contacts with the thiolase and 
the HMGCS dimers with a total interface of 2019 Å² and 1640 Å² respectively (Figure S4). Compared to 
the DUF35 interaction, thiolase and HMGCS dimers perform only direct contacts with an area of 
interaction below 300 Å². The interface area between thiolase‐DUF35‐HMGCS is governed by 
electrostatic ring‐like interactions in the periphery and some hydrophobic contacts close to the center, 
which are largely conserved throughout methanogens (Figure S5). Thus, the small DUF35 protein 
functions as a scaffold to connect the thiolase and HMGCS dimers.  
 Thiolase and HMGCS share a single CoA binding site 
We investigated the substrate‐binding sites of the thiolase/HMGCS complex by soaking with CoA, 
acetyl‐CoA and HMG‐CoA. We obtained one dataset at 2.95 Å resolution (see Table S1) from a soak 
with 100 mM acetyl‐CoA for 1.5 min at 18 °C (see Materials and Methods). In this structure, an extra 
electron density appeared at the interface of the two enzyme‐subunits and was modeled as an acetyl‐
CoA molecule (Figure S6). The adenine moiety of the acetyl‐CoA molecule was bound to the thiolase 
part and the phosphate groups were fixed by three salt‐bridges to the HMGCS part. The adenine‐ and 
phosphate‐binding sites are located at the equivalent positions of the acetyl‐CoA binding sites of the 
lone‐standing thiolase and HMGCS, respectively (Figure S7). This finding indicated that thiolase and 
HMGCS in the enzyme complex, have only one common acyl‐CoA‐binding site, which is shared by both 
enzymes (Figure 2B). While the adenine interaction is well resolved in our structure, there is only 
partial electron density visible for the pantetheinyl‐arm reaching into the thiolase active site. This is 
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probably due to the flexibility of the pantetheinyl‐arm that can swing between the thiolase and HMGCS 
active sites. By using non‐crystallographic symmetry on the omit map, we were able to detect peaks 
of electron density close to the two known catalytic cysteines in the thiolase (Cys85) and HMGCS 
(Cys114) (Figure S8). Since these two residues could be temporally acetylated in the catalytic reactions 
15, we interpreted these densities as partially acetylated cysteine‐sulfurs. The fused acetyl‐CoA binding‐
site suggested that the two enzymatic reactions are directly coupled via the common CoA‐binding site. 
In this hypothetical mechanism, the intermediate acetoacetyl‐CoA swings from the thiolase active site 
to the HMGCS active site, where the intermediate is directly converted to HMG‐CoA without releasing 
it into the bulk solvent. 
 
Figure 2. Thiolase and HMGCS are assembled in an active complex via the DUF35 protein, which provides a bridging platform 
for the organization of a shared CoA‐binding site. (A) Quaternary representation of the thiolase/HMGCS complex in cartoon 
and surface models. Zn(II) ion and reactive cysteines are shown in ball and stick models. Color code highlights the different 
protein: yellow/orange for thiolase dimers, cyan/dark blue for the HMGCS dimers and purple for the DUF35 protein. (B) 
Binding site of acyl‐CoA made at the interface of both enzymes. CoA (adenosine moiety in green) and CoA‐binding residues 
are shown with stick model. The active‐site cysteines are shown in yellow ball and sticks. The 2Fo-Fc electron density from the 
omit map for CoA‐SH is contoured at 1.0 σ. 
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 Kinetic assays indicate channeling 
The enzyme assay using HPLC‐MS showed that the thiolase/HMGCS complex alone is able to convert 
acetyl‐CoA to HMG‐CoA (Figure 3A). Addition of an excess amount of HMGCR to the assay increased 
neither the reaction rate nor the stoichiometry of the final products (Figure 3B). These findings 
indicated that the coupled reactions of thiolase and HMGCS are thermodynamically favorable, which 
allows the production of HMG‐CoA from acetyl‐CoA. To determine the kinetic parameters of the 
thiolase/HMGCS complex, we used a photometrical assay with an excess amount of HMGCR. In this 
assay, oxidation of NADPH was followed. The thiolase/HMGCS complex showed a specific activity of 
2.9 ± 0.2 U/mg considering the purity of the complex (60% judged by SDS‐PAGE) and a Km,app for acetyl‐
CoA of 210 μM at 65 °C and at pH of 7.5 (Figure 3C).  
 
Figure 3. Activity assay of the thiolase/HMGCS complex. (A) Production of acetoacetyl‐CoA, HMG‐CoA and CoA catalyzed by 
the thiolase/HMGCS complex at 60 °C determined by the LC/MS analysis. The assays contained 100 mM HEPES‐KOH pH 7.5, 
0.1 mg/mL thiolase/HMGCS complex and 2 mM acetyl‐CoA. (B) Production of acetoacetyl‐CoA, HMG‐CoA, CoA and 
mevalonate catalyzed by the thiolase/HMGCS complex in the presence of HMGCR at 60 °C determined by the LC/MS analysis. 
The assay contained 100 mM HEPES‐KOH pH 7.5, 0.1 mg/mL thiolase/HMGCS complex, 200 µM NADPH and 1.35 µM HMGCR.  
(C) Effect of substrate (acetyl‐CoA) concentration on the reaction rate catalyzed by the thiolase/HMGCS complex. The activity 
was measured with the HMGCR coupled assay by following the oxidation of NADPH at 340 nm. Standard errors of triplicate 
samples are shown. 
In the next step, we tested whether acetoacetyl‐CoA is released into the bulk solvent during the 
catalysis. We quenched assays during the steady state of the reactions that either contained only the 
thiolase/HMGCS complex or the complex and HMGCR. Using HPLC‐MS analysis we could not detect 
any acetoacetyl‐CoA above the detection limit of 100 nM in any of the assays, indicating that 
acetoacetyl‐CoA concentrations were below 100 nM during steady state catalysis of the 
thiolase/HMGCS complex. It is unlikely that such low concentrations of acetoacetyl‐CoA in solution can 
account for the measured turnover rates of 2.9 U/mg (kcat,app = 4.6 s‐1) of the complex if we compare it 
to the kinetic parameters of the archaeal HMGCS of H. volcanii (kcat = 4.6 s‐1, Km,acetoacetyl‐CoA = 1.4 µM 23). 
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The data therefore indicates that acetoacetyl‐CoA was consumed directly by the HMGCS without 
release of the intermediate from the active site of the thiolase into the bulk solvent.  
We next investigated whether external acetoacetyl‐CoA can enter the active site of the HMGCS by 
adding external acetoacetyl‐CoA to the thiolase/HMGCS complex. The kinetic data shows that addition 
of external acetoacetyl‐CoA slows down the overall turnover of the reaction, which suggests that 
external acetoacetyl‐CoA is able to diffuse into the active site and acts as a competitive inhibitor by 
binding to the acetyl‐CoA binding site (Figure S9). Such an inhibitory effect of acetoacetyl‐CoA was 
shown for several lone‐standing HMGCS 24‐25. Furthermore, we tested the utilization of acetoacetyl‐
CoA by a stable isotope‐labeling experiment using the HMGCR‐coupled assay. We started the reaction 
of the complex in the presence of 1 mM [1,2‐13C2] acetyl‐CoA and 1 mM unlabeled acetoacetyl‐CoA 
(Figure S10). Mass spectrometric analysis of the HMGCR‐coupled reaction products showed that the 
thiolase/HMGCS complex preferentially used the unlabeled acetoacetyl‐CoA (Table S2). This finding 
confirmed that external acetoacetyl‐CoA was diffusible into the active site, which suggested that the 
acetoacetyl‐CoA intermediate formed from acetyl‐CoA is not trapped in an internal compartment. 
To assess the effect of complex formation on activity, we heterologously expressed the three proteins 
individually in E. coli. Unfortunately we were unable to purify the thiolase, as it was always found in 
insoluble inclusion bodies. The purified HMGCS did not show any activity towards acetoacetyl‐CoA 
(concentrations of up to 10 mM acetoacetyl‐CoA were tested) in coupled assays with HMGCR 
suggesting that the contribution of the thiolase to the binding site is required for activity. 
 DUF35 protein is a universal scaffold in archaea for lipid and PHA biosynthesis 
We found that almost all archaea encode the three proteins of the thiolase/HMGCS complex; the 
thiolase, the HMGCS and the DUF35 protein (Figure S11, Table S3 and S4), which indicated that the 
tripartite complex is essential in archaea for lipid biosynthesis. In some archaea, the DUF35 protein is 
directly fused to the C‐terminus of HMGCS (i.e. in Halobacteria). The only exception is the recently 
discovered group of Lokiarchaea, which neither encodes a lone‐standing DUF35 protein nor a DUF35‐
HMGCS fusion protein. However, the HMGCS of Lokiarchaea contains a C‐terminal extension with a 
similar size as the DUF35 protein but a unique sequence. This C‐terminal extension might fulfil a similar 
role as the DUF35 protein in the thiolase/HMGCS complex.  
The DUF35 proteins are also found in the two PHA biosynthetic gene clusters of Haloferax mediterranei 
that is known to produce branched and unbranched polyalkanoates 26. Hou et al. showed that the 
DUF35 proteins are essential for PHA biosynthesis. A double knock out of both DUF35 proteins 
completely abolished PHA production in H. mediterranei. This suggests that in PHA biosynthesis, the 
DUF35 protein also acts as a scaffold that brings together the thiolase with a 3‐ketoacyl‐CoA reductase, 
which couples the endergonic thiolase reaction to the exergonic reduction of acetoacetyl‐CoA to 3‐
hydroxybutyryl‐CoA.  
Notably, the DUF35 scaffolding proteins are also found throughout the genomes of many bacteria 
(Table S4). The bacterial DUF35 homologues are co‐located with a thiolase and in many cases either a 
HMGCS or a 3‐ketoacyl‐CoA reductase homolog, which suggests that these DUF35 proteins also 
organize tripartite mevalonate and/or PHA biosynthetic complexes in bacteria although no such 
enzyme complexes are reported so far. 
In eukaryotes that also synthesize isoprenoids via the mevalonate pathway, no DUF35 homologues are 
found. Interestingly, however, eukaryotic and bacterial lone‐standing HMGCS contain a C‐terminal 
hairpin (e.g., 487‐508 for the mitochondrial human HMGCS, PDB: 2WYA 19) that superimposes well 
with the C‐terminal part of the DUF35 scaffolding protein (i.e., residues 100‐129 of the DUF35) from 
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the archaeal tripartite complex (Figure S12). These eukaryotic HMGCS have been characterized to act 
as lone‐standing enzymes, however, the structural homology of the C‐terminus suggests that they 
might complex with other protein in the cells. 
 Discussion 
The identification of this natural channeling complex highlights the importance of native purification 
as a method to discover physiological enzyme complexes. The isolation of the native thiolase/HMGCS 
complex enabled us to find the third partner of these two enzymes, the DUF35 protein family, whose 
functions have been enigmatic. The DUF35 protein organizes the spatial co‐localization of the thiolase 
and HMGCS dimers to form the thiolase/HMGCS complex. A shared acyl‐CoA binding site is formed 
between the thiolase and the HMGCS. This shared binding site could enable acetoacetyl‐CoA produced 
by the thiolase to swing directly from the thiolase into the HMGCS active site. This couples the 
endergonic first reaction with the exergonic second one to increase overall biosynthetic flux. The 
proposed reaction scheme is shown in Figure 4. Both active‐site cysteines have to be acetylated first 
in order to ensure formation of acetoacetyl‐CoA and HMG‐CoA. Desynchronized reaction order will 
lead to unreactive enzyme substrate/intermediate complexes, as seen in the inhibitory effect of added 
bulk‐solvent acetoacetyl‐CoA (see above). To perform such a sequential ordered reaction, the thiolase 
and HMGCS subunits have to communicate with each other through conformational changes.  
 
Figure 4. Proposed reaction sequence of the thiolase/HMGCS complex. The active‐site Cys85 of thiolase (in yellow) and 
Cys114 of HMGCS (in blue) are shown as S‐(H). In the initial two steps, both specific cysteine residues of thiolase and the 
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HMGCS are acetylated. In the next step, thiolase forms acetoacetyl‐CoA using the third molecule of acetyl‐CoA. The 
acetoacetyl‐S‐pantetheinyl‐arm of acetoacetyl‐CoA swings to the acetylated HMGCS active site and is converted to the final 
product HMG‐CoA. The released HMG‐CoA is further processed by HMGCR to form mevalonate through the mevalonate 
pathway.  
The high total kinetic rate of the thiolase/HMGCS complex (2.9 ± 0.2 U/mg) indicated that the highly 
endergonic thiolase reaction was not only thermodynamically overcome but also kinetically 
accelerated by the channeling system in this enzyme complex, most probably by means of the shared 
CoA‐binding site. A similar shared CoA‐binding site has been reported for the bacterial multi‐enzyme 
complex that catalyzes the last three sequential reactions in the fatty acid β‐oxidation cycle 27. In this 
complex, 2‐enoyl‐CoA hydratase, 3‐ketoacyl‐CoA thiolase and 3‐hydroxyacyl‐CoA dehydrogenase 
share the same CoA‐binding site and use the long‐spanning pantetheinyl arm to swing the 
intermediate from one active site to the next ones.  
This mode of action of the thiolase/HMGCS complex resembles that of polyketide and fatty acid 
synthases that also channel catalytic intermediates from one active site to the other 28. However, in 
contrast to the latter complexes, the intermediates of the thiolase/HMGCS are not covalently bound. 
It should be noted that polyketide synthases and the fatty acid synthases use decarboxylative Claisen 
condensation for the C‐C bond formation. Instead of condensing two molecules of acetyl‐CoA, they 
condense acetyl‐CoA with malonyl‐CoA releasing CO2 during the reaction. This release of CO2 serves as 
the driving force to catalyze the condensation reaction. The malonyl‐CoA is synthesized from acetyl‐
CoA via ATP dependent carboxylation by acetyl‐CoA carboxylase (ACC). The condensation of two 
molecules of acetyl‐CoA by polyketide synthases and fatty acid synthases therefore uses one molecule 
of ATP. The archaeal tripartite complex on the other hand saves one molecule of ATP by coupling the 
endergonic condensation of two molecules of acetyl‐CoA directly to the exergonic formation of HMG‐
CoA.  
Although the presented tripartite complex is universal to most archaea, it does not appear to be 
essential for acetyl‐CoA condensation reactions in some bacteria and in particular eukaryotes, which 
completely lack a DUF35 scaffolding protein. However, in bacteria and eukaryotes the demand for 
isoprenoids is generally lower compared to archaea, which use isoprenoids as a major component of 
membrane lipids. It remains to be seen whether in bacteria and eukarya lone‐standing enzymes are 
sufficient to sustain isoprenoid production, or whether other mechanisms might be operating that help 
to overcome the unfavorable condensation reaction (e.g. high acetyl‐CoA pools, 
compartmentalization).  
Dueber et al. found that channeling by artificial connection of E. coli thiolase AtoB with the HMGCS 
and HMGCR from S. cerevisiae increased the production of mevalonate over lone‐standing enzymes in 
E. coli by about 77 fold 29. Our discovery of a naturally evolved channeling strategy in archaea harbors 
great potential to further improve the heterologous production of mevalonate in biotechnologically 
relevant strains. 
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 Materials and Methods 
 Cultivation condition of Methanothermococcus thermolithotrophicus 
M. thermolithotrophicus was grown at 65 °C in 1.5 liters of medium in the 2‐liter fermenters. The 
growth medium is similar to that described by Belay et al. 30, but contained in addition 1 μM NaHSeO3 
per liter of the medium 31, 25 mM piperazine‐N,N’‐bis(2‐ethanesulfonic acid) (PIPES) and 25 mM 2‐(N‐
morpholino)ethanesulfonic acid (MES). The inoculum was cultivated in anoxic bottles (50 ml) 
containing 5 ml of medium, whose gas phase included 20% CO2/80% H2 with +0.6 bar. M. 
thermolithotrophicus cells needs 1‐2 weeks to adapt to the growth medium containing PIPES and MES 
in the preculture. In the fermenter cultures, the medium was gassed with 80% H2/20% CO2/0.01% H2S 
with a flow of 1 liter per min and stirred at 1,000 rpm. The 1.5‐l cultivation started with inoculation of 
120−150‐ml preculture. During the exponential phase, the doubling time was 25−30 min. When the 
optical density at 600 nm (OD600) reached 2−3, the cells were harvested by centrifugation (6,000  g) 
for 30 min under anoxic conditions at 8 °C, yielding approximately 2.5 g cells (wet mass) per liter. The 
cell pellets were frozen and stored at −75 °C before enzyme puriﬁca on.  
 Shotgun purification of the native proteins 
To determine the structure of the enzymes, which are able to be only functionally produced in the 
native microorganism, we purified proteins from the cell extract. The cells were disrupted and the 
proteins were fractionated by multiple column chromatography (i.e. DEAE Sepharose, Q Sepharose, 
Source 15 Phe, gel filtration). When several proteins were dominated in SDS‐PAGE, the samples were 
subjected for crystallization. When protein crystals were obtained, the crystals were picked up from 
the crystallization drops, washed three times with reservoir solutions, dissolved in water and analyzed 
by SDS‐PAGE. The protein bands obtained in the SDS‐PAGE gel were sequenced with matrix‐assisted 
laser desorption/ionization time of flight (MALDI‐TOF) mass spectrometry as described previously 32. 
After examination of the importance of the proteins, the crystals obtained were structurally analyzed 
by X‐ray crystallography. When the function of the protein was predictable, the enzymatic activity of 
the dissolved crystals was confirmed. To obtain the target enzyme for further studies of their catalytic 
properties, the target was purified from the cell extract again using the enzyme activity assay to 
improve purification. 
 HMG-CoA reductase purification and characterization 
The gene of HMG‐CoA reductase (HMGCR) amplified by PCR from M. thermolithotrophicus DNA was 
cloned into the pET28b expression vector using the forward primer 
GCGGACATATGATGGAAAAAGGAAATAACGAAATAC and the reverse primer 
GTCCGAATTCTTATCTGCCTAATTGGGCATG, which included NdeI and EcoRI restriction sites, 
respectively. HMGCR was produced in Escherichia coli BL21‐AI in Terrific Broth (TB) medium containing 
50 µg/ml kanamycin. The overnight preculture (5 ml) was inoculated into 1‐liter TB medium and 
cultivated at 37 °C until the OD600 reached 0.8. The culture was cooled to 30 °C and the gene expression 
was induced with 0.25 mM IPTG and 0.02% L‐arabinose (final concentrations in the medium) and 
further cultivated for 12 h. Cells were harvested by centrifugation and resuspended in 20 mM Tris‐HCl 
pH 8.0 containing 500 mM NaCl and 5 mM ‐mercaptoethanol (buffer A). Cells were disrupted by 
sonication and then the lysate was centrifuged at 40,000  g for 60 min at 4°C. Supernatant was applied 
onto the HisTrap FF (5 ml) column (GE Healthcare, Freiburg, Germany) equilibrated with buffer A with 
a flow rate of 1 ml/min and washed with 30‐column volumes of buffer A containing 75 mM imidazole. 
The protein was then eluted with buffer A containing 500 mM imidazole. The protein was desalted 
with a HiTrap Desalting column (GE Healthcare) into 20 mM Tris‐HCl pH 8.0, 10 mM DTT, 150 mM NaCl, 
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20% glycerol and stored at 20 °C. Protein concentration was determined spectrophotometrically 
(ε280nm = 23.8 cm−1 mM−1). The enzyme activity was measured at 60 °C by following NADPH 
consumption at 340 nm using a Carry‐60 UV‐Vis spectrophotometer (Agilent) using 10mm quartz 
cuvettes (Hellma, Mülheim, Germany). The assay mixture contained 100‐mM Tris‐HCl pH 8.0, 12.6‐nM 
HMGCR, 250‐µM NADPH and various amounts of HMG‐CoA. Its kinetic parameters were characterized; 
apparent kcat = 22 ± 1 s‐1 and apparent Km for HMG‐CoA = 28 ± 4 µM. 
 Native purification of the thiolase/HMGCS complex 
The subsequent steps were performed under anoxic conditions (95%N2/5%H2) at 18 °C. Routinely 35‐
45 g of wet cell pellets are used for purification. Cells were thawed at room temperature. Lysis buffer 
(50‐mM MOPS/NaOH, pH 7.0, 10‐mM MgCl2 and 2‐mM dithiothreitol) was added at a ratio of 10 ml 
per g pellet to lyse the cells by osmotic shock. Lysis is performed at 18 °C under gentle stirring with an 
addition of 2.0 U/ml benzonase. The lysate was centrifuged twice at 10,000 ×g for 60 min at 4−10 °C. 
After the cell lysis, enzymes were purified without any freezing steps. The soluble fraction was applied 
on a DEAE Sepharose fast‐flow column (75 ml) equilibrated with 50 mM Tricine‐NaOH pH 8.0 
containing 2‐mM dithiothreitol (DTT) (buffer B). The column was washed at a flow rate of 4.5 ml/min 
for two column volumes. Elution was performed with an increasing gradient of NaCl from 50 mM to 
350 mM in five column volumes. The thiolase/HMGCS complex eluted in the 130‐240 mM NaCl 
fractions. The fractions were pooled and diluted with an equal volume of buffer B and the sample was 
loaded on a Q‐Sepharose fast‐flow column (55 ml) (GE Healthcare), which was pre‐equilibrated in 
buffer B. The column was washed with 200‐mM NaCl, and the proteins were eluted at a flow rate of 
3.0 ml/min with an increasing gradient of NaCl from 200 mM to 400 mM in three column volumes. The 
thiolase/HMGCS complex typically eluted at 235–370‐mM NaCl. Fractions containing the complex 
were diluted with an equal volume of 25‐mM sodium phosphate buffer pH 7.6, containing 2‐mM DTT 
(buffer C) and passed through a Ceramic Hydroxyapatite Type I column (40 ml) (Macroprep; Bio‐Rad; 
München, Germany) equilibrated with buffer C. The column was washed with five‐column volumes of 
buffer C and the enzyme complex was eluted with an increasing gradient of sodium phosphate buffer 
pH 7.6 from 25 to 500 mM with four‐column volumes. The complex eluted at 220490 mM of sodium 
phosphate buffer pH 7.6. Pooled fractions were subsequently diluted with three volume of 25‐mM 
Tris‐HCl pH 7.6, containing 2.0‐M (NH4)2SO4 and 2‐mM DTT (buffer D), and loaded on a Source 15 Phe 
column (15 ml) that was equilibrated in the same buffer. After washing the column with one‐column 
volume of buffer D, the enzymes were eluted at a flow rate of 1 ml/min with a decreasing gradient of 
(NH4)2SO4 from 2.0 M to 0 M in a fourteen‐column volumes. The thiolase/HMGCS complex eluted at 
1.06–0.92 M (NH4)2SO4. The fractions were pooled and concentrated by passing through a 50‐kDa cut‐
off filter (Merck Millipore, Darmstadt, Germany). Finally, the concentrated sample was loaded on a 
10/300 Superose 6 column (GE Healthcare) equilibrated with 25‐mM Tris‐HCl pH 7.6, containing 10% 
glycerol and 2‐mM DTT and eluted at a flow rate of 0.4 ml/min. The thiolase/HMGCS complex eluted 
at 11.814.4 ml with a peak at 12.9 ml. 
 Enzymatic activity assay of the thiolase/HMGCS complex 
The assay coupled with HMGCR was carried out with a Cary‐4000 UV‐Vis spectrometer (Agilent) at 
60°C by following NADPH consumption at 340 nm using 10 mm quartz cuvettes (Hellma, Mülheim, 
Germany). To measure the activity of the fractions obtained in the purification steps, the assay solution 
contained 100 mM HEPES‐KOH pH 7.5, 2 mM acetyl‐CoA, 450 µM NADPH and 2 µM HMGCR. Kinetic 
parameters of the purified thiolase/HMGCS complex were determined at 60 °C using the assay solution 
containing 500 mM potassium phosphate buffer pH 7.5, 400 µM NADPH, 2 µM HMGCR, 4.5 µg/mL 
thiolase/HMGCS complex and varying concentrations of acetyl‐CoA. The LC‐MS experiments were 
done with the Agilent 6550 iFunnel Q‐TOF LC‐MS system equipped with an electrospray ionization 
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source set to positive ionization mode. Compounds were separated on a RP‐18 column (50 mm x 2.1 
mm, particle size 1.7 µm, Kinetex XB‐C18, Phenomenex) using a mobile phase system comprised of 50 
mM ammonium formate pH 8.1 and methanol. Assays contained 100 mM HEPES/KOH pH 7.5, 0.1 
mg/mL thiolase/HMGCS complex, 2 mM acetyl‐CoA and in the coupled assay additionally 200 µM 
NADPH and 1.35 µM HMGCR. Samples were quenched with 5% formic acid (final concentration) and 
centrifuged for 5 min at 17,000 × g to remove precipitated proteins and then the supernatant was 
analyzed by LC‐MS. For this assay, the thiolase/HMGCS complex stored for about 2 weeks at −80°C was 
used. The activity of the stored preparation was 15% of that of the fresh sample. Compounds in the 
assay was quantified using external standard curves prepared in the same buffer system (Figure S13). 
 Crystallization of the thiolase/HMGCS complex from M. thermolithotrophicus 
Crystallization was done under air at 18−20 °C. The best‐diffracting crystals were obtained using the 
sitting drop method (in a 24‐well junior clover plate from Jena Bioscience). The crystallization reservoir 
contained 100 mM Tris‐HCl pH 8.0, 25−28% v/v pentaerythritol ethoxylate (15/4 EO/OH, average 
molecular mass ≈ 797 Da) and 50 mM MgCl2. The crystallization drop contained 1−2 μl of the purified 
complex (50−60 mg/ml) and 1 μl of the mother liquor. The best diffracted crystal was obtained in the 
presence of 10 mM Tb‐Xo4 (14) (Table S1). For phasing, the crystals obtained in the crystallization 
solution in the presence of 10 mM Tb‐Xo4 were soaked with 100 mM Tb‐Xo4. Substrate‐soaking 
experiment was done using crystals, which were obtained in the absence of Tb‐Xo4. The best data 
were obtained when the crystals were soaked for 1.5 min in the mother liquor supplemented with 100 
mM acetyl‐CoA. The thiolase/HMGCS crystals were also soaked with several concentrations of CoA, 
acetyl‐CoA and HMG‐CoA; however, the majority of the crystals lost diffraction power, which probably 
came from conformational changes of the enzymes upon substrate‐binding. 
 Structural analysis 
A first intensive screening using crystals soaked in heavy atoms was performed on the BM30A beamline 
at ESRF. Soaking of the crystals in the mother liquor supplemented with 100 mM Tb‐Xo4 14 for 6 min 
gave the best result. The heavy atom derivative exhibited a very strong anomalous signal without 
altering the diffraction quality. After a fluorescent scan, a dataset was collected at the Tb LIII edge on 
Proxima 2A beamline (Synchrotron SOLEIL). Diffraction frames were integrated using XDS 33 and the 
integrated intensities were scaled using the CCP4 programs SCALA 34. The structure was solved de novo 
by the single‐wavelength anomalous diffraction method. Firstly, we localized the 39 terbium sites using 
SHELX software 35 and phased with Autosol from the PHENIX package 36. The model building was 
completed with Buccaneer from the CCP4 package 37. Molecular replacements were done with PHASER 
using this first model to solve the structure of the native and the acyl‐CoA thiolase/HMGCS complex. 
Models were completed and improved in COOT 38 prior to refine with BUSTER 39 or PHENIX (33). These 
models were then optimized through iterative rounds of refinement and model building. Automated 
non‐crystallography symmetry (NCS) and translation‐liberation‐screw‐rotation (TLS) provided in the 
BUSTER and PHENIX program suits were applied. The final refinement rounds were carried out with 
the hydrogens in riding position and were omitted for the final deposition. Refinement statistics are 
summarized in Table S1. The figures were generated with PyMOL (Version 1.5, Schrödinger, LLC). The 
structural homologs search was done with the DALI server 40. Contact areas between the DUF35 
protein and the two‐other enzyme were analyzed with the PISA server 41.  
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 Supplementary Information 
 
 
Figure S1. Gel filtration profile of the thiolase/HMGCS complex. The major contaminant thiazole synthase is not co‐eluting 
with the thiolase/HMGCS complex. 
 
Figure S2. The terbium‐binding sites of the thiolase/HMGCS complex and experimental map. (A) Terbium localization in the 
quaternary structure of the thiolase/HMGCS complex obtained from the experimental data of the Tb‐Xo4 derivative. The 
anomalous map contoured at 6.0 σ (blue mesh and cyan surface) indicates the localization of a total of 39 sites. (B) A close‐
up view of an experimental density map contoured at 1.5 σ after solvent flattening and electron density modification.  
Archaeal acetoacetyl-CoA-thiolase/HMG-CoA-synthase complex channels the intermediate via a 
fused CoA-binding site 
150 
 
 
Figure S3. Superposition of the three independent‐subunits of the thiolase/HMGCS complex with their closest structural 
homologs. The N‐ and C‐termini of each models are highlighted in blue and red spheres, respectively. To avoid confusion, the 
representation contains only one protomer. (A) Superposition of the cartoon models of thiolase from M. thermolithotrophicus 
(orange) and the thiolase Scp2 from Leishmania mexicana (green, PDB: 3ZBG). The acetyl‐CoA, shown in pink comes from the 
superposition of Scp2 C123A mutant from L. mexicana (PDB: 5LOT). (B) Superposition of the cartoon models of HMGCS from 
M. thermolithotrophicus (blue) and HMGCS1 from Homo sapiens (green, PDB: 2P8U) in complex with CoA. The C‐terminal 
extension contained in lone‐standing HMGCS is highlighted in red. (C) Superposition of the cartoon models of the DUF35 
protein of the thiolase/HMGCS complex from M. thermolithotrophicus (purple) and the DUF35 family protein from Sulfolobus 
solfataricus (green, PDB: 3IRB). The thiolase (orange) and HMGCS subunits (blue) from M. thermolithotrophicus are shown in 
transparent cartoon models. (D) Same view than C turn at 90°, without the thiolase and HMGCS from M. 
thermolithotrophicus. 
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Figure S4. Binding interface area of the DUF35 protein and the enzyme partners in the thiolase/HMGCS complex from M. 
thermolithotrophicus. The electrostatic feature of the surface of DUF35 protein is represented using a color codes with charge 
gradients from acidic (in red) to basic (in blue). The amino‐acid residues of each thiolase protomer at the interface are colored 
in orange and yellow. The amino‐acid residues of each HMGCS protomer at the interface are colored in cyan and blue. (A) 
View from thiolase. (B) View from the HMGCS.  
Archaeal acetoacetyl-CoA-thiolase/HMG-CoA-synthase complex channels the intermediate via a 
fused CoA-binding site 
152 
 
 
Figure S5. DUF35 sequence conservation. (A-D) CONSURF representation of the sequence conservation, using the same view 
than Figure S4. The conservation is made by a color gradient: from blue, not conserved, to red perfectly conserved. (A, B) 
Conservation among 160 methanogens DUF35. (C, D) Conservation among the archaea from the table S3. (E) Sequence 
alignment among the archaea species of table S3, using Espript server 42. For Pyrococcus furiosus one of the highly conserved 
cysteine part of the Zn(II) finger seems absent. 
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Figure S6. CoA‐SH presence at the interface of the thiolase / HMGCS complex. (A) Same representation shown in Figure 2B 
with an electron density map after refinement of the model including CoA‐SH. The 2Fo-Fc electron density map is contoured 
at 1.0 σ. (B) Non‐crystallography symmetry applied to the omit map for the CoA‐SH. This map corresponds to the signal of 
the 2Fo-Fc after averaging of the 4 binding sites in the asymmetric unit and is contoured at 1.0 σ. 
 
Figure S7. Comparison of the fused‐CoA binding site in the thiolase/HMGCS complex from M. thermolithotrophicus and the 
CoA‐binding site of the lone‐standing thiolase and HMGCS. Top picture represents the CoA‐binding site made of the thiolase 
(orange), and the HMGCS (blue) in the thiolase/HMGCS complex. The two pictures at the bottom represent the CoA‐binding 
site structures of human cytosolic lone‐standing thiolase (PDB: 1WL4) (bottom, left) and lone‐standing HMGCS from human 
mitochondria (PDB: 2WYA) (bottom, right). The angle of the three structures are unified by superposition of the lone‐standing 
ones to the thiolase/HMGCS complex. The CoA moiety (carbons in green) and the amino‐acid residues interacting with the 
phosphate groups of CoA (lysine and arginine) are shown in sticks. The positively charged residues forming the electrostatic 
clamp are highlighted with a “+” symbol, and the cleft for binding of the adenine moiety of CoA is highlighted by a red dashed 
line.  
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Figure S8. The electron‐density map calculated with non‐crystallography symmetry (NCS) suggested a partial acetylation of 
the active cysteines (C85 in the thiolase subunit and C114 in the HMGCS subunit). Since the resolution is borderline to 
differentiate between an acetylation and an oxidation we cannot exclude the possibility that these extra electron densities 
come from a partial cysteine oxidation. The NCS map was calculated by the COOT software from the Fo‐Fc map and is 
contoured at 6.5 σ in (A) the thiolase (in orange) and (B) HMGCS subunits (in blue). In panel A, close to the Cys85, a water 
molecule was omitted during the refinement as a control. The thick black arrows indicate the entrance of the tunnel of the 
active site. 
 
Figure S9. Inhibition of the thiolase/HMGCS complex by external acetoacetyl‐CoA. The assay contained 1.6‐µM HMGCR, 400‐
µM NADPH, 1‐mM acetyl‐CoA in 500‐mM potassium phosphate buffer pH 7.5. The reaction was started by adding 45 µg/ml 
of the thiolase/HMGCS complex (final concentration) at the time indicated with red and blue arrows. Progress of the reaction 
was monitored spectrophotometrically at 340 nm. In the test, acetoacetyl‐CoA (1mM final concentration) was added to the 
assay at the time indicated by an arrow (blue curve). In a control experiment, acetoacetyl‐CoA was not added (red curve). 
Gaps of the curves come from the injections and mixing events during experiments. 
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Figure S10. Predicted labeling‐patterns of mevalonate produced from [1,2‐13C2]acetyl‐CoA and non‐labeled acetoacetyl‐CoA 
in the reactions catalyzed by the thiolase/HMGCS complex and HMGCR. The assay contained 1.6 µM HMGCR, 400 µM NADPH, 
1 mM [1,2‐13C2]acetyl‐CoA and 1 mM unlabeled acetoacetyl‐CoA in 500 mM potassium phosphate buffer pH 7.5. The reaction 
was started by adding 45 µg/ml of the thiolase/HMGCS complex (final concentration). Progress of the reaction was monitored 
spectrophotometrically at 340 nm. When 50% of NADPH was consumed, the reaction was quenched with 5% formic acid 
(final concentration) and centrifuged for 5 min at 17,000 × g to remove precipitated proteins and then the supernatant was 
analyzed by LC‐MS (See Method section in the main text). If external unlabeled‐acetoacetyl‐CoA was not used by the 
thiolase/HMGCS complex, only [1,2,3,4,5,6‐13C6]mevalonate is produced. If external unlabeled‐acetoacetyl‐CoA was used by 
the thiolase/HMGCS complex, [1,2‐13C2]mevalonate is additionally produced. In the latter case, the external acetoacetyl‐CoA 
could be transformed to unlabeled acetyl‐CoA by the thiolase reverse‐reaction and then the unlabeled acetyl‐CoA could then 
be condensed with the unlabeled‐acetoacetyl‐CoA, which yield unlabeled mevalonate. 
 
Figure S11. The thiolase/HMGCS complex operon is widespread among archaea. All three proteins, thiolase (yellow), HMGCS 
(blue) and the DUF35 (purple) are conserved in archaea with only one exception, Lokiarchaeota. HMGCS from Lokiarchaeota 
(gray background) and Eukarya (green background) contain a C‐terminal extension (highlighted in green and gray, 
respectively) which are not conserved each other. The genes encoding the three proteins are organized in a conserved operon 
in most archaea (light blue background) with the exception of Thaumarchaeota and Halobacteria. In Thaumarchaeota (light 
orange background) HMGCS is encoded in a different region of the chromosome. In Halobacteria (yellow background) the 
DUF35 protein is fused to the C‐terminus of HMGCS. *In Caldivirga and Staphylothermus in Crenarcheota and 
Methanobacterium in Euryarchaeota, the three genes encoding HMGCS, thiolase and the DUF35 proteins are separated in 
the genome. 
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Figure S12. Structural similarity of the C‐terminal motifs of the lone‐standing HMGCS and the DUF35 protein of the 
thiolase/HMGCS complex. The human HMGCS1 (PDB: 2P8U) in orange is superposed to the archaeal HMGCS from M. 
thermolithotrophicus shown in blue. The DUF35 of the thiolase/HMGCS complex is colored in purple. The C‐terminal 
extension of the human HMGCS (residues 434‐470) and the DUF35 (residues 94‐129) are highlighted in non‐transparent 
compared to the rest of the sequence. The spheres indicate the C‐terminal amino acid.   
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Figure S13. Standard curves used for HPLC‐MS quantification of assay substrates, intermediates and products.  Standard 
curves were fitted with a quadratic regression for all compounds. 
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Table S1. X-ray analysis statistics. 
 Thiolase/HMGCS complex  
with Tb-Xo4 (SAD) 
Thiolase/HMGCS complex 
native 
Thiolase/HMGCS soaked 
with     acetyl-CoA 
Data collection    
  Synchrotron SOLEIL, Proxima 2A ESRF, ID29 ESRF, ID23-1 
  Wavelength (Å) 1.64851 1.38546 1.64861 
  Space group P212121 P212121 P212121 
  Resolution (Å) 
49.20 – 3.29  
(3.47 – 3.29) 
48.90 – 2.75  
(2.90 – 2.75) 
49.30 – 2.95  
(3.11 – 2.95) 
  Cell dimensions    
    a, b, c (Å) 107.4, 145.1, 230.9 106.6, 144.0, 230.6 107.6, 145.2, 230.9 
    α, β, γ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
  R
merge
 (%)
a
 11.4 (63.6) 27.9 (124.9) 14.3 (202.4) 
  Rpim (%)a 4.6 (27.2) 7.9 (35.4) 4.0 (57.7) 
  CC1/2
 
(%)
a
 99.8 (91.9) 99.3 (32.4) 99.9 (48.1) 
  I/σ
I
a
 18.8 (4.4) 8.6 (2.1) 14.9 (1.3) 
  Completeness (%)
 a
 99.7 (98.4) 100.0 (100.0) 99.4 (98.8) 
  Redundancy
a
 13.4 (12.3) 13.4 (13.3) 13.3 (13.1) 
  Number of unique reflections
 a
 55597 (7919) 92965 (13426) 76363 (10942) 
    
Refinement    
  Resolution (Å)  48.39 – 2.75 49.29 – 2.95 
  Number of reflections  92874 76299 
  R
work
/R
free
b
 (%)  19.0 / 22.5 18.2 / 23.0 
  Number of atoms    
    Protein  26314 26334 
    Ligands/ions  146 172 
    Solvent  471 61 
  Mean B-value (Å
2
)  52.62 106.71 
  Molprobity clash score,         
  all atoms 
 2.82 (100th percentile) 4.68 (100th percentile) 
  Ramachandran plot    
    Favoured regions (%)  97.01 97.07 
    Outlier regions (%)  0.23 0.29 
  rmsd
c
 bond lengths (Å)  0.008 0.005 
  rmsd
c
 bond angles (°)  0.825 0.58 
 
PDB code 
 
 
6ET9 
 
6ESQ 
a Values relative to the highest resolution shell are within parentheses. b Rfree was calculated as the Rwork for 5% of the 
reflections that were not included in the refinement. c rmsd, root mean square deviation. 
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Table S3. Examples of HMGCS complexes found in archaea. Representative organisms from each phyla were picked and searched for the DUF35 protein in the 
Integrated Microbial Genomes system (IMG). Subsequently they were checked for the HMGCS and thiolase (abbreviated Thio). GenBank accession code is given 
for all the proteins, if available, otherwise the locus tag from JGI IMG is given. 
 
Phylum Class Organism Thiolase DUF35 HMGCS Cluster architecture 
       
Euryarchaeota Halobacteria Haloferax volcanii DS2 WP_004040873.1 WP_004040874.1 WP_004040874.1 Thio-HMGCS DUF35 
      
(HMGCS and DUF35 are 
fused)    
YP_003534895 YP_003534894 
 
Thio-DUF35 
 
Methanococci Methanocaldococcus jannaschii  NP_248557 NP_248560 NP_248554 TR-HMGCS-Thio-HP-HP-
DUF35    
DSM 2661 
   
(TR=transcript. regulator; 
HP=hypothet. protein)  
Thermococci Pyrococcus furiosus COM1 AFN03768.1 AFN03769.1 AFN03767.1 HMGCS-Thio-DUF35 
       
Korarchaeota 
 
Korarchaeum cryptofilum OPF8 YP_001737605 YP_001737606 YP_001737604 HMGCS-Thio-DUF35 
       
Thaumarchaeota 
 
Nitrosopumilus maritimus SCM1 WP_012216014.1 WP_012216013.1 
 
Thio-DUF35 
       
Crenarchaeota Thermoprotei Sulfolobus acidocaldarius DG1 B6A19_RS06605 B6A19_RS06600 B6A19_RS06610 HMGCS-Thio-DUF35 
  
Metallosphaera sedula ARS120-1 Ga0100896_112014 Ga0100896_112015 Ga0100896_112013 HMGCS-Thio-DUF35-
HMGCR    
Ga0100896_111636 Ga0100896_111637 
 
Thio-DUF35 
   
Ga0100943_11682 Ga0100943_11683 
 
Thio-DUF35-phAC-CoA 
ligase-3OHacyl-CoADH   
Ignicoccus hospitalis KIN4 Igni_0377 Igni_0378 Igni_0376 DUF84-HMGCS-Thio-DUF35 
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Table S4. Examples of the predicted thiolase/HMGCS complexes found in bacteria. Completed bacterial genomes from the Integrated Microbial Genomes system 
(IMG) were searched for the DUF35 protein. Subsequently the presence of HMGCS, thiolase (abbreviated as Thio) and HMGCR were analyzed. GenBank accession 
code is given for all the proteins, if available, otherwise the locus tag from JGI IMG is given. 
 
Phylum Organism Thiolase DUF35 HMGCS HMGR Cluster architecture 
       
Chloroflexi Roseiflexus sp. RS-1 YP_001274810 YP_001274809 YP_001274811 YP_001274812 HMGR-HMGCS-Thio-DUF35 
 Anaerolinea thermophila UNI-1 YP_004175506 YP_004175505 YP_004175507 YP_004175508 HMGR-HMGCS-Thio-DUF35 
 
Chloroflexus aurantiacus J-10-fl YP_001633876 YP_001633874 YP_001633877 YP_001633878 HMGR-HMGCS-Thio-duf-
DUF35 
 
Herpetosiphon aurantiacus DSM 
785 
ABX06504.1 ABX06505.1 ABX06503.1 not in same cluster HMGCS-Thio-DUF35 
       
Actinobacteria Streptomyces albus DSM 41398 Ga0077996_113376/ 
Ga0077996_113374 
Ga0077996_113375 Ga0077996_113375 not in same cluster Thio-HMGCS DUF35-Thio  
(HMGCS and DUF35 fused) 
       
Firmicutes Streptococcus mutans NN2025  YP_003485695 YP_003485694 YP_003485002 YP_003485003 Thio- DUF35 
………HMGCS-HMGR 
 
Desulfosporosinus orientis 
DSM765 
AET68488.1 AET68487.1 AET68487.1 not in same cluster  
HMGCS DUF35-Thio 
(HMGCS and DUF35 fused) 
 
Desulfonomaculum kuznetsovii 
DSM6115 
AEG13966.1 AEG13968.1  
AEG13967.1 
not in same cluster Thio-HMGCS- DUF35 
 
Clostridium autoethanogenum  
DSM 10061 
 
AGY77788.1 
AGY77789.1 AGY77787.1 not in same cluster HMGCS-Thio- DUF35 
 
Carboxydothermus 
hydrogenoformans 
Z-2901  
ABB16153.1 ABB15728.1  
ABB15916.1 
not in same cluster Thio-HMGCS- DUF35 
       
Proteobacteria Desulfococcus oleovorans Hdx3 ABW67355.1 ABW67354.1 ABW67354.1 not in same cluster HMGCSDUF35SDR-Thio  
(HMGS fused to DUF35 and 
SDR) 
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8. Conclusions and General Discussion 
Enzymes are able to catalyze a myriad of chemical reactions with high regio‐ and stereo‐specificity 
under very mild reaction conditions and in the context of the whole cellular metabolism (more than 
2700 different metabolites). To achieve this remarkable specificity enzymes have evolved various 
strategies to i) control reactive intermediates within an enzymes active site by both lowering the 
activation energies along the desired reaction pathway (´positive catalysis´) and by increasing the 
activation energies of side reactions (´negative catalysis´) and to ii) control the transfer of reactive 
intermediates between enzyme active sites (´substrate channeling´).  
In the first part of this thesis we looked at NAD(P)H dependent enoyl‐thioester reductases from both 
the short‐chain reductase/dehydrogenase (SDR) and the medium‐chain reductase/dehydrogenase 
(MDR) superfamilies. We were able to dissect the catalytic cycle of these enzymes in two distinct steps, 
the hydride transfer and the proton transfer. We identified a covalent C2‐adduct as an intermediate 
that is part of the reaction coordinate or lays at least very close to it. The detailed implications of this 
detected intermediate for our understanding of the reaction mechanism of enoyl‐thioester reductases 
and it´s use as a molecular probe are discussed in chapter 8.1 below. We were also able to identify the 
function of multiple residues in the active site of these reductases and showed that some of them 
mainly destabilize transition states of unwanted side reactions (i.e. have a negative catalytic function). 
The concept of such negative catalysis as a key principle in enzyme catalysis and the control of reactive 
intermediates is discussed in detail in chapter 8.2.  
In the second part of this thesis we then have a close look at two examples of substrate channeling 
between enzyme active sites of a metabolic pathway. The general strategies nature has evolved to 
control the flux of intermediates between enzymes are discussed in chapter 8.3. In the outlook 
(chapter 8.4) we then outline possible ways to build artificial substrate channeling.  
 C2-adducts in enoyl-thioester reductases 
The detection of covalent C2‐adducts between the nicotinamide cofactor and the enoyl‐thioester 
substrate in zink‐free enzymes from the both the MDR and SDR superfamily as well as in the 
biosynthesis of the natural product sanguinarine1 and in chemical model reactions using modified 
dihydropyridine substrates2 suggests that such intermediates are a more general phenomenon than 
so far assumed and may even be a general catalytic principle at the active site of oxidoreductases. 
Interestingly, there is also a report of a transient intermediate formed during the catalytic cycle of the 
zinc dependent horse liver alcohol dehydrogenase with the model substrate 3‐hydroxy‐4‐
nitrobenzaldehyde, which shows an absorption maximum around 370 nm 3, which is similar to the C2‐
adducts we described. 
It is not yet clear through what mechanism the C2 adduct is formed and whether it is on the reaction 
coordinate (RC) or just energetically very close to it. One possibility is that the hydride transfer from 
NAD(P)H to the ‐carbon of the substrate proceeds through a pericyclic transition state following an 
ene‐mechanism as proposed over 50 years ago by Hamilton4. This would put the C2 adduct on the RC 
and challenge the canonical mechanism of direct hydride transfer used to describe NAD(P)H 
dependent reduction reactions of oxidoreductases. The formed C2 adduct would then decay to a 
reactive enolate, which can attack the resolving electrophile (a proton in reductases or CO2 in reductive 
carboxylases), either in a concerted mechanism or in successive steps. 
Alternatively, the hydride is transferred in a more canonical mechanism to the ‐carbon forming the 
reactive enolate directly. The enolate could then either attack the resolving electrophile or instead re‐
attack the nicotinamide ring in a Michael type addition reaction to form the C2 adduct. In this case the 
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C2 adduct is just a catalytically competent side product formed during the reaction, which can 
successively be transformed into the products. Note that the lack of good electron acceptors in 
proximity to the C of the enolate would favor such a Michael addition, as for instance is the case in 
ECRs when CO2 is omitted 5, Etr1p when the proton donor is mutated (Chapter 2), or in InhA, where no 
protic group is positioned well for protonation (Chapter 4). The enzymes additionally still need to 
actively prevent the formation of the toxic C4 side product (Chapter 3). In reductive carboxylases the 
C2 adduct could serve an additional purpose of storing the reactive enolate until CO2 is positioned 
correctly for carboxylation, thus preventing the reactive enolate from prematurely reacting with a 
proton instead. Further experiments are needed to decipher the precise reaction mechanism and the 
role of the C2 adduct during catalysis (see Outlook). 
Independent of the fundamental question of how the hydride is transferred, the C2 adduct has some 
interesting applications. Because it is a competent substrate for all enoyl‐thioester reductases tested 
so far and represents an intermediate state in catalysis, where the hydride transfer has already 
occurred, it is a great tool to study the second part of the catalytic cycle of these enzymes (whether 
it’s the protonation or the carboxylation). We demonstrated this by successfully changing the 
protonation specificity of the enoyl‐thioester reductase Etr1p from re- to si- face (Chapter 2). It 
additionally allowed us to assign the function of individual amino acids in Etr1p as well as in InhA. Due 
to its close proximity to the catalytic transition state it also poses an interesting starting point for the 
design of mechanistic inhibitors. The fact that the C4 adduct observed in the Y79F variant of Etr1p is a 
nano molar inhibitor for the wild type enzyme highlights this potential. The design of a substrate 
analogue that shifts the formation of the C2 adduct towards the C4 adduct could therefore already act 
as such an inhibitor. Introduction of functional groups that stabilize the C2 or C4 adduct and prevent 
its uncatalyzed decay in solution could additionally help in the design of such inhibitors. Finasteride, a 
mechanistic inhibitor of 5‐reductase used to treat benign prostatic hyperplasia and hair loss in men, 
uses both of these principles and has been shown to form a covalent intermediate with NADPH. It is a 
structural analogue to testosterone, the natural substrate of 5‐reductase, but the enoyl‐double bond 
is shifted (most likely positioning the enolate better for Michael addition to the cofactor) and an amide 
group is introduced in the molecule (which stabilizes the intermediate and prevents it from fast decay). 
It therefore represents a blue print for the development of further NADPH oxidoreductase inhibitors 
that are interesting drug targets (for a list of potential candidates see Chen et al. 6).  
The detailed understanding of enoyl‐thioester reductases and reductive carboxylases then allowed us 
to use them for the up scaled synthesis of a large library of malonyl‐CoA derivatives, which can be used 
as atypical extender units in polyketide synthases (Chapter 5). Interestingly our approach included a 
metabolic proofreading step. Another strategy nature often uses to deal with side reaction of enzymes 
that can occur when the mechanisms to control reaction selectivity at an enzymes active site are 
unable to prevent the formation of side products. These mechanisms to control reactive intermediates 
are discussed in detail in the following chapter. 
  
Conclusions and General Discussion 
164 
 
 
 
 
8.2 ‘Negative’ and ‘positive catalysis’: 
Complementary principles that shape the 
catalytic landscape of enzymes 
 
 
 
 
Authors: 
Bastian Vögeli1 and Tobias J. Erb1,2 
 
Submitted to: 
Current Opinion in Chemical Biology 
 
 
 
Author contributions:  
B.V. and T.J.E. wrote the paper.  
Conclusions and General Discussion 
165 
 
 ‘Negative’ and ‘positive catalysis’: Complementary principles that shape 
the catalytic landscape of enzymes 
 Abstract 
Our understanding of enzyme catalysis is dominated by transition state theory. According to this 
concept, an enzymatic reaction is guided along a desired reaction coordinate through the stabilization 
of favorable transition state. But how much is the outcome of an enzyme reaction controlled by the 
destabilization of unwanted transition states? Here, we revive and critically review the hypothesis that 
the active site of enzymes also features elements of ‘negative catalysis’. We provide examples that 
show that enzyme catalysis can be achieved by the combined action of positive and negative 
constraints at the active site of an enzyme. This integrated view of enzyme catalysis has direct 
consequences for our studies on the catalytic landscape of enzymes, as well as current efforts in 
enzyme engineering and the de novo‐design of enzymes. 
 Introduction 
Enzymes are remarkable catalysts that can achieve rate accelerations of up to nineteen orders of 
magnitude at high regio‐, stereo‐ and reaction specificity compared to the uncatalyzed reaction 7. The 
concept of enzyme catalysis as formulated by Pauling states that enzymes accelerate reaction rates by 
binding transition states better than substrates thereby lowering the activation energy of the reaction 
8. Pauling’s original concept was expanded and further refined, by including additional factors that also 
contribute to the lowering of activation energies, such as ground state destabilization, conformational 
substrate stabilization and enzyme preorganization 9‐12. Besides catalyzing a given reaction enzymes 
are very efficient at preventing alternative reaction outcomes, which would be favored in solution or 
in the gas phase over the desired reaction. This enables enzymes to catalyze chemically ‘difficult’ or 
‘improbable’ reactions involving highly reactive intermediates 13. The exquisite control of 
intermediates over the course of a reaction is a key feature of enzyme catalysis. 
 The catalytic landscape of enzymes is multi-dimensional and shaped by positive and negative 
contributions 
The progress of enzyme reactions is typically visualized in two‐dimensional plots, the free energy along 
the reaction coordinate (RC). In these graphs, transition states are depicted as energy maxima along 
the reaction path (Figure 1B). Although used very often to describe enzyme reactions, the two‐
dimensional representation of catalysis is rather misleading. Transition states actually represent local 
energy minima along the chosen RC when compared to the non‐catalyzed reaction or alternative 
reaction outcomes (i.e., side reactions). Conceptually it is thus more correct (and more helpful) to think 
of enzyme catalysis in a multi‐dimensional landscape, where transition states represent saddle‐points 
along different possible reaction outcomes (Figure 1C). 
How do enzymes control their catalytic landscape to form the correct reaction product? In principle 
the outcome of a reaction can be determined through two different mechanisms: Enzymes could guide 
a reaction along a minimum energy path by lowering the energy of productive transition states that 
lead to formation of the wanted product, as formulated by Pauling (Figure 1D). Alternatively, enzymes 
could increase the energy of competing transition states that would lead to the formation of 
alternative reaction products (Figure 1E). Even though the final product of the reaction would be the 
same, it is a conceptual, as well as a mechanistic difference whether a preferred reaction is promoted, 
or whether competing side reactions are suppressed by an enzyme during catalysis.  
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Figure 1 Visualization of a chemical reaction. A) Simple reaction scheme depicting the possible outcomes of a chemical 
reaction. B) Two dimensional free energy plot along the reaction coordinate (RC). RC1 (light blue) shows the RC for the 
formation of the desired product P1. RC2 (pink) shows the RC for the formation of the side product P2. Transition states are 
shown as local maxima. C) Three dimensional free energy landscape showing the transition states as saddle points along the 
RCs. D) ´ Positive´ contributions that stabilization of the productive transition states lead to increased formation of the desired 
product (P1). E) ´Negative´contributions that destabilize the unwanted transition states also lead to the increased formation 
of the desired product (P1) compared to the side product (P2) 
In the past, most of the research focused on understanding the principles that are used by active site 
residues to promote catalysis. In contrast, much less is understood about the mechanisms that 
suppress the formation of competing transition states leading to unwanted side reactions, even though 
a concept of ‘negative catalysis’ was developed by Rétey almost 30 years ago 13. According to Rétey 
the suppression of unwanted side reactions (‘negative catalysis’) can be equally important as the 
promotion of the desired reaction (‘positive catalysis’). 
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 A simple way to visualize positive and negative contributions of active site residues to 
catalysis 
How can positive and negative contributions of active site amino acids to catalysis be assessed? In 
principle, the role of a given amino acid can be described in two dimensions. One dimension is the 
contribution of an active site residue to the apparent turnover frequency of an enzyme (kcat), while the 
other is the contribution of an active site residue to reaction specificity, expressed as the relative ratio 
of side product (P2) to reaction product (P1), expressed as log[P2/P1].  
In a first approximation residues conferring positive contributions would mainly affect the kcat of an 
enzyme (measured as rate of substrate consumption or formation of all products). Residues conferring 
negative contributions on the other hand would mainly affect log[P2/P1]. Note that positive and 
negative contributions are of course not completely independent (e.g., an increase in kcat for the 
desired reaction would also decrease the amount of side product formed). Yet, plotting the effect of 
an active site mutation onto both dimensions (kcat versus log[P2/P1]) in an activity/specificity‐graph 
allows for an intuitive way to visualize and understand its contribution to catalysis, as exemplified 
below. 
In principle, the activity/specificity‐graph is an intriguingly simple way to assess the catalytic functions 
of an active site residue of an enzyme. However, in practice, while the turnover frequencies of an 
enzyme and its active site variants are usually well documented, the relative ratios of side product to 
product for the same set of enzyme variants are very often not reported. In many cases the side 
reactions of enzymes remain unknown, because they are not systematically identified, hard to 
measure (due to their low occurrence in the WT), or simply not considered in the study design and 
thus not investigated, let alone quantified. It is mainly this lack of data that prevents the possibility to 
assess the different contributions of active site amino acids to catalysis more systematically. For this 
review, we have surveyed the literature to identify studies that explicitly report the function of amino 
acids in both catalytic dimensions (Figure 2). 
 A growing body of evidence for the existence of ‘negative catalysis’ 
Mutation of conserved active site residues very often affect the catalytic rate of an enzyme, meaning 
that these residues serve in promoting the catalyzed reaction. But how much do they additionally 
contribute to controlling the formation of the correct reaction product, i.e., how big is there 
contribution on the log[P2/P1] coordinate? And even more extreme: Are there dedicated amino acid 
residues at the active site of enzymes that only exist to suppress the formation of side products without 
affecting the overall catalytic rate of an enzyme? In other words: Are there amino acids that almost 
exclusively operate in ‘negative catalysis’? In the kcat versus log[P2/P1] plot of our selected examples, 
such residues should be shifted left on the x‐axis, while appearing mostly unchanged on the y‐axis. In 
the following, we will discuss several examples of amino acids that guide and control the outcome of 
catalysis in different enzymes by ‘negative catalysis’ and discuss their mode of action. 
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Figure 2 Relative log(kcat) vs. log[P2/P1] plot for active site mutants of selected enzymes. A) Conventional one dimensional 
plot of kcat for active site mutants of Etr1p, TXS, aMOx and TIM. B) log(kcat) vs. log[P2/P1] plot of the same variants highlighting 
the additional dimension/information that can be gained by including a measure for side product formation/reaction 
selectivity of the enzyme. DL; product P1 below the detection limit. 
Enoyl-thioester reductase Etr1p. Etr1p operates in mitochondrial fatty acid biosynthesis and reduces 
enoyl‐CoA thioestesters into their saturated counterparts at the expense of NADPH. In the enzyme a 
conserved threonine 175 was proposed to interact with the NADPH cofactor 14. When this threonine 
is converted into an isosteric valine, the catalytic rate of the enzyme is decreased ‘only’ by a factor of 
ten. The error rate of the enzyme, however, becomes dramatically increased by this mutation. The 
T175V variant forms a covalent adduct between the NADPH cofactor and the enoyl‐CoA substrate (‘C4‐
adduct’) as a side product at high rates. While the WT enzyme does not form the side product above 
the detection limit (less than one per 1.7·10‐7 turnovers), the side product is formed in the T175V 
mutant approximately every third turnover. In other words, the T175V variant still operates at 10% WT 
turnover frequency, but its error rate increased by almost six orders of magnitude (Figure 2B) 15. This 
strong increase in side product formation by the T175V mutation can be explained through a lowered 
energetic barrier to a competing transition state leading to formation of the side product. In summary, 
T175 probably represents one of the most striking examples of an active site residue that almost 
exclusively functions in ‘negative catalysis’.  
Note that the function of T175 is very different from the function of other amino acids at the active 
site of the enzyme. A conserved tyrosine 79, for instance, is the proton donor in the Etr1p reaction 16. 
When this residue is mutated to phenylalanine, the Y79F variant also shows almost exclusively 
formation of the side product. However, at the same time the kcat of the WT reaction is dramatically 
decreased (below the background rate of the spontaneous decay of the C4‐adduct in solution). Y79 is 
an essential residue in catalysis and its mutation strongly increases the energetic barrier to the 
preferred transition state. This blocks the original trajectory of the enzyme and opens the path to the 
formation of the side product instead. This is represented by a decrease in both dimensions on the 
specificity‐activity plot. Therefore, unlike T175 that increases the energetic barrier leading to 
unwanted side product, Y79 controls the reaction outcome by promoting formation of the preferred 
reaction product. A similar positive effect on catalysis can be attributed to the two residues within 
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hydrogen bond distance to the hydroxyl group of Y79; S70V and T324A. Both of them only affect kcat 
by lowering the pKa of the proton donor, thus lowering the activation barrier for protonation. In 
conclusion, Etr1p represents a case example of how different amino acid residues at the active site 
work together to control the outcome of an enzyme reaction through positive (Y79, S70V and T324A) 
and negative (T175) catalytic contributions.  
Taxadiene synthase (TXS). TXS cyclizes geranylgeranyl diphosphate (GGPP) to taxadiene (taxa‐
4(5),11(12)‐diene), a precursor of the antitumor compound Taxol17. The enzyme forms taxadiene at a 
yield of 93%. However, TXS also forms 5% of the taxadiene isomer taxa‐4(20),11‐diene, <1% of 
verticillia‐3,7,12(13)‐triene, as well as 1% of verticillia‐3,7,11(12)‐triene as naturally occurring side 
products 18. Site‐directed mutagenesis in combination with molecular mechanic simulations identified 
multiple residues that play an essential role in guiding the reaction towards the desired taxadiene 
product. Catalysis in TXS is initiated by a Mg2+‐mediated pyrophosphate elimination step, forming a 
highly reactive carbocation, which is converted over multiple other carbocation intermediates to the 
final product.  
Site directed mutagenesis studies revealed multiple residues in TXS that contribute mainly to reaction 
specificity and do not affect the kcat of the reaction 18. Substitution of W753 by a histidine, for instance, 
lowers enzyme activity by 50%, but completely redirects the reaction to the formation of one side 
product only, (‐)‐(R)‐cembrene A, which is formed below the detection limit in the WT enzyme. This 
strongly suggests that W753 functions mainly in preventing the premature termination of the reaction. 
Another essential residue in catalysis is V584, which is positioned very closely to the positively charged 
monocyclic carbocation. The V584L variant still operates with 90% activity, while formation of the side 
product verticillia‐3,7,12(13)‐triene is increased by two orders of magnitude (from 0.8% to 84%). This 
suggests that V584 and W753, mainly guide the reactive intermediate along the reaction coordinate 
by actively preventing competing side reactions to take place. Note that alternatively the introduced 
variant could also lower the activation energy for the side reaction (e.g. the histidine could serve as a 
base for premature deprotonation), this would however be expected to be accompanied by an 
increase in kcat for this side reaction. Therefore, these residues most likely play a similar role as T175 in 
Etr1p by directing, but not accelerating the chemistry of the enzyme to control the catalytic outcome, 
as suggested recently 19. 
Triosephosphate isomerase (TIM). During the interconversion of GA3P and DHAP, TIM forms a 
reactive enediol(ate) phosphate intermediate as part of the catalytic cycle in the WT enzyme. This 
enediol(ate) phosphate intermediates are unstable in water and prone for β‐elimination of the 
phosphate with estimated rate constants between 8·106 and 8·108 s‐1, which is at least 100 times faster 
than the protonation in solution 20. The side product of this elimination is methylglyoxal which is only 
formed once every million reactions in the WT enzyme. Knowles and coworkers showed that a loop in 
the enzyme closes the active site upon substrate binding, which stabilizes the enediol(ate) 
intermediate 21. This induced fit allows the enzyme to bind the enediol(ate) intermediate stronger than 
both substrate and product, which locks the phosphate group in a conformation disfavoring 
elimination22‐24. A critical residue in catalysis is lysine 12 that forms direct contacts with both the 
phosphate and one of the hydroxyl groups of the enediol(ate). Mutagenesis of the L12 by a glycine 
lead to a 12,000 fold decrease in kcat of the enzyme, accompanied by a 180,000 fold increase of 
methylglyoxal formation 25. Consequently, L12 is important in stabilizing the enediol(ate) phosphate 
intermediate transition state. At the same time L12 also destabilizes the transition state leading to the 
β‐elimination side reaction. L12 seems to exert both positive, as well as negative control on the 
outcome of the reaction of TIM (Figure 2B).  
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Studies on the phosphate binding pocket of TIM have additionally revealed the importance of leucine 
232 and isoleucine 172 in binding and positioning the phosphate group. Mutation of either L232A or 
I172A lead to the increased formation of methylglyoxal (around one every ten turnover in both cases) 
but a less pronounced loss in kcat than for the L12G variant (10% of WT activity for L234A and 0.5% 
activity for I172A) 26. These residues are therefore all influencing both the promotion of the transition 
state stabilizing the enediol(ate) intermediate for the isomeration reaction and the suppression of the 
transition state leading to the unwanted β‐elimination, but to a different extent. Future theoretical 
and experimental investigations on TIM might lead to a clearer separation between the individual 
contributions of these residues towards catalysis. 
 Implications of the existence of ‘negative catalysis’ in enzymes 
Above examples provide evidence that the active destabilization of unfavorable transition states is a 
strategy used by enzymes to control the outcome of catalysis. This strategy is complementary to the 
well‐known principle of promoting favorable transition states, which is commonly used to explain 
enzyme catalysis. Accordingly, enzyme catalysis is the combined result of both positive and negative 
constraints on the substrate‐to‐product reaction landscape, which are determined by the amino acid 
residues at the active site. Notably, positive and negative contributions can be unified in one and the 
same active site residue (e.g., L12 of TIM), but also separated onto different amino acids (e.g., T175 
and Y79 in Etr1p). Assessing the contribution of individual active site residue onto turnover frequency 
as well as reaction specificity is an important prerequisite to understand the full catalytic landscape of 
an enzyme.  
Even though simple in principle, the assignment of positive and negative catalytic contributions to 
individual amino acids is not straight forward in practice. This becomes especially apparent in cases 
like V584 in TXS that almost exclusively serve a negative catalytic function. When using standard 
enzyme assays that are based on measuring substrate or cofactor consumption, such residues would 
obviously not show a difference compared to the WT. Only the complete characterization of the 
enzyme reaction, i.e. the quantification of all reaction products formed, will allow to understand the 
contribution of these residues to catalysis. In this context, it might be worthwhile to speculate how 
many of the active site residues that have been investigated in respect to their effect onto kcat but were 
found to be non‐important, might actually serve a function in suppressing unwanted side reactions.  
Another difficulty is that even when an active site mutant is strongly affected in kcat upon mutation, 
this does not exclude the (additional) function of the particular residue in negative catalysis. One 
example is L12 in TIM that supposedly serves both a positive and a negative function. Another example 
is actually T175 in Etr1p, whose function in negative catalysis was initially masked by the fact that the 
T175V variant appeared to be catalytically dead on first glance, when using conventional 
spectrophotometric assays. Only close inspection using stopped‐flow spectroscopy demonstrated that 
the T175V variant is basically still completely functional, but quickly accumulates the C4‐adduct side 
product, which in turn appeared to be a very strong inhibitor of the enzyme at nM concentration 15. In 
summary, these examples show that the quantification of the positive and negative contributions of 
active site residues onto catalysis is not a simple task that can be achieved through a standard 
procedure, but requires the careful attention and experimental planning of the researcher. 
 Using ‘negative catalysis’ in enzyme engineering, de novo-design and directed evolution 
In de novo design and engineering of enzymes towards new chemical reactions, the focus almost 
exclusively lies on the introduction of residues that lower the activation energy for the desired 
reaction. Based on the examples discussed above, it might be of equal importance to consider the 
introduction of residues conferring a negative contribution towards undesired reactions. Similar to the 
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concept of negative design that is already used in the de novo design of proteins 27, including negative 
catalytic elements as a basic design constraint could pave the way for new efficient and more precise 
catalysts in biology and chemistry. A recent example emphasizing these aspects is the successful 
engineering of an anti‐Markovnikov alkene oxidase (aMOx) from a P450 alkene epoxidase form 
Labrenzia aggregate, which displayed some oxidase side reactivity 28. The desired oxidase reaction 
strongly competes with an energetically favorable epoxidation reaction. To achieve a change in 
chemical reactivity, the path of the reaction needs to be shifted from a concerted oxo transfer to a 
stepwise oxidation pathway involving a 1,2‐hydride migration. In principle, this switch could be 
achieved by stabilizing the desired transition states along the anti‐Markovnikov oxidation coordinate 
or on the destabilization of the epoxidation reaction. Initial directed evolution did only increase the 
overall enzyme activity but not the reaction selectivity towards the anti‐Markovnikov oxidation (Figure 
1B, points 1A and 2). Further evolution selecting on the ratio between anti‐Markovnikov oxidation and 
epoxidation led to the desired switch in chemical reactivity (Figure 1B, points 5 and 10). The amino 
acids mutated during the directed evolution rounds are widely distributed over the enzyme and their 
detailed functions are not yet characterized. It will be interesting to assess the positive and negative 
contributions of these residues to catalysis.  
 Final remarks 
In summary, we hope that this work revives the discussion about the negative contributions in enzyme 
catalysis. The concept of active site residues that function in destabilizing unwanted transition states 
may not only help to identify the role of conserved residues, who lack an apparent function in catalysis 
so far, but might also help in the design and engineering of enzymes with new, unusual or altered 
reaction specificity.  
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 Substrate channeling 
Millions of years of evolution produced biological systems able to catalyze a myriad of reactions in 
parallel and in one compartment, the cell. In that process nature had to find solutions that are able to 
manage cross talk between pathways, competing side reactions, toxic and unstable intermediates and 
can overcome unfavorable thermodynamic bottlenecks to ensure efficient metabolic flux through 
metabolism to sustain life. It has been frequently observed that enzymes within a metabolic pathway 
are able to transfer intermediates directly from one enzyme to the next without releasing it into the 
bulk solvent, thus avoiding the above mentioned problems of pathway cross‐talk and toxicity. This 
process is termed substrate channeling. The design of similar cascade reactions with controllable 
product distribution, excellent molecular efficiencies and high selectivity are a great challenge in 
chemistry and synthetic biology, there is therefore great interest in understanding natural systems as 
well as in applying those to novel cascade reactions 29.  
Theoretical calculations show that proximity of enzymes alone is usually insufficient to produce 
effective channeling, as the diffusion of small molecules in the cytoplasm is often orders of magnitudes 
faster than the reaction rates. To be able to observe a channeling effect purely based on proximity it 
has been calculated that the distance between active site should not exceed 1 nm 30. Longer distances 
require bonded diffusion (e.g. chemical gradients or intermolecular interactions) or sequestration (e.g. 
compartmentalization or a molecular tunnel) 29. Methods to evaluate substrate channeling are largely 
indirect and often difficult to interpret. This makes it challenging to generate clear evidence of 
channeling for a designated reaction cascade and it is often advised to use multiple independent 
methods. These include transient time analysis, isotope dilution and enrichment studies, cascade 
resistance to a competing side reaction or to a reaction inhibitor 29. Accompanying structural 
information is also very helpful to analyze natural and artificial systems for their capacity to channel 
substrates.  
A recent study on the proximity effect of enzyme cascades scaffolded on DNA nicely highlights these 
difficulties. Multiple studies had previously shown that scaffolding enzyme cascades on DNA enhances 
the overall activity and a channeling effect was evoked to explain the observed improvement. 
Theoretical calculations and models however predicted that in these cases proximity cannot explain 
the observed rate enhancement. Careful reanalysis of the scaffolded cascade revealed that the reason 
for the observed enhancement is that the pH near the surface of negatively charged DNA 
nanostructures is lower than in the bulk solution, which created a more optimal pH environment for 
the scaffolded enzymes 31. 
There are many different ways natural systems control the diffusion of cascade intermediates, 
including intramolecular tunnels (eg. tryptophane synthase , carbamoyl‐phosphate synthase), 
electrostatic guidance (eg. malate dehydrogenase – citrate synthase complex), covalent bonding of 
intermediates (eg. polyketide synthases, pyruvate dehydrogenase complex) and micro‐
compartmentalization (eg. carboxysomes, bacterial micro‐compartments) 29. In this work we 
characterize two natural enzyme cascades and show biochemically as well as structurally that they 
channel their intermediates.  
The trifunctional propionyl‐CoA synthase (PCS) forms a closed reaction chamber to sequester the 
reactive acrylyl‐CoA intermediate (Chapter 6). PCS therefore seems to use a slightly different 
mechanism than the ones described above. The reaction chamber encloses all three active sites, but 
does not show the directionality of a conventional tunnel, and the CoA ester intermediates are not 
covalently attached to the enzyme but freely diffuse within the compartment. The reaction chamber 
is completely formed by the enzyme itself and does not require any structural proteins to form the 
compartment, which is in strong contrast to other described micro‐compartments. The volume of the 
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reaction chamber is about an order of magnitude smaller than the smallest described bacterial micro 
compartment. PCS therefore represents an intriguing, alternative mechanism of substrate channeling 
which harbors great potential for the engineering of a new class of dynamically regulated 
nanoreactors. 
The substrate channeling mechanism of the thiolase/HMG‐CoA synthase complex of archaea (Chapter 
7) most closely resembles the covalent swinging arm fatty acid and polyketide synthases use to channel 
their intermediates. In the thiolase/HMG‐CoA synthase complex the intermediate is however not 
covalently attached, but instead tightly bound in a shared CoA binding site, enabling the pantothenyl‐
arm of CoA to swing from the thiolase active site to the HMG‐CoA synthase active site. The two 
channeling systems described in this work therefore represent two alternative ways of channeling CoA 
ester intermediates in a non‐covalent fashion. 
 Outlook 
The goal of this thesis was to study the mechanisms that enzymes use to control reactive 
intermediates, both inside one active site and between enzymes of a metabolic pathway. The recently 
discovered catalytically competent C2 intermediate formed at the active site of enoyl‐thioester 
reductases and reductive carboxylases served as a starting point to study reactive intermediates within 
the active site of an enzyme. We were able to assign the function of most active site residues in Etr1p 
and used the C2 adduct successfully to engineer the stereo specificity of protonation. It is however still 
unclear whether the C2 adduct is part of the reaction coordinate or just an energetically close side 
product. Measurements of the secondary kinetic isotope effect of NAD(P)H containing a deuterium 
label at the C2 position could help to clarify this question. If the C2 adduct lays on the reaction 
coordinate and a covalent bond between the C2 of NAD(P)H and the substrate is formed during the 
reaction, which changes the hybridization of the C2 carbon, a secondary kinetic isotope effect should 
be detectable. QM/MM modeling could additionally help to estimate the activation energies involved 
in either mechanism. 
The C2 adduct is additionally a great tool to study the detailed molecular mechanism of CO2 activation 
in reductive carboxylases, a principle, which is not well understood for any CO2 fixing enzymes. The 
combination of structural data gained during this work as well as the ability to probe the carboxylation 
step independent of the reduction/hydride transfer makes enoyl‐CoA carboxylase/reductase a very 
good model system for such investigations. Additionally it would be interesting to look at the 
evolutionary history of CO2 fixation in the MDR superfamily. Initial phylogenetic analysis indicates that 
the CO2 fixing function evolved from simple reductases, which acquired a CO2 binding pocket and 
changed the resolving electrophile from a proton to CO2. 
With the established biosynthesis method in this work using reductive carboxylation, the synthesis of 
diverse libraries of malonyl‐CoA derivatives is now feasible. These libraries can now be used to 
systematically screen and engineer the specificity of extender unit incorporation in polyketide 
synthases. The change in stereochemistry of the protonation in Etr1p could be transferred to the enoyl 
reductase domains of these polyketide synthases to further increase the polyketide diversity. 
With the description of two natural substrate channeling systems able to non‐covalently channel CoA 
ester intermediates, it would be interesting to adapt/engineer those for the use in other challenging 
pathways, which involve such intermediates. 
 
Conclusions and General Discussion 
174 
 
 References 
1. Sandor, R.; Slanina, J.; Midlik, A.; Sebrlova, K.; Novotna, L.; Carnecka, M.; Slaninova, I.; 
Taborsky, P.; Taborska, E.; Pes, O., Phytochemistry 2018, 145, 77‐84. 
2. Libby, R. D.; Mehl, R. A., Bioorg Chem 2012, 40, 57‐66. 
3. Macgibbon, A. K. H.; Koerber, S. C.; Pease, K.; Dunn, M. F., Biochemistry 1987, 26 (11), 3058‐
3067. 
4. Hamilton, G. A., Progress in Bioorganic Chemistry 1971, 1, 83‐157. 
5. Rosenthal, R. G.; Ebert, M. O.; Kiefer, P.; Peter, D. M.; Vorholt, J. A.; Erb, T. J., Nat Chem Biol 
2014, 10 (1), 50‐U85. 
6. Chen, L.; Petrelli, R.; Felczak, K.; Gao, G.; Bonnac, L.; Yu, J. S.; Bennett, E. M.; Pankiewicz, K. W., 
Curr Med Chem 2008, 15 (7), 650‐670. 
7. Wolfenden, R.; Snider, M. J., Accounts of chemical research 2001, 34 (12), 938‐45. 
8. Pauling, L., Chemical and Engineering News 1946, 24 (10), 1375‐1377. 
9. Garcia‐Viloca, M.; Gao, J.; Karplus, M.; Truhlar, D. G., Science 2004, 303 (5655), 186‐95. 
10. Benkovic, S. J.; Hammes‐Schiffer, S., Science 2003, 301 (5637), 1196‐1202. 
11. Zinovjev, K.; Tunon, I., P Natl Acad Sci USA 2017, 114 (47), 12390‐12395. 
12. Boehr, D. D.; Nussinov, R.; Wright, P. E., Nat Chem Biol 2009, 5 (11), 789‐796. 
13. Retey, J., Angew Chem Int Edit 1990, 29 (4), 355‐361. 
14. Khare, D.; Hale, W. A.; Tripathi, A.; Gu, L. C.; Sherman, D. H.; Gerwick, W. H.; Hakansson, K.; 
Smith, J. L., Structure 2015, 23 (12), 2213‐2223. 
15. Rosenthal, R. G.; Vogeli, B.; Wagner, T.; Shima, S.; Erb, T. J., Nat Chem Biol 2017, 13 (7), 745‐
749. 
16. Rosenthal, R. G.; Vogeli, B.; Quade, N.; Capitani, G.; Kiefer, P.; Vorholt, J. A.; Ebert, M. O.; Erb, 
T. J., Nat Chem Biol 2015, 11 (6), 398‐+. 
17. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; Mcphail, A. T., Journal of the American 
Chemical Society 1971, 93 (9), 2325‐&. 
18. Schrepfer, P.; Buettner, A.; Goerner, C.; Hertel, M.; van Rijn, J.; Wallrapp, F.; Eisenreich, W.; 
Sieber, V.; Kourist, R.; Bruck, T., P Natl Acad Sci USA 2016, 113 (8), E958‐E967. 
19. Freud, Y.; Ansbacher, T.; Major, D. T., ACS catalysis 2017, 7 (11), 7653‐7657. 
20. Richard, J. P., Biochemistry 1991, 30 (18), 4581‐5. 
21. Rozovsky, S.; Jogl, G.; Tong, L.; McDermott, A. E., Journal of molecular biology 2001, 310 (1), 
271‐280. 
22. Pompliano, D. L.; Peyman, A.; Knowles, J. R., Biochemistry 1990, 29 (13), 3186‐3194. 
23. Alahuhta, M.; Wierenga, R. K., Proteins-Structure Function and Bioinformatics 2010, 78 (8), 
1878‐1888. 
24. Morell, M. K.; Paul, K.; Oshea, N. J.; Kane, H. J.; Andrews, T. J., Journal of Biological Chemistry 
1994, 269 (11), 8091‐8098. 
25. Go, M. K.; Koudelka, A.; Amyes, T. L.; Richard, J. P., Biochemistry 2010, 49 (25), 5377‐5389. 
26. Malabanan, M. M.; Amyes, T. L.; Richard, J. P., Journal of the American Chemical Society 2011, 
133 (41), 16428‐16431. 
27. Noivirt‐Brik, O.; Horovitz, A.; Unger, R., Plos Comput Biol 2009, 5 (12). 
28. Hammer, S. C.; Kubik, G.; Watkins, E.; Huang, S.; Minges, H.; Arnold, F. H., Science 2017, 358 
(6360), 215‐+. 
29. Wheeldon, I.; Minteer, S. D.; Banta, S.; Barton, S. C.; Atanassov, P.; Sigman, M., Nat Chem 2016, 
8 (4), 299‐309. 
30. Eun, C.; Kekenes‐Huskey, P. M.; Metzger, V. T.; McCammon, J. A., J Chem Phys 2014, 140 (10). 
31. Zhang, Y.; Tsitkov, S.; Hess, H., Nature communications 2016, 7, 13982. 
 175 
 
  
 176 
 
Acknowledgements 
This work could not have been accomplished without the help and support of many wonderful people 
which I would like to acknowledge and thank at this point.  
First of all I would like to thank my supervisor Tobi Erb for all his guidance, trust and enthusiasm. He 
gave me the freedom to explore all my crazy ideas and found a way to motivate me to keep trying 
when they failed. I immensely enjoyed all the brainstorming sessions talking about random scientific 
ideas and projects and it taught me to keep an open mind for what is possible.  
I would also like to thank Prof. Mohamed Marahiel, Prof. Johann Heider, Prof. Martin Grininger and 
Dr. Hannes Link for being part of my thesis advisory committee and for giving valuable input and 
advice. 
Many thanks also go to Raoul, who was not only the supervisor of my master thesis, contributed 
greatly to many projects in this thesis and to improve my scientific skills, but also showed me how cool 
enzymes really are. Tristan (´the Frenchy´) taught me the ways of X‐ray crystallography and solved 
many of the structures in this work. It was a lot of fun figuring out together, how my biochemical 
measurements correlate with those structures. Many of the projects in this thesis were the result of 
great collaborations and I would like to thank Iria for letting me work with her pet enzyme, Pete for 
showing me how to synthesize all the CoA esters my heart desires, Kookie and Heidi for providing MS 
data and analysis, Kyra for her support in characterizing Ccr´s and Gabo for his work on InhA and his 
appropriate jokes at appropriate times. This work would not be where it is now without the valuable 
help of of the two master students, whom I was privileged to supervise. Thank you Sarah and Patrick! 
A scientist is nothing without a laboratory and great lab mates. I am grateful to all the former and 
present members of the AG Erb, who all contributed in their way to this work. It was a pleasure to see 
the lab grow so much over the last years and gain so many great new members. I deeply enjoyed the 
mixture between good science, hard work and the anarchic lighthearted atmosphere we all shared. 
It´s great to work with friends instead of only colleagues. I would also like to thank Jan and all the staff 
that help keeping the lab from falling into complete chaos and apologize for my mess. At this point I 
would especially like to thank Thomi, who started this great Marburg experience together with me and 
was a good friend and support along the way. Without you I would have never been able to overcome 
the challenges of German bureaucracy. 
I would not be where I am today without the love and support of my friends and family and I can never 
thank them enough for always standing by my side and believing in me. Special thanks also goes to my 
parents, who enabled me to get to this point and were always there for me! 
 
 
“So long, and thanks for all the (back)fish!” 
 
